<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Corp. - Form 10-K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES </FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT></B><BR>Washington, D.C. 20549
</P>
<P align=center><B><FONT size=5>FORM 10-K </FONT></B></P>
<P align=center>(Mark One) </P>
<P align=center>[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 </P>
<P align=center>For the fiscal year ended <B><U>September 30, 2013</U></B></P>
<P align=center>[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 </P>
<P align=center>For the transition period from ________________
to________________</P>
<P align=center>Commission file number<B>: </B><B><U>000-51652</U></B><B>
</B></P>
<P align=center><B><U><FONT size=5>ANAVEX LIFE SCIENCES CORP.</FONT></U></B><B>
</B><BR>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
  <TD align=center width="50%"><B><U>20-8365999 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of incorporation or
      organization) </TD>
  <TD align=center width="50%">(I.R.S. Employer Identification No.) </TD>
  </TR>
  <TR>
    <TD align=center>&nbsp; </TD>
  <TD align=center width="50%">&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center><B><U>51 W 52</U></B><B><U><SUP>nd
      </SUP></U></B><B><U>Street, 7</U></B><B><U><SUP>th
      </SUP></U></B><B><U>Floor, New York, NY </U></B></TD>
  <TD align=center width="50%"><B><U>10019-6163 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(Address of principal executive offices) </TD>
  <TD align=center width="50%">(Zip Code) </TD>
  </TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code
<U>1-800-689-3939 </U></P>
<P align=center>Securities registered under Section 12(b) of the Act: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>None </U></B></TD>
  <TD align=center width="50%"><B><U>N/A </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>Title of each class </TD>
    <TD align=center width="50%">Name of each exchange on which registered  </TD>
  </TR></TABLE>
<P align=center>Securities registered pursuant to Section 12(g) of the Act:
<BR><B><U>Common Stock, $0.001 par value</U></B><B> </B><BR>(Title of class)
<BR></P>
<P align=justify>Indicate by checkmark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act. <BR>Yes [&nbsp;
&nbsp;]&nbsp;&nbsp;&nbsp;&nbsp; No [X] </P>
<P align=justify>Indicate by checkmark if the registrant is not required to file
reports pursuant to Section 13 or 15(d) of the Act. <BR>Yes [&nbsp;&nbsp;
]&nbsp;&nbsp;&nbsp;&nbsp; No [X] </P>
<P align=justify>Indicate by checkmark whether the registrant has (1) filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. <BR>Yes [X]&nbsp;&nbsp;&nbsp;&nbsp; No
[&nbsp;&nbsp; ] </P>
<P align=center>i </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=justify>Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation
S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files).
<BR>Yes [X]&nbsp;&nbsp;&nbsp;&nbsp; No [&nbsp;&nbsp; ] </P>
<P align=justify>Indicate by checkmark if disclosure of delinquent filers
pursuant to Item 405 of Regulation S-K (&#167; 229.405 of this chapter) is not
contained herein, and will not be contained, to the best of registrant&#146;s
knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-K or any amendment to this Form 10-K.
[&nbsp; &nbsp;]</P>
<P align=justify>Indicate by checkmark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148;
&#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the
Exchange Act. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Large accelerated filer [&nbsp;&nbsp; ] </TD>
    <TD align=left width="33%">&nbsp; </TD>
    <TD align=left width="33%">Accelerated
      filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      [&nbsp;&nbsp; ] </TD></TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="33%">&nbsp; </TD>
    <TD align=left width="33%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Non-accelerated filer&nbsp;&nbsp; [&nbsp; &nbsp;] </TD>
    <TD align=left width="33%">(Do not check if a smaller reporting </TD>
    <TD align=left width="33%">Smaller reporting company [X] </TD></TR>
  <TR vAlign=bottom>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="33%"
    >company)&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD align=left width="33%" >&nbsp;</TD></TR></TABLE>
<P align=justify>Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Act). <BR>Yes [&nbsp;&nbsp;
]&nbsp;&nbsp;&nbsp;&nbsp; No [X] </P>
<P align=justify>State the aggregate market value of the voting and non-voting
common equity held by non-affiliates computed by reference to the price at which
the common equity was last sold, or the average bid and asked price of such
common equity, as of the last business day of the registrant&#146;s most recently
completed second fiscal quarter: $16,460,398 based on a price of $0.70 per
share, being the closing price of the registrant&#146;s common stock on March 29,
2013. </P>
<P align=justify>Indicate the number of shares outstanding of each of the registrant&#146;s classes of common stock, as of the latest practicable date  37,237,588 issued and outstanding as of December 24, 2013.</P>
<P align=center>DOCUMENTS INCORPORATED BY REFERENCE </P>
<P align=justify>None. </P>
<P align=center>ii </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_3></A>
<P align=center><B><U>TABLE OF CONTENTS</U></B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="11%" align=left bgColor=#eeeeee><B>PART I</B> </TD>
    <TD align=left width="83%" bgColor=#eeeeee >&nbsp; </TD>
    <TD align=left width="6%" bgColor=#eeeeee >&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="83%" >&nbsp; </TD>
    <TD width="6%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="#page_5">Item 1. </a></TD>
    <TD align=left width="83%" bgColor=#eeeeee ><a href="#page_5">Business. </a></TD>
    <TD align=right width="6%" bgColor=#eeeeee ><a href="#page_5">1</a></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><a href="#page_13">Item 1A. </a></TD>
    <TD align=left width="83%" ><a href="#page_13">Risk Factors. </a></TD>
    <TD align=right width="6%" ><a href="#page_13">9</a></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="#page_23">Item 1B. </a></TD>
    <TD align=left width="83%"  bgColor=#eeeeee
      ><a href="#page_23">Unresolved Staff Comments. </a></TD>
    <TD align=right width="6%"  bgColor=#eeeeee
      ><a href="#page_23">19</a></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><a href="#page_23">Item 2. </a></TD>
    <TD align=left width="83%" ><a href="#page_23">Properties. </a></TD>
    <TD align=right width="6%" ><a href="#page_23">19</a></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="#page_23">Item 3. </a></TD>
    <TD align=left width="83%" bgColor=#eeeeee ><a href="#page_23">Legal
      Proceedings. </a></TD>
    <TD align=right width="6%" bgColor=#eeeeee ><a href="#page_23">19</a></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><a href="#page_24">Item 4. </a></TD>
    <TD align=left width="83%" ><a href="#page_24">Mine safety disclosures. </a></TD>
    <TD align=right width="6%" ><a href="#page_24">20</a></TD>
  </TR>
  <TR>
    <TD bgColor=#eeeeee>&nbsp; </TD>
    <TD width="83%" bgColor=#eeeeee >&nbsp; </TD>
    <TD width="6%" align="right" bgColor=#eeeeee >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><B>PART II</B> </TD>
    <TD align=left width="83%" >&nbsp; </TD>
    <TD align=right width="6%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD bgColor=#eeeeee>&nbsp; </TD>
    <TD width="83%" bgColor=#eeeeee >&nbsp; </TD>
    <TD width="6%" align="right" bgColor=#eeeeee >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><a href="#page_25">Item 5. </a></TD>
    <TD align=left width="83%" ><a href="#page_25">Market for Registrant&#146;s Common
      Equity, Related Stockholder Matters and Issuer Purchases of Equity
      Securities </a></TD>
    <TD align=right width="6%" ><a href="#page_25">21</a></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="#page_27">Item 6. </a></TD>
    <TD align=left width="83%" bgColor=#eeeeee ><a href="#page_27">Selected
      Financial Data </a></TD>
    <TD align=right width="6%" bgColor=#eeeeee ><a href="#page_27">23</a></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><a href="#page_27">Item 7. </a></TD>
    <TD align=left width="83%" ><a href="#page_27">Management's Discussion and
      Analysis of Financial Condition and Results of Operations. </a></TD>
    <TD align=right width="6%" ><a href="#page_27">23</a></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="#page_33">Item 7A. </a></TD>
    <TD align=left width="83%" bgColor=#eeeeee ><a href="#page_33">Quantitative and
      Qualitative Disclosures about Market Risk. </a></TD>
    <TD align=right width="6%" bgColor=#eeeeee ><a href="#page_33">29</a></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><a href="#page_33">Item 8. </a></TD>
    <TD align=left width="83%" ><a href="#page_33">Financial Statements and
      Supplementary Data. </a></TD>
    <TD align=right width="6%" ><a href="#page_33">29</a></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="#page_35">Item 9. </a></TD>
    <TD align=left width="83%" bgColor=#eeeeee ><a href="#page_35">Changes In and
      Disagreements with Accountants on Accounting and Financial Disclosure.  </a></TD>
    <TD align=right width="6%" bgColor=#eeeeee ><a href="#page_35">30</a></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><a href="#page_35">Item 9A </a></TD>
    <TD align=left width="83%" ><a href="#page_35">Controls and Procedures</a></TD>
    <TD align=right width="6%" ><a href="#page_35">30</a></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="#page_38">Item 9B </a></TD>
    <TD align=left width="83%" bgColor=#eeeeee ><a href="#page_38">Other
      Information</a></TD>
    <TD align=right width="6%" bgColor=#eeeeee ><a href="#page_38">33</a></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD width="83%" ></TD>
    <TD width="6%" align="right" ></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left
    >&nbsp;</TD>
    <TD align=right
    >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#EEEEEE><B>PART III</B> </TD>
    <TD width="83%" align=left  bgColor=#EEEEEE
    >&nbsp;</TD>
    <TD width="6%" align=right  bgColor=#EEEEEE
    >&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="83%" >&nbsp; </TD>
    <TD width="6%" align="right" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#EEEEEE><a href="#page_39">Item 10. </a></TD>
    <TD width="83%" align=left bgColor=#EEEEEE ><a href="#page_39">Directors,
      Executive Officers and Corporate Governance. </a></TD>
    <TD width="6%" align=right bgColor=#EEEEEE ><a href="#page_39">34</a></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><a href="#page_41">Item 11. </a></TD>
    <TD align=left width="83%" ><a href="#page_41">Executive Compensation. </a></TD>
    <TD align=right width="6%" ><a href="#page_41">36</a></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#EEEEEE><a href="#page_45">Item 12. </a></TD>
    <TD width="83%" align=left bgColor=#EEEEEE ><a href="#page_45">Security
      Ownership of Certain Beneficial Owners and Management and Related
      Stockholder Matters. </a></TD>
    <TD width="6%" align=right bgColor=#EEEEEE ><a href="#page_45">40</a></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><a href="#page_47">Item 13. </a></TD>
    <TD align=left width="83%" ><a href="#page_47">Certain Relationships and Related
      Transactions, and Director Independence </a></TD>
    <TD align=right width="6%" ><a href="#page_47">42</a></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#EEEEEE><a href="#page_47">Item 14. </a></TD>
    <TD width="83%" align=left bgColor=#EEEEEE ><a href="#page_47">Principal
      Accountant Fees and Services </a></TD>
    <TD width="6%" align=right bgColor=#EEEEEE ><a href="#page_47">42</a></TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="83%" >&nbsp; </TD>
    <TD width="6%" align="right" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#EEEEEE><B>PART IV</B> </TD>
    <TD width="83%" align=left  bgColor=#EEEEEE
    >&nbsp;</TD>
    <TD width="6%" align=right  bgColor=#EEEEEE
    >&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="83%" >&nbsp; </TD>
    <TD width="6%" align="right" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#EEEEEE><a href="#page_49">Item 15. </a></TD>
    <TD width="83%" align=left bgColor=#EEEEEE ><a href="#page_49">Exhibits and
      Financial Statement Schedules </a></TD>
    <TD width="6%" align=right bgColor=#EEEEEE ><a href="#page_49">44</a></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><a href="#page_55">Signatures </a></TD>
    <TD align=left width="83%"
><a href="#page_55"></a></TD>
    <TD align=right width="6%"
><a href="#page_55">50</a></TD>
  </TR></TABLE>
<P align=center>iii </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_4></A>
<P align=justify><B>Forward Looking Statements. </B></P>
<P align=justify>This Annual Report on Form 10-K includes forward-looking
statements. All statements other than statements of historical facts contained
in this Annual Report on Form 10-K, including statements regarding our
anticipated future clinical and regulatory milestone events, future financial
position, business strategy and plans and objectives of management for future
operations, are forward-looking statements. The words &#147;believe,&#148; &#147;may,&#148;
&#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;expect&#148; and similar
expressions, as they relate to us, are intended to identify forward-looking
statements. Such forward-looking statements include, without limitation,
statements regarding the anticipated start dates, durations and completion dates
of our ongoing and future clinical studies, statements regarding the anticipated
designs of our future clinical studies, statements regarding our anticipated
future regulatory submissions and statements regarding our anticipated future
cash position. We have based these forward-looking statements largely on our
current expectations and projections about future events, including the
responses we expect from the U.S. Food and Drug Administration, or FDA, and
other regulatory authorities and financial trends that we believe may affect our
financial condition, results of operations, business strategy, preclinical and
clinical trials and financial needs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions including without
limitation the risks described in &#147;Risk Factors&#148; in Part I, Item 1A of this
Annual Report on Form 10-K. These risks are not exhaustive. Other sections of
this Annual Report on Form 10-K include additional factors which could adversely
impact our business and financial performance. Moreover, we operate in a very
competitive and rapidly changing environment. New risk factors emerge from time
to time and it is not possible for our management to predict all risk factors,
nor can we assess the impact of all factors on our business or the extent to
which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements. You should
not rely upon forward-looking statements as predictions of future events. We
cannot assure you that the events and circumstances reflected in the
forward-looking statements will be achieved or occur and actual results could
differ materially from those projected in the forward-looking statements. Except
as required by applicable laws including the securities laws of the United
States and Canada, we assume no obligation to update or supplement
forward-looking statements. </P>
<P align=justify>As used in this Annual Report on Form 10-K, the terms &#147;we,&#148;
&#147;us,&#148; &#147;our,&#148; and &#147;Anavex&#148; mean Anavex Life Sciences Corp., unless the context
clearly requires otherwise.</P>
<P align=center>iv </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>



<A name="page_5"></A>

<P align="justify">
<B>PART I </B></P>
<P align="justify">
<B>ITEM 1. BUSINESS</B></P>
<P align="justify">
We are a pharmaceutical company engaged in the development of drug candidates. Our lead compounds ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept&reg;) are being developed to treat Alzheimer&rsquo;s disease and
potentially other central nervous system (CNS) diseases. </P>
<P align="justify">
In pre-clinical studies conducted in France, and in Greece, ANAVEX 2-73 demonstrated anti-amnesic and neuroprotective properties in various animal models including the transgenic mouse model Tg2576. Based on pre-clinical studies, we sponsored a
Phase 1 single ascending dose study of ANAVEX 2-73 initiated and completed in 2011. This study was conducted in Germany in collaboration with ABX-CRO Advanced Pharmaceutical Services (ABX-CRO). The study indicated that ANAVEX 2-73 was well tolerated
by study subjects in doses up to 55mg. As of the end of the period covered by this report, we have not yet continued our clinical trials due to a lack of funding. </P>
<P align="justify">
The Company plans to continue human clinical trials, among them a multiple ascending dose study of ANAVEX 2-73 and ANAVEX PLUS and a Phase 2 thereafter in the first half of fiscal year 2014. Additionally we intend to identify and initiate
discussions with potential partners in the next 12 months. Further, we may acquire or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further our goals. </P>
<P align="justify">
<B><I>Our Pipeline</I></B> </P>
<P align="justify">
Our pipeline includes one drug candidate and several compounds in different stages of pre-clinical study. </P>
<P align="justify">
Our proprietary SIGMACEPTOR&trade; Discovery Platform produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases,
including Alzheimer&rsquo;s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease. </P>
<P align="justify">
Compounds that have been subjects of our research include the following: </P>
<P align="justify">
<B>ANAVEX 2-73</B> </P>
<P align="justify">
ANAVEX 2-73 may offer a disease-modifying approach in Alzheimer&rsquo;s disease (AD) by using ligands that activate sigma-1 receptors. </P>
<P align="justify">
In AD animal models, ANAVEX 2-73 has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity to sigma-1 receptors and
moderate affinities to M1-4 type muscarinic receptors. In addition, ANAVEX 2-73 has shown a potential dual mechanism which may impact both amyloid and tau pathology. In a transgenic AD animal model Tg2576 ANAVEX 2-73 induces a statistically
significant neuroprotective effect against the development of oxidative stress in the mouse brain, as well as significantly increased the expression of functional and synaptic plasticity markers that is apparently amyloid-beta independent. It also
statistically alleviated the learning and memory deficits developed over
time in the animals, regardless of sex, both in terms of spatial working memory and long-term spatial reference memory. </P>
<P align="center">1</P>
<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_6"></A>
<P align="justify">
Based on the results of pre-clinical testing, we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX 2-73 in 2011. In this Phase 1 SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg.
This dose is above the equivalent dose shown to have positive effects in mouse models of AD. There were no significant changes in laboratory or electrocardiogram (ECG) parameters. ANAVEX 2-73 was well tolerated below the 55-60 mg dose with only mild
adverse events in some subjects. Observed adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were moderate in severity and reversible. These side effects are often seen with drugs that target
central nervous system (CNS) conditions, including AD. </P>
<P align="justify">
The ANAVEX 2-73 Phase 1 SAD trial was conducted as a randomized, placebo-controlled study. Healthy male volunteers between the ages of 18 and 55 received single, ascending oral doses over the course of the trial. Study endpoints included safety and
tolerability together with pharmacokinetic parameters. Pharmacokinetics includes the absorption and distribution of a drug, the rate at which a drug enters the blood and the duration of its effect, as well as chemical changes of the substance in the
body. This study was conducted in Germany in collaboration with ABX-CRO, a clinical research organization that has conducted several Alzheimer&rsquo;s disease studies, and the Technical University of Dresden. </P>
<P align="justify">
<B>ANAVEX PLUS</B> </P>
<P align="justify">
ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept&reg;) is a potential novel combination drug for Alzheimer&rsquo;s disease. Aricept&reg; (donepezil) is now generic and had until recently total sales of about &#36;4 billion annually.
ANAVEX 2-73 showed in combination with Aricept&reg; (donepezil) results for memory improvement by up to 80% in animal models. A patent application was filed in the US for the combination of donepezil (Aricept&reg;) and ANAVEX 2-73 and, if granted,
would extend at least until 2033. ANAVEX PLUS showed an ADAS-Cog response of 7 points at 12 weeks and 5.5 points at 26 weeks. These data represent more than twice the ADAS-Cog response exhibited by Aricept&reg; (donepezil) alone. </P>
<P align="justify">
The animal data was consistent with a humanized calibrated cortical network computer model indicating synergy for ANAVEX 2-73 with Aricept&reg; (donepezil) . </P>
<P align="justify">
<B>ANAVEX 19-144</B> </P>
<P align="justify">
ANAVEX 19-144 is the sole active metabolite of ANAVEX 2-73. Like ANAVEX 2-73, pre-clinical data reveals that ANAVEX 19-144 exhibits significant anti-amnesic, neuroprotective and anticonvulsant properties in a variety of in vitro systems and
specialized animal models. </P>
<P align="justify">
In animal models, ANAVEX 19-144 controls seizures and the epileptogenesis process. Moreover, its neuroprotective properties may prevent the process that causes long-term damage to tissue and cells as well as biochemical and physiological alterations
to the brain from epileptic seizures. </P>
<P align="justify">
<B>ANAVEX 1-41</B> </P>
<P align="justify">
ANAVEX 1-41 is a sigma-1 agonist. Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death) through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and destroys
cells and is believed by some scientists to be a primary cause of AD. In
addition, in animal models, ANAVEX 1-41 prevented the expression of caspase-3,
an enzyme that plays a key role in apoptosis (programmed cell death) and loss of
cells in the hippocampus, the part of the brain that regulates learning, emotion
and memory. These activities involve both muscarinic and sigma-1 receptor
systems through a novel mechanism of action. </P>
<P align="center">2</P>
<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">

<A name=page_7></A>
<P align=justify><B>ANAVEX 7-1037</B> </P>
<P align=justify>ANAVEX 7-1037 is designed for the treatment of prostate cancer.
It is a low molecular weight, synthetic compound exhibiting high affinity for
sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2
receptors and sodium channels at micromolar levels. In advanced pre-clinical
studies, this compound revealed antitumor potential with no toxic side effects.
It has also been shown to selectively kill human cancer cells without affecting
normal/healthy cells and also to significantly suppress tumor growth in
immune-deficient mice models. </P>
<P align=justify>Scientific publications describe sigma receptor ligands
positively, highlighting the possibility that these ligands may stop tumor
growth and induce selective cell death in various tumor cell lines. Sigma
receptors are highly expressed in different tumor cell types. Binding by
appropriate sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In
addition, through tumor cell membrane reorganization and interactions with ion
channels, our drug candidates may play an important role in inhibiting the
processes of metastasis (spreading of cancer cells from the original site to
other parts of the body), angiogenesis (the formation of new blood vessels) and
tumor cell proliferation. </P>
<P align=justify>Our compounds are in the pre-clinical and clinical testing
stages of development, and there is no guarantee that the activity demonstrated
in pre-clinical models will be shown in human testing. </P>
<P align=justify><B><I>Our Target Indications</I></B> </P>
<P align=justify>We have developed compounds with potential application to two
broad categories and several specific indications. The two categories are
diseases of the central nervous system, and cancer. Specific indications
include: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>Alzheimer&#146;s disease &#150; In 2012, 5 million Americans suffered from
  Alzheimer&#146;s disease. The Alzheimer&#146;s Association&#174; reports that by 2025, 6.7
  million Americans will be afflicted by the disease. Medications on the market
  today treat only the symptoms of AD and do not have the ability to stop its
  onset or its progression. There is an urgent and unmet need for a disease
  modifying cure for Alzheimer&#146;s disease. </P>
  <LI>
  <P>Depression - Depression is a major cause of morbidity worldwide according
  to the World Health Organization (&#147;WHO&#148;). Pharmaceutical treatment for
  depression is dominated by blockbuster brands, with the leading nine brands
  accounting for approximately 75% of total sales. However, the dominance of the
  leading brands is waning, largely due to the effects of patent expiration and
  generic competition. Our market research leads us to believe that the
  worldwide market for pharmaceutical treatment of depression exceeds $11
  billion annually. </P>
  <LI>
  <P>seizures. These seizures are transient signs and/or symptoms of abnormal,
  excessive or synchronous neuronal activity in the brain. According to the
  Centers for Disease Control and Prevention, epilepsy affects 2.2 million
  Americans. Today, epilepsy is often controlled, but not cured, with medication
  that is categorized as older traditional anti epileptic drugs and second
  generation anti epileptic drugs. Because epilepsy afflicts sufferers in
  different ways, there is a need for drugs used in combination with both traditional anti epileptic drugs and second generations anti epileptic drugs. Our market research leads us to believe the American market for pharmaceutical treatment of epilepsy exceeds &#36;12 billion
annually. <br>
</P></LI>
</UL><P align="center">3</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>



<A name="page_8"></A>

<UL style="text-align:justify;"><LI>
Neuropathic Pain &ndash; We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of the body. Neuralgia is more difficult to treat than some other types of pain because it does not
respond well to normal pain medications. Special medications have become more specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants. Our market research leads us to believe the worldwide market
for pharmaceutical treatment of neuropathic pain exceeds &#36;5 billion annually. Malignant Melanoma - Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant melanoma accounts for 75%
of all deaths associated with skin cancer. The treatment includes surgical removal of the tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy. Our market research leads us to believe the worldwide market for the pharmaceutical
treatment of malignant melanoma exceeds &#36;200 million annually.<br>
<br>
</LI>
<LI>
Prostate Cancer &ndash; Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. The cancer cells may metastasize from the prostate to other parts of the body, particularly the
bones and lymph nodes. Our market research leads us to believe the worldwide market for the pharmaceutical treatment of prostate cancer exceeds &#36;4 billion annually.<br>
<br>
</LI>
<LI>
Pancreatic Cancer - Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States approximately 45,000 new cases of pancreatic cancer will be diagnosed this year and approximately 38,000 patients will die as a result of their
cancer. Our market research leads us to believe that the market for the pharmaceutical treatment of pancreatic cancer will exceed &#36;1.2 billion by 2015.</LI>
</UL>
<P align="justify">
<B><I>Competition</I></B> </P>
<P align="justify">
The pharmaceutical industry is intensely competitive. </P>
<P align="justify">
At this time, we view our competition as biomedical development companies that are trying to discover and develop compounds to be used in the treatment of Alzheimer&rsquo;s disease, and those companies already doing so. Those companies include Prana
Biotechnology Ltd. (NASDAQ:PRAN), Elan Corporation, PLC (NYSE:ELN), Pfizer Inc. (NYSE:PFE), Forest Laboratories Inc. (NYSE:FRX), Novartis AG (NYSE:NVS), GlaxoSmithKline PLC (NYSE:GSK), Merck &amp; Co. Inc. (NYSE:MRK), Eli Lilly &amp; Co. (NYSE:
LLY), Johnson &amp; Johnson (NYSE:JNJ) and Roche Holding AG (VTX:ROG). </P>
<P align="justify">
Each of our competitors have greater capital resources, larger overall research and development staffs and facilities, and a longer history in drug discovery and development, obtaining regulatory approval, and pharmaceutical product manufacturing
and marketing than we do. With these additional resources, our competitors will be able to respond to the rapid and significant technological changes in the biotechnology and pharmaceutical industries faster than we can. Our future success will
depend in large part on our ability to acquire funding for our research and development. To continue to acquire funding for our research and development, we will likely have to show progress toward our goals and we will eventually be expected to
develop a compound that may result in a transaction with another pharmaceutical company. </P><P align="center">4</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">

<A name=page_9></A>
<P align=justify>Our research and development is highly speculative and we may
never discover or develop any compounds that we are capable of selling. </P>
<P align=justify>Rapid technological development, as well as new scientific
developments, and economic circumstances may result in our compounds becoming
obsolete before we can recover any of the expenses incurred to develop them.
</P>
<P align=justify><B><I>Patents, Trademarks and Intellectual Property
</I></B></P>
<P align=justify>We are pursuing three U.S. patent applications. Two of the
three patent applications are based on parent Greek patent applications. There
are corresponding international patent filings. The most recent of the three
applications was independently drafted and filed July 12, 2013. On this most
recent patent application, Anavex is awaiting a contractually obligated patent
assignment document from one of the two named inventors. </P>
<P align=justify>Patents we currently own include:</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left bgcolor="#D8CEFE">
      <P align=justify>Patent <BR>Number </P></TD>
    <TD width="18%" align=left bgcolor="#D8CEFE">
      <P align=justify>Jurisdiction <BR></P></TD>
    <TD width="18%" align=left bgcolor="#D8CEFE">
      <P align=justify>Filing and <BR>Expiration Dates </P></TD>
    <TD width="45%" align=left bgcolor="#D8CEFE" >
    <P align=justify>Invention Title <BR></P></TD></TR>
  <TR vAlign=top>
    <TD align=left bgcolor="#D8CEFE">
      <P align=justify>1002616 </P></TD>
    <TD width="18%" align=left bgcolor="#D8CEFE">
      <P align=justify>Greece </P></TD>
    <TD width="18%" align=left bgcolor="#D8CEFE">
      <P align=justify>February 21, 1996 <BR>February 22, 2016 </P></TD>
    <TD width="45%" align=left bgcolor="#D8CEFE" >
      <P align=justify>Synthesis and method of synthesis of a molecular (AE 37)
    of anticonvulsant, antidepressant and neuroleptic tropic action.</P></TD></TR>
  <TR vAlign=top>
    <TD align=left bgcolor="#D8CEFE">
      <P align=justify>1004208 </P></TD>
    <TD width="18%" align=left bgcolor="#D8CEFE">
      <P align=justify>Greece </P></TD>
    <TD width="18%" align=left bgcolor="#D8CEFE">
      <P align=justify>October 15, 2001 <BR>October 14, 2021 </P></TD>
    <TD width="45%" align=left bgcolor="#D8CEFE" >
      <P align=justify>AMINOTETRAHYDROFURAN DERIVATIVES, MUSCARINIC/SIGMA/SODIUM
      CHANNEL LIGANDS, WITH SYNERGIC SIGMA/MUSCARINIC (NEUROACTIVATING) AND
      SIGMA/SODIUM CHANNEL (NEUROPROTECTIVE) COMPONENTS, AS PROTOTYPICAL
      ACTIVATING - NEUROPROTECTORS AND NEUROREGENERATIVE DRUGS </P></TD></TR>
  <TR vAlign=top>
    <TD align=left bgcolor="#D8CEFE">
      <P align=justify>1004868 </P></TD>
    <TD width="18%" align=left bgcolor="#D8CEFE">
      <P align=justify>Greece </P></TD>
    <TD width="18%" align=left bgcolor="#D8CEFE">
      <P align=justify>April 22, 2003 <BR>April 21, 2023 </P></TD>
    <TD width="45%" align=left bgcolor="#D8CEFE" >
      <P align=justify>AMINOTETRAHYDROFURAN DERIVATIVES, MUSCARINIC/SIGMA/SODIUM
      CHANNEL LIGANDS, ORTHO-AND ALLO-STERICALLY OPERATING, AS PROTOTYPICAL
      NEUROMEODULATING AND NEUROREGENERATIVE DRUGS. </P></TD></TR>
  <TR vAlign=top>
    <TD align=left bgcolor="#D8CEFE">
      <P align=justify>1005865 </P></TD>
    <TD width="18%" align=left bgcolor="#D8CEFE">
      <P align=justify>Greece </P></TD>
    <TD width="18%" align=left bgcolor="#D8CEFE">
      <P align=justify>January 17, 2007 <BR>January 16, 2027 </P></TD>
    <TD width="45%" align=left bgcolor="#D8CEFE" >
      <P align=justify>NEW SIGMA LIGANDS with anti-apoptotic and/or
      pro-apoptotic action on the cells biochemical mechanisms and
      neuroprotective, anti-cancer, anti- metastatic, and anti-chronic
      inflammatory properties. </P></TD></TR>
  <TR vAlign=top>
    <TD align=left bgcolor="#D8CEFE">
      <P align=justify>1006794 </P></TD>
    <TD width="18%" align=left bgcolor="#D8CEFE">
      <P align=justify>Greece </P></TD>
    <TD width="18%" align=left bgcolor="#D8CEFE">
      <P align=justify>February 26, 2009 <BR>February 27, 2029 </P></TD>
    <TD width="45%" align=left bgcolor="#D8CEFE" >
      <P align=justify>THE NEW SIGMA(&#963;)-RECEPTOR LIGANDS WITH ANTI-APOPTOTIC
      AND/OR PRO- APOPTOTIC PROPERTIES OVER CELLULAR BIOCHEMICAL MECHANISMS,
  WITH NEUROPROTECTIVE, ANTI-CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION.  </P></TD></TR></TABLE>
</DIV><BR><P align="center">5</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_10></A><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>
  <TR vAlign=top>
    <TD align=left bgcolor="#D8CEFE">1007686 </TD>
    <TD width="18%" align=left bgcolor="#D8CEFE">Greece </TD>
    <TD width="18%" align=left bgcolor="#D8CEFE">July 8, 2011 <BR>
      July 9, 2031 </TD>
    <TD width="45%" align=left bgcolor="#D8CEFE" >
      <P align=justify>SYNTHESIS OF (+)- AND (-)-1-(5,5-
      DIPHENYLTETRAHYDROFURAN-3-YL)-N,N- DIMETHYLMETHYLAMINE, (+)-AND (-)-1-
      (2,2-DIPHENYLTETRAHYDROFURAN-3-YL)- N,N-DIMETHYLMETHYLAMINE AND (+)- AND
      (-)-1-(2,2- DIPHENYLTETRAHYDROFURAN-3-YL)-N- METHYLMETHYLAMINE </P></TD></TR>
  <TR>
    <TD vAlign=top bgcolor="#D8CEFE">1007322 </TD>
    <TD width="18%" vAlign=top bgcolor="#D8CEFE">Greece </TD>
    <TD width="18%" vAlign=top bgcolor="#D8CEFE">March 9, 2010<BR>
      March 10, 2030 </TD>
    <TD width="45%" vAlign=top bgcolor="#D8CEFE" >
      <P align=justify>SYNTHESIS OF 1-METHYL-4-[4,4-DIPHENYL-4-
      (1-ADAMANTYL)-BUTYL] PIPERAZINE AND ANALOGUES THEREOF WITH ANTI-CANCER
      PROPERTIES </P></TD></TR></TABLE>
</DIV>
<P align=justify>We regard patents and other proprietary technology rights as
corporate assets. Accordingly, we attempt to optimize the value of intellectual
property in developing our business strategy including the selective
development, protection, and exploitation of our intellectual property rights.
</P>
<P align=justify>In addition to filings made with intellectual property
organizations, we protect our intellectual property and confidential information
by means of carefully considered processes of communication and the sharing of
information, and by the use of confidentiality and non-disclosure agreements and
provisions for the same in contractor&#146;s agreements. While no agreement offers
absolute protection, such agreements provide some form of recourse in the event
of disclosure, or anticipated disclosure. </P>
<P align=justify>Our patent position, like that of many biomedical companies, is
uncertain and involves complex legal and technical questions for which important
legal principles are unresolved. We may file additional patent applications in
the United States, or in other jurisdictions for further inventions. We may not
be successful in obtaining critical claims or in protecting our potential drug
compounds or processes. Even if we do obtain patents, they may not adequately
protect the technology we own or have licensed. In addition, others may
challenge, seek to invalidate, infringe or circumvent any patents we own or
license, and rights we receive under those patents may not provide competitive
advantages to us. Further, the manufacture, use or sale of our potential drug
compounds may infringe the patent rights of others. </P>
<P align=justify>Our success will also depend in part on our ability to
commercialize our compounds without infringing the proprietary rights of others.
We have not conducted extensive freedom of use patent searches and no assurance
can be given that patents do not exist or could not be filed which would have an
adverse effect on our ability to market our technology or maintain our
competitive position with respect to our technology. If our compounds or other
subject matter are claimed under other existing United States or other patents
or are otherwise protected by third party proprietary rights, we may be subject
to infringement actions. In such event, we may challenge the validity of such
patents or other proprietary rights or we may be required to obtain licenses
from such companies in order to develop, manufacture or market our technology.
There can be no assurances that we would be able to obtain such licenses or that
such licenses, if available, could be obtained on commercially reasonable terms.
Furthermore, the failure to either develop a commercially viable alternative or
obtain such licenses could result in delays in marketing all of our potential
drug compounds based on our drug technology or the inability to proceed
with the development, manufacture or sale of potential drug compounds requiring such licenses, which could have a material adverse effect on our business, financial condition and results of operations. If we defend ourselves against charges of
patent infringement or to protect our proprietary rights against third parties, substantial costs will be incurred regardless of whether we are successful. Such proceedings are typically protracted with no certainty of success. An adverse outcome
could subject us to significant liabilities to third parties and force us to curtail or cease our research and development of our technology. </P><P align="center">6</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>



<A name="page_11"></A>
<P align="justify">
<B><I>Government Approval </I></B></P>
<P align="justify">
Regulation by governmental authorities in the United States and foreign countries is a significant factor in the development, manufacture, and expected marketing of our potential drug compounds and in potential future research and development
activities. The nature and extent to which such regulation will apply to us will vary depending on the nature of any potential drug compounds developed. We anticipate that all of our potential drug compounds will require regulatory approval by
governmental agencies prior to commercialization. </P>
<P align="justify">
In particular, human therapeutic products are subject to rigorous non-clinical and clinical testing and other approval procedures of the FDA and similar regulatory authorities in other countries. Various federal statutes and regulations also govern
or influence testing, manufacturing, safety, labeling, storage, and record-keeping related to such products and their marketing. The process of obtaining these approvals and the subsequent compliance with the appropriate federal statutes and
regulations requires substantial time and financial resources. Any failure by us or our collaborators to obtain, or any delay in obtaining, regulatory approval could adversely affect the marketing of any potential drug compounds developed by us, our
ability to receive product revenues, and our liquidity and capital resources. </P>
<P align="justify">
The steps ordinarily required before a new drug may be marketed in the United States, which are similar to steps required in most other countries, include: </P>
<UL style="text-align:justify;">
<LI>
non-clinical laboratory tests, non-clinical studies in animals, formulation studies and the submission to the FDA of an investigational new drug application;</LI>
<LI>
adequate and well-controlled clinical trials to establish the safety and efficacy of the drug;</LI>
<LI>
the submission of a new drug application or biologic license application to the FDA; and</LI>
<LI>
FDA review and approval of the new drug application or biologics license application.</LI>
</UL>
<P align="justify">
Non-clinical tests include laboratory evaluation of potential drug compound chemistry, formulation and toxicity, as well as animal studies. The results of non-clinical testing are submitted to the FDA as part of an investigational new drug
application. A 30-day waiting period after the filing of each investigational new drug application is required prior to commencement of clinical testing in humans. At any time during the 30-day period or at any time thereafter, the FDA may halt
proposed or ongoing clinical trials until the FDA authorizes trials under specified terms. The investigational new drug application process may be extremely costly and substantially delay the development of our potential drug compounds. Moreover,
positive results of non-clinical tests will not necessarily indicate positive results in subsequent clinical trials. The FDA may require additional animal testing after an initial investigational new drug application is approved and prior to Phase
III trials. </P>
<P align="justify">
Clinical trials to support new drug applications are typically conducted in three sequential phases, although the phases may overlap. During Phase I, clinical trials are conducted with a small number of subjects to assess metabolism,
pharmacokinetics, and pharmacological actions and safety, including side effects associated with increasing doses. Phase II usually involves studies in a limited patient population
to assess the efficacy of the drug in specific, targeted indications; assess dosage tolerance and optimal dosage; and identify possible adverse effects and safety risks. </P>
<P align="center">7</P>
<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_12"></A>
<P align="justify">
If a compound is found to be potentially effective and to have an acceptable safety profile in Phase I and II evaluations, Phase III trials are undertaken to further demonstrate clinical efficacy and to further test for safety within an expanded
patient population at geographically dispersed clinical trial sites. </P>
<P align="justify">
After successful completion of the required clinical trials, a new drug application is generally submitted. The FDA may request additional information before accepting the new drug application for filing, in which case the new drug application must
be resubmitted with the additional information. Once the submission has been accepted for filing, the FDA reviews the new drug application and responds to the applicant. The FDA&rsquo;s requests for additional information or clarification often
significantly extends the review process. The FDA may refer the new drug application to an appropriate advisory committee for review, evaluation, and recommendation as to whether the new drug application should be approved, although the FDA is not
bound by the recommendation of an advisory committee. </P>
<P align="justify">
Sales outside the United States of potential drug compounds we develop will also be subject to foreign regulatory requirements governing human clinical trials and marketing for drugs. The requirements vary widely from country to country, but
typically the registration and approval process takes several years and requires significant resources. In most cases, if the FDA has not approved a potential drug compound for sale in the United States, the potential drug compound may be exported
for sale outside of the United States, only if it has been approved in any one of the following: the European Union, Canada, Australia, New Zealand, Japan, Israel, Switzerland and South Africa. There are specific FDA regulations that govern this
process. </P>
<P align="justify">
<B><I>Research and Development Expenses</I></B> </P>
<P align="justify">
Historically, a significant portion of our operating expenses has related to research and development. Recently, we have significantly curtailed our spending on research and development. See Item 8 &ldquo;Financial Statements and Supplementary
Data&rdquo; of this Annual Report on Form 10-K for costs and expenses related to research and development, and other financial information for fiscal years 2013 and 2012. </P>
<P align="justify">
<B><I>Scientific Advisors</I></B> </P>
<P align="justify">
We are advised by scientists and physicians with experience relevant to our company and our product candidates. In the past twelve months, our advisors included Alexandre Vamvakides, Ph.D., Tangui Nicolas Maurice, Ph.D., Christopher Missling, Ph.D.,
Dr. Paul Aisen, Dr. Rachelle Doody, and Dr. Jeffrey Cummings. </P>
<P align="justify">
<B><I>Officers</I></B> </P>
<P align="justify">
One of our directors is engaged as an officer-employee of the Company serving in the capacity of president, secretary, treasurer, chief executive officer and chief financial officer. </P>
<P align="justify">
<B><I>Employees</I></B> </P>
<P align="justify">
We currently have one (1) full-time employee, and we retain several independent contractors on an as-needed basis. We believe that we have good relations with our employees. </P>
<P align="center">8</P>
<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_13"></A>

<P align="justify">
<B>ITEM 1 A. RISK FACTORS </B></P>
<P align="justify">
In addition to other information in this Annual Report on Form 10-K, the following risk factors should be carefully considered in evaluating our business because such factors may have a significant impact on our business, operating results,
liquidity and financial condition. As a result of the risk factors set forth below, actual results could differ materially from those projected in any forward-looking statements. Additional risks and uncertainties not presently known to us, or that
we currently consider to be immaterial, may also impact our business, operating results, liquidity and financial condition. If any such risks occur, our business, operating results, liquidity and financial condition could be materially affected in
an adverse manner. Under such circumstances, the trading price of our securities could decline, and you may lose all or part of your investment. </P>
<P align="justify">
<B><I>Risks Related to our Company</I></B> </P>
<P align="justify">
<B><I>We have had a history of losses and no revenue, which raise substantial doubt about our ability to continue as a going concern.</I></B> </P>
<P align="justify">Since inception on January 23, 2004 through September 30, 2013, we have accumulated losses of $40,654,168. As of September 30, 2013, we had a working capital deficiency of $1,559,211. We can offer no assurance that we will ever operate profitably or that we will generate positive cash flow in the future. To date, we have not generated any revenues from our operations. Our history of losses and no revenues raise substantial doubt about our ability to continue as a going concern. As a result, our management expects the business to continue to experience negative cash flow for the foreseeable future and cannot predict when, if ever, our business might become profitable. We will need to raise additional funds, and such funds may not be available on commercially acceptable terms, if at all. If we are unable to raise funds on acceptable terms, we may not be able to execute our business plan, take advantage of future opportunities, or respond to competitive pressures or unanticipated requirements. This may seriously harm our business, financial condition and results of operations.</P>
<P align="justify">
<B><I>We are an early development stage pharmaceutical research and development company and may never be able to successfully develop marketable products or generate any revenue. We have a very limited relevant operating history upon which an
evaluation of our performance and prospects can be made. There is no assurance that our future operations will result in profits. If we cannot generate sufficient revenues, we may suspend or cease operations.</I></B> </P>
<P align="justify">
We are an early development stage company and have not generated any revenues to date and have no operating history. All of our potential drug compounds are in the concept stage or early clinical development stage. Moreover, we cannot be certain
that our research and development efforts will be successful or, if successful, that our potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues. We have no relevant operating history upon
which an evaluation of our performance and prospects can be made. We are subject to all of the business risks associated with a new enterprise, including, but not limited to, risks of unforeseen capital requirements, failure of potential drug
compounds either in non-clinical testing or in clinical trials, failure to establish business relationships and competitive disadvantages against larger and more established companies. If we fail to become profitable, we may suspend or cease
operations. </P>
<P align="justify">
<B><I>We will need additional funding and may be unable to raise additional capital when needed, which would force us to delay, reduce or eliminate our research and development activities.</I></B> </P>
<P align="center">9</P>
<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">

<A name=page_14></A>
<P align=justify>We will need to raise additional funding and the current
economic conditions may have a negative impact on our ability to raise
additional needed capital on terms that are favorable to our company or at all.
We may not be able to generate significant revenues for several years, if at
all. Until we can generate significant revenues, if ever, we expect to satisfy
our future cash needs through equity or debt financing. We cannot be certain
that additional funding will be available on acceptable terms, or at all. If
adequate funds are not available, we may be required to delay, reduce the scope
of, or eliminate one or more of our research and development activities. </P>
<P align=justify><B><I>We may be unable to continue as a going concern in which
case our securities will have little or no value.</I></B> </P>
<P align=justify>Our independent auditors have noted in their report concerning
our annual financial statements for the fiscal year ended September 30, 2013
that we have incurred substantial losses since inception, which raises
substantial doubt about our ability to continue as a going concern. In the event
we are not able to continue operations you will likely suffer a complete loss of
your investment in our securities. </P>
<P align=justify><B><I>Risks Related to our Business</I></B> </P>
<P align=justify><B><I>Even if we are able to develop our potential drug
compounds, we may not be able to receive regulatory approval, or if approved, we
may not be able to generate significant revenues or successfully commercialize
our products, which will adversely affect our financial results and financial
condition and we will have to delay or terminate some or all of our research and
development plans and we may be forced to cease operations.</I></B> </P>
<P align=justify>All of our potential drug compounds will require extensive
additional research and development, including non-clinical testing and clinical
trials, as well as regulatory approvals, before we can market them. We cannot
predict if or when any of the potential drug compounds we intend to develop will
be approved for marketing. There are many reasons that we may fail in our
efforts to develop our potential drug compounds. These include: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>the possibility that non-clinical testing or clinical trials may show that
  our potential drug compounds are ineffective and/or cause harmful side
  effects; </P>
  <LI>
  <P>our potential drug compounds may prove to be too expensive to manufacture
  or administer to patients; </P>
  <LI>
  <P>our potential drug compounds may fail to receive necessary regulatory
  approvals from the United States Food and Drug Administration or foreign
  regulatory authorities in a timely manner, or at all; </P>
  <LI>
  <P>even if our potential drug compounds are approved, we may not be able to
  produce them in commercial quantities or at reasonable costs; </P>
  <LI>
  <P>even if our potential drug compounds are approved, they may not achieve
  commercial acceptance; </P>
  <LI>
  <P>regulatory or governmental authorities may apply restrictions to any of our
  potential drug compounds, which could adversely affect their commercial
  success; and </P>
  <LI>
  <P>the proprietary rights of other parties may prevent us or our potential
  collaborative partners from marketing our potential drug compounds.
</P></LI></UL><P align="center">10</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_15></A>
<P align=justify>If we fail to develop our potential drug compounds, our
financial results and financial condition will be adversely affected, we will
have to delay or terminate some or all of our research and development plans and
may be forced to cease operations. </P>
<P align=justify><B><I>Our research and development plans will require
substantial additional future funding which could impact our operational and
financial condition. Without the required additional funds, we will likely cease
operations.</I></B> </P>
<P align=justify>It will take several years before we are able to develop
potentially marketable products, if at all. Our research and development plans
will require substantial additional capital, arising from costs to: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>conduct research, non-clinical testing and human studies; </P>
  <LI>
  <P>establish pilot scale and commercial scale manufacturing processes and
  facilities; and </P>
  <LI>
  <P>establish and develop quality control, regulatory, marketing, sales,
  finance and administrative capabilities to support these programs.
</P></LI></UL>
<P align=justify>Our future operating and capital needs will depend on many
factors, including: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>the pace of scientific progress in our research and development programs
  and the magnitude of these programs; </P>
  <LI>
  <P>the scope and results of pre-clinical testing and human studies; </P>
  <LI>
  <P>the time and costs involved in obtaining regulatory approvals; </P>
  <LI>
  <P>the time and costs involved in preparing, filing, prosecuting, maintaining
  and enforcing patents; </P>
  <LI>
  <P>competing technological and market developments; </P>
  <LI>
  <P>our ability to establish additional collaborations; </P>
  <LI>
  <P>changes in our existing collaborations; </P>
  <LI>
  <P>the cost of manufacturing scale-up; and </P>
  <LI>
  <P>the effectiveness of our commercialization activities. </P></LI></UL>
<P align=justify>We base our outlook regarding the need for funds on many
uncertain variables. Such uncertainties include the success of our research
initiatives, regulatory approvals, the timing of events outside our direct
control such as negotiations with potential strategic partners and other
factors. Any of these uncertain events can significantly change our cash
requirements as they determine such one-time events as the receipt or payment of
major milestones and other payments. </P>
<P align=justify>Additional funds will be required to support our operations and
if we are unable to obtain them on favorable terms, we may be required to cease
or reduce further research and development of our drug product programs, sell
some or all of our intellectual property, merge with another entity or cease
operations. </P>
<P align=justify><B><I>If we fail to demonstrate efficacy in our non-clinical
studies and clinical trials our future business prospects, financial condition
and operating results will be materially adversely affected.</I></B> </P>
<P align=center>11</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_16></A>
<P align=justify>The success of our research and development efforts will be
greatly dependent upon our ability to demonstrate potential drug compound
efficacy in non-clinical studies, as well as in clinical trials. Non-clinical
studies involve testing potential drug compounds in appropriate non-human
disease models to demonstrate efficacy and safety. Regulatory agencies evaluate
these data carefully before they will approve clinical testing in humans. If
certain non-clinical data reveals potential safety issues or the results are
inconsistent with an expectation of the potential drug compound&#146;s efficacy in
humans, the regulatory agencies may require additional more rigorous testing,
before allowing human clinical trials. This additional testing will increase
program expenses and extend timelines. We may decide to suspend further testing
on our potential drug compounds if, in the judgment of our management and
advisors, the non-clinical test results do not support further development. </P>
<P align=justify>Moreover, success in non-clinical testing and early clinical
trials does not ensure that later clinical trials will be successful, and we
cannot be sure that the results of later clinical trials will replicate the
results of prior clinical trials and non-clinical testing. The clinical trial
process may fail to demonstrate that our potential drug compounds are safe for
humans and effective for indicated uses. This failure would cause us to abandon
a drug candidate and may delay development of other potential drug compounds.
Any delay in, or termination of, our non-clinical testing or clinical trials
will delay the filing of an investigational new drug application and new drug
application with the Food and Drug Administration or the equivalent applications
with pharmaceutical regulatory authorities outside the United States and,
ultimately, our ability to commercialize our potential drug compounds and
generate product revenues. In addition, we expect that our early clinical trials
will involve small patient populations. Because of the small sample size, the
results of these early clinical trials may not be indicative of future results.
</P>
<P align=justify>Following successful non-clinical testing, potential drug
compounds will need to be tested in a clinical development program to provide
data on safety and efficacy prior to becoming eligible for product approval and
licensure by regulatory agencies. From the first human trial through to
regulatory approval can take many years and 10-12 years is not unusual for
certain compounds. </P>
<P align=justify>If any of our future clinical development potential drug
compounds become the subject of problems, our ability to sustain our development
programs will become critically compromised. For example, efficacy or safety
concerns may arise, whether or not justified, that could lead to the suspension
or termination of our clinical programs. Examples of problems that could arise
include, among others: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>efficacy or safety concerns with the potential drug compounds, even if not
  justified; </P>
  <LI>
  <P>manufacturing difficulties or concerns; </P>
  <LI>
  <P>regulatory proceedings subjecting the potential drug compounds to potential
  recall; </P>
  <LI>
  <P>publicity affecting doctor prescription or patient use of the potential
  drug compounds; </P>
  <LI>
  <P>pressure from competitive products; or </P>
  <LI>
  <P>introduction of more effective treatments. </P></LI></UL>
<P align=justify>Each clinical phase is designed to test attributes of the drug
and problems that might result in the termination of the entire clinical plan
can be revealed at any time throughout the overall clinical program. The failure
to demonstrate efficacy in our clinical trials would have a material adverse
effect on our future business prospects, financial condition and operating
results. </P>
<P align=justify><B><I>If we do not obtain the support of qualified scientific
collaborators, our revenue, growth and profitability will likely be limited,
which would have a material adverse effect on our business.</I></B> </P>
<P align=center>12</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_17></A>
<P align=justify>We will need to establish relationships with leading scientists
and research institutions. We believe that such relationships are pivotal to
establishing products using our technologies as a standard of care for various
indications. Additionally, although in discussion, there is no assurance that
our current research partners will continue to work with us or that we will be
able to attract additional research partners. If we are not able to establish
scientific relationships to assist in our research and development, we may not
be able to successfully develop our potential drug compounds. If this happens,
our business will be adversely affected. </P>
<P align=justify><B><I>We may not be able to develop market or generate sales of
our products to the extent anticipated. Our business may fail and investors
could lose all of their investment in our company.</I></B> </P>
<P align=justify>Assuming that we are successful in developing our potential
drug compounds and receiving regulatory clearances to market our products, our
ability to successfully penetrate the market and generate sales of those
products may be limited by a number of factors, including the following: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>If our competitors receive regulatory approvals for and begin marketing
  similar products in the United States, the European Union, Japan and other
  territories before we do, greater awareness of their products as compared to
  ours will cause our competitive position to suffer; </P>
  <LI>
  <P>Information from our competitors or the academic community indicating that
  current products or new products are more effective or offer compelling other
  benefits than our future products could impede our market penetration or
  decrease our future market share; and </P>
  <LI>
  <P>The pricing and reimbursement environment for our future products, as well
  as pricing and reimbursement decisions by our competitors and by payers, may
  have an effect on our revenues. </P></LI></UL>
<P align=justify>If this happens, our business will be adversely affected. </P>
<P align=justify><B><I>None of our potential drug compounds may reach the
commercial market for a number of reasons and our business may fail.</I></B>
</P>
<P align=justify>Successful research and development of pharmaceutical products
is high risk. Most products and development candidates fail to reach the market.
Our success depends on the discovery of new drug compounds that we can
commercialize. It is possible that our products may never reach the market for a
number of reasons. They may be found ineffective or may cause harmful
side-effects during non-clinical testing or clinical trials or fail to receive
necessary regulatory approvals. We may find that certain products cannot be
manufactured at a commercial scale and, therefore, they may not be economical to
produce. Our potential products could also fail to achieve market acceptance or
be precluded from commercialization by proprietary rights of third parties. Our
patents, patent applications, trademarks and other intellectual property may be
challenged and this may delay or prohibit us from effectively commercializing
our products. Furthermore, we do not expect our potential drug compounds to be
commercially available for a number of years, if at all. If none of our
potential drug compounds reach the commercial market, our business will likely
fail and investors will lose all of their investment in our company. If this
happens, our business will be adversely affected. </P>
<P align=justify><B><I>If our competitors succeed in developing products and
technologies that are more effective or with a better profile than our own, or
if scientific developments change our understanding of the potential scope and
utility of our potential products, then our technologies and future products may
be rendered undesirable or obsolete.</I></B> </P>
<P align=center>13</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>



<A name="page_18"></A>

<P align="justify">
We face significant competition from industry participants that are pursuing technologies in similar disease states to those that we are pursuing and are developing pharmaceutical products that are competitive with our products. Nearly all of our
industry competitors have greater capital resources, larger overall research and development staffs and facilities, and a longer history in drug discovery and development, obtaining regulatory approval and pharmaceutical product manufacturing and
marketing than we do. With these additional resources, our competitors may be able to respond to the rapid and significant technological changes in the biotechnology and pharmaceutical industries faster than we can. Our future success will depend in
large part on our ability to maintain a competitive position with respect to these technologies. Rapid technological development, as well as new scientific developments, may result in our products becoming obsolete before we can recover any of the
expenses incurred to develop them. For example, changes in our understanding of the appropriate population of patients who should be treated with a targeted therapy like we are developing may limit the drug&rsquo;s market potential if it is
subsequently demonstrated that only certain subsets of patients should be treated with the targeted therapy. </P>
<P align="justify">
<B><I>Our reliance on third parties, such as university laboratories, contract manufacturing organizations and contract or clinical research organizations, may result in delays in completing, or a failure to complete, non-clinical testing or
clinical trials if they fail to perform under our agreements with them.</I></B> </P>
<P align="justify">
In the course of product development, we may engage university laboratories, other biotechnology companies or contract or clinical manufacturing organizations to manufacture drug material for us to be used in non-clinical and clinical testing and
contract research organizations to conduct and manage non-clinical and clinical studies. If we engage these organizations to help us with our non-clinical and clinical programs, many important aspects of this process have been and will be out of our
direct control. If any of these organizations we may engage in the future fail to perform their obligations under our agreements with them or fail to perform non-clinical testing and/or clinical trials in a satisfactory manner, we may face delays in
completing our clinical trials, as well as commercialization of any of our potential drug compounds. Furthermore, any loss or delay in obtaining contracts with such entities may also delay the completion of our clinical trials, regulatory filings
and the potential market approval of our potential drug compounds. </P>
<P align="justify">
<B><I>If we fail to compete successfully with respect to partnering, licensing, mergers, acquisitions, joint venture and other collaboration opportunities, we may be limited in our ability to research and develop our potential drug
compounds.</I></B> </P>
<P align="justify">
Our competitors compete with us to attract established biotechnology and pharmaceutical companies or organizations for partnering, licensing, mergers, acquisitions, joint ventures or other collaborations. Collaborations include contracting with
academic research institutions for the performance of specific scientific testing. If our competitors successfully enter into partnering arrangements or license agreements with academic research institutions, we will then be precluded from pursuing
those specific opportunities. Since each of these opportunities is unique, we may not be able to find a substitute. Other companies have already begun many drug development programs, which may target diseases that we are also targeting, and have
already entered into partnering and licensing arrangements with academic research institutions, reducing the pool of available opportunities. </P>
<P align="justify">
Universities and public and private research institutions also compete with us. While these organizations primarily have educational or basic research objectives, they may develop proprietary technology and acquire patent applications and patents
that we may need for the development of our potential drug compounds. We will attempt to license this proprietary technology, if available. These licenses may not be available to us on acceptable terms, if at all. If we are unable to compete
successfully with respect to acquisitions, joint venture and other collaboration
opportunities, we may be limited in our ability to develop new products. </P>
<P align="center">14</P>
<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">

<A name=page_19></A>
<P align=justify><B><I>The use of any of our products in clinical trials may
expose us to liability claims, which may cost us significant amounts of money to
defend against or pay out, causing our business to suffer.</I></B> </P>
<P align=justify>The nature of our business exposes us to potential liability
risks inherent in the testing, manufacturing and marketing of our products. We
currently have one drug compound in clinical trials, however, when any of our
products enter into clinical trials or become marketed products they could
potentially harm people or allegedly harm people and we may be subject to costly
and damaging product liability claims. Some of the patients who participate in
clinical trials are already ill when they enter a trial or may intentionally or
unintentionally fail to meet the exclusion criteria. The waivers we obtain may
not be enforceable and may not protect us from liability or the costs of product
liability litigation. Although we intend to obtain product liability insurance
that we believe is adequate, we are subject to the risk that our insurance will
not be sufficient to cover claims. The insurance costs along with the defense or
payment of liabilities above the amount of coverage could cost us significant
amounts of money and management distraction from other elements of the business,
causing our business to suffer. </P>
<P align=justify><B><I>The patent positions of biopharmaceutical products are
complex and uncertain and we may not be able to protect our patented or other
intellectual property. If we cannot protect this property, we may be prevented
from using it or our competitors may use it and our business could suffer
significant harm. Also, the time and money we spend on acquiring and enforcing
patents and other intellectual property will reduce the time and money we have
available for our research and development, possibly resulting in a slow down or
cessation of our research and development.</I></B> </P>
<P align=justify>We own patents and patent applications (or have contractual
obligations of assignment) related to our potential drug compounds. However,
neither the patents nor patent applications ensure the protection of our
intellectual property for a number of reasons, including the following:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">1. </TD>
    <TD>
      <P align=justify>Competitors may interfere with our patenting process in a
      variety of ways. Competitors may claim that they invented the claimed
      invention prior to us. Competitors may also claim that we are infringing
      their patents and restrict our freedom to operate. Competitors may also
      contest our patents and patent application, if issued, by showing the
      patent examiner that the invention was not original, was not novel or was
      obvious. In litigation, a competitor could claim that our patents and
      patent application are not valid for a number of reasons. If a court
      agrees, we would lose that patents or patent application. As a company, we
      have no meaningful experience with competitors interfering with our
      patents or patent applications.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">2. </TD>
    <TD>
      <P align=justify>Because of the time, money and effort involved in
      obtaining and enforcing patents, our management may spend less time and
      resources on developing potential drug compounds than they otherwise
      would, which could increase our operating expenses and delay product
      programs.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">3. </TD>
    <TD>
      <P align=justify>Issuance of a patent may not provide much practical
      protection. If we receive a patent with a narrow scope, then it may be
      easier for competitors to design products that do not infringe our
      patent(s).</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">4. </TD>
    <TD>
      <P align=justify>No patents have been issued yet in the United
    States.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">5. </TD>
    <TD>
      <P align=justify>Our primary patent application for the combination of
      ANAVEX 2-73 with donepezil is pending only in the United States Patent and
      Trademark Office The lack of patent protection in global markets may
      inhibit our ability to advance our compounds and may make Anavex less
      attractive to potential partners We would scale this paragraph back. We
      have discussed Greece IP before. Also India, Russia and China. The edit is
  my take on a far more limited statement.</P></TD></TR></TABLE>
<BR><P align="center">15</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_20></A>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>Defending a lawsuit takes significant time and can be
      very expensive.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>If a court decides that our drug compound, its method of
      manufacture or use, infringes on the competitor&#146;s patent, we may have to
      pay substantial damages for past infringement.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>The court may prohibit us from making, selling or
      licensing the potential drug compound unless the patent holder grants a
      license. The patent holder is not required to grant us a license. If a
      license is available, we may have to pay substantial royalties or grant
      cross licenses to our patents, and the license terms may be
      unacceptable.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(d) </TD>
    <TD>
      <P align=justify>Redesigning our potential drug compounds so that they do
      not infringe on other patents may not be possible or could require
      substantial funds and time.</P></TD></TR></TABLE>
<P align=justify>It is also unclear whether our trade secrets are adequately
protected. While we use reasonable efforts to protect our trade secrets, our
employees or consultants may unintentionally or willfully disclose our
information to competitors. Enforcing a claim that someone illegally obtained
and is using our trade secrets, like patent litigation, is expensive and time
consuming, and the outcome is unpredictable. In addition, courts outside the
United States are sometimes less willing to protect trade secrets. Our
competitors may independently develop equivalent knowledge, methods and
know-how. </P>
<P align=justify>We may also support and collaborate in research conducted by
government organizations, hospitals, universities or other educational
institutions. These research partners may be unable or unwilling to grant us
exclusive rights to technology or products derived from these collaborations
prior to entering into the relationship. </P>
<P align=justify>If we do not obtain required licenses or rights, we could
encounter delays in our product development efforts while we attempt to design
around other patents or even be prohibited from developing, manufacturing or
selling potential drug compounds requiring these rights or licenses. There is
also a risk that disputes may arise as to the rights to technology or potential
drug compounds developed in collaboration with other parties. </P>
<P align=justify><B><I>Our substantial debt and other financial obligations
could impair our financial condition and our ability to fulfill our debt
obligations. Any refinancing of this substantial debt could be at significantly
higher interest rates.</I></B> </P>
<P align=justify>As of September 30, 2013, we had total liabilities of $2,856,660 and accumulated deficit of $41,204,972. Our substantial indebtedness and other current financial obligations and any that we may become a party to in the future could:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>impair our ability to obtain financing in the future for working capital,
  capital expenditures, or general corporate purposes; </P>
  <LI>
  <P>have a material adverse effect on us if we fail to comply with financial
  and affirmative and restrictive covenants in debt agreements and an event of
  default occurs as a result of a failure that is not cured or waived; </P>
  <LI>
  <P>require us to dedicate a substantial portion of our cash flow for interest
  payments on our indebtedness and other financial obligations, thereby reducing
  the availability of our cash flow to fund working capital and capital
  expenditures; </P>
  <LI>
  <P>limit our flexibility in planning for, or reacting to, changes in our
  business and the industry in which we operate; and </P></LI></UL><P align="center">16</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_21></A>
<UL style="TEXT-ALIGN: justify">
  <LI>place us at a competitive disadvantage compared to our competitors that
  have proportionally less debt. </LI></UL>
<P align=justify>If we are unable to meet our debt service obligations and other
financial obligations, we could be forced to restructure or refinance our
indebtedness and other financial transactions, seek additional equity capital,
sell our assets or curtail our operations. We might then be unable to obtain
such financing or capital or sell our assets on satisfactory terms, if at all.
Any refinancing of our indebtedness could be at significantly higher interest
rates, and/or incur significant transaction fees. </P>
<P align=justify><B><I>Risks Related to our Common Stock</I></B> </P>
<P align=justify><B><I>A decline in the price of our common stock could affect
our ability to raise further working capital and adversely impact our operations
and would severely dilute existing or future investors if we were to raise funds
at lower prices.</I></B> </P>
<P align=justify>A prolonged decline in the price of our common stock could
result in a reduction in our ability to raise capital. Because our operations
have been financed through the sale of equity securities, a decline in the price
of our common stock could be especially detrimental to our continued operations.
Any reduction in our ability to raise equity capital in the future would force
us to reallocate funds from other planned uses and would have a significant
negative effect on our business plans and operations, including our ability to
develop new products and continue our current operations. If our stock price
declines, there can be no assurance that we can raise additional capital or
generate funds from operations sufficient to meet our obligations. We believe
the following factors could cause the market price of our common stock to
continue to fluctuate widely and could cause our common stock to trade at a
price below the price at which you purchase your shares of common stock: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>actual or anticipated variations in our quarterly operating results; </P>
  <LI>
  <P>announcements of new services, products, acquisitions or strategic
  relationships by us or our competitors; </P>
  <LI>
  <P>changes in accounting treatments or principles; </P>
  <LI>
  <P>changes in earnings estimates by securities analysts and in analyst
  recommendations; and </P>
  <LI>
  <P>general political, economic, regulatory and market conditions. </P></LI></UL>
<P align=justify>The market price for our common stock may also be affected by
our ability to meet or exceed expectations of analysts or investors. Any failure
to meet these expectations, even if minor, could materially adversely affect the
market price of our common stock. </P>
<P align=justify><B><I>If we issue additional shares of common stock in the
future it will result in the dilution of our existing stockholders.</I></B> </P>
<P align=justify>Our articles of incorporation authorize the issuance of
150,000,000 shares of common stock. Our board of directors has the authority to
issue additional shares of common stock up to the authorized capital stated in
the articles of incorporation. Our board of directors may choose to issue some
or all of such shares of common stock to acquire one or more businesses or to
provide additional financing in the future. The issuance of any such shares of
common stock will result in a reduction of the book value or market price of the
outstanding shares of our common stock. If we do issue any such additional
shares of common
stock, such issuance also will cause a reduction in the proportionate ownership and voting power of all other stockholders. Further, any such issuance may result in a change of control of our corporation. </P>
<P align=center>17</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>



<A name="page_22"></A>
<P align="justify">
<B><I>Trading of our common stock may be volatile and sporadic, which could depress the market price of our common stock and make it difficult for our stockholders to resell their shares.</I></B> </P>
<P align="justify">
There is currently a limited market for our common stock and the volume of our common stock traded on any day may vary significantly from one period to another. Our common stock is quoted on OTC Market&rsquo;s OTCQB. Trading in stock quoted on OTC
Market&rsquo;s OTCQB is often thin and characterized by wide fluctuations in trading prices, due to many factors that may have little to do with our operations or business prospects. The availability of buyers and sellers represented by this
volatility could lead to a market price for our common stock that is unrelated to operating performance. Moreover, OTC Market&rsquo;s OTCQB is not a stock exchange, and trading of securities quoted on OTC Market&rsquo;s OTCQB is often more sporadic
than the trading of securities listed on a stock exchange like NASDAQ. There is no assurance that a sufficient market will develop in the stock, in which case it could be difficult for our stockholders to resell their stock. </P>
<P align="justify">
<B><I>Our stock is classed as a &ldquo;penny stock&rdquo;. Trading of our stock may be restricted by the Securities and Exchange Commission&rsquo;s penny stock regulations which may limit a stockholder&rsquo;s ability to buy and sell our
stock.</I></B> </P>
<P align="justify">
Our stock is a penny stock. The Securities and Exchange Commission has adopted Rule 15g-9 which generally defines &ldquo;penny stock&rdquo; to be any equity security that has a market price (as defined) less than &#36;5.00 per share or an exercise
price of less than &#36;5.00 per share, subject to certain exceptions. Our securities are covered by the penny stock rules, which impose additional sales practice requirements on broker-dealers who sell to persons other than established customers
and &ldquo;accredited investors&rdquo;. The term &ldquo;accredited investor&rdquo; refers generally to institutions with assets in excess of &#36;5,000,000 or individuals with a net worth in excess of &#36;1,000,000 (excluding the value of the
primary residence of such individuals) or annual income exceeding &#36;200,000 or &#36;300,000 jointly with their spouse. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to
deliver a standardized risk disclosure document in a form prepared by the Securities and Exchange Commission which provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must
provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction and monthly account statements showing the market value of each penny stock held in the
customer&rsquo;s account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in
writing before or with the customer&rsquo;s confirmation. In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from these rules; the broker-dealer must make a special written determination that
the penny stock is a suitable investment for the purchaser and receive the purchaser&rsquo;s written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market
for the stock that is subject to these penny stock rules. Consequently, these penny stock rules may affect the ability of broker-dealers to trade our securities. We believe that the penny stock rules discourage investor interest in and limit the
marketability of our common stock. </P>
<P align="justify">
<B><I>The Financial Industry Regulatory Authority sales practice requirements may also limit a stockholder&rsquo;s ability to buy and sell our stock.</I></B> </P>
<P align="center">18</P>
<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_23"></A>

<P align="justify">
In addition to the &ldquo;penny stock&rdquo; rules described above, the Financial Industry Regulatory Authority or FINRA has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds
for believing that the investment is suitable for that customer. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the
customer&rsquo;s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at
least some customers. The FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may limit your ability to buy and sell our stock and have an adverse effect on the market for shares
of our common stock. </P>
<P align="justify">
<B><I>The sale or issuance of our common stock to Lincoln Park may cause dilution and the sale of the shares of common stock acquired by Lincoln Park, or the perception that such sales may occur, could cause the price of our common stock to
fall</I></B> </P>
<P align="justify">
On July 5, 2013, we entered into a Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;) with Lincoln Park Capital Fund, LLC (&ldquo;<U>Lincoln Park</U>&rdquo;), pursuant to which Lincoln Park committed to purchase up to &#36;10,000,000
of our common stock. Concurrently with the execution of the Purchase Agreement, we issued 341,858 shares of our common stock to Lincoln Park as a fee for its commitment to purchase shares of our common stock under the Purchase Agreement. The
purchase shares that may be sold pursuant to the Purchase Agreement may be sold by us to Lincoln Park at our discretion from time to time over a 25-month period commencing after the SEC declared effective the related registration statement. The
purchase price for the shares that we may sell to Lincoln Park under the Purchase Agreement will fluctuate based on the price of our common stock. Depending on market liquidity at the time, sales of such shares may cause the trading price of our
common stock to fall. </P>
<P align="justify">
We generally have the right to control the timing and amount of any sales of our shares to Lincoln Park, except that, pursuant to the terms of our agreements with Lincoln Park, we would be unable to sell shares to Lincoln Park if and when the
closing sale price of our common stock is below &#36;0.50 per share, subject to adjustment as set forth in the Purchase Agreement. Additional sales of our common stock, if any, to Lincoln Park will depend upon market conditions and other factors to
be determined by us. Lincoln Park may ultimately purchase all of the shares of our common stock that may be sold pursuant to the Purchase Agreement and, after it has acquired shares, Lincoln Park may sell all, some or none of those shares.
Therefore, sales to Lincoln Park by us could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our common stock to Lincoln Park, or the anticipation of
such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales. </P>
<P align="justify">
<B>ITEM 1B. UNRESOLVED STAFF COMMENTS</B></P>
<P align="justify">
Not Applicable. </P>
<P align="justify">
<B>ITEM 2. PROPERTIES </B></P>
<P align="justify">
We do not own or lease any property. We expect to enter into a lease agreement for principal executive office space in New York City, during the first half of fiscal 2014.</P>
<P align="justify">
<B>ITEM 3. LEGAL PROCEEDINGS </B></P>
<P align="center">19</P>
<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_24"></A>

<P align="justify">
We know of no material, existing or pending legal proceedings to which we are a party or of which any of our properties is the subject. In addition, we do not know of any such proceedings contemplated by any governmental authorities. We know of no
proceedings in which any of our directors, officers or affiliates, or any registered or beneficial stockholder is a party adverse to our company or has a material interest adverse to our company.</P>
<P align="justify">
<B>ITEM 4. MINE SAFETY DISCLOSURES </B></P>
<P align="justify">
Not applicable. </P>
<P align="center">20</P>
<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">

<A name=page_25></A>
<P align=left><B>PART II </B></P>
<P align=justify><B>ITEM 5. MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED
STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </B></P>
<P align=justify><B><I>Market information </I></B></P>
<P align=justify>Our common stock is quoted on OTCQB under the symbol &#147;AVXL.&#148;
</P>
<P align=justify>The following table shows the quarterly range of high and low
bid information for our common stock over the fiscal quarters for the last two
fiscal years as quoted on OTCQB. We obtained the following high and low bid
information from OTCQB. These over-the-counter market quotations reflect
inter-dealer prices without retail mark-up, mark-down or commission, and may not
represent actual transactions. Investors should not rely on historical prices of
our common stock as an indication of its future price performance. On December
24, 2013, the closing price of our common stock as reported by OTCQB was $0.25
per share. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center>Quarter Ended </TD>
    <TD align=center width="30%">High </TD>
    <TD align=center width="30%">Low </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>September 30, 2013 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$0.75 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$0.49 </TD></TR>
  <TR vAlign=top>
    <TD align=left>June 30, 2013 </TD>
    <TD align=center width="30%">$0.83 </TD>
    <TD align=center width="30%">$0.45 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>March 31, 2013 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$0.81 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$0.51 </TD></TR>
  <TR vAlign=top>
    <TD align=left>December 31, 2012 </TD>
    <TD align=center width="30%">$1.12 </TD>
    <TD align=center width="30%">$.072 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>September 30, 2012 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$1.35 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$0.75 </TD></TR>
  <TR vAlign=top>
    <TD align=left>June 30, 2012 </TD>
    <TD align=center width="30%">$1.26 </TD>
    <TD align=center width="30%">$0.51 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>March 31, 2012 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$1.94 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$1.10 </TD></TR>
  <TR vAlign=top>
    <TD align=left>December 31, 2011 </TD>
    <TD align=center width="30%">$1.90 </TD>
    <TD align=center width="30%">$1.20 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>September 30, 2011 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$2.50 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$1.29 </TD></TR></TABLE>
<P align=justify><B><I>Transfer Agent </I></B></P>
<P align=justify>Shares of our common stock are issued in registered form. The
Nevada Agency and Trust Company, 50 West Liberty Street, Reno, Nevada
(Telephone: (775) 322-0626; Facsimile: (775) 322-5623) is the registrar and
transfer agent for shares of our common stock. </P>
<P align=justify><B><I>Holders of Common Stock</I></B></P>
<P align=justify>As of December 24, 2013, there were 89 holders of record of our common stock. As of such date, 37,237,588 shares of our common stock were issued and outstanding.</P>
<P align=justify><B><I>Dividends</I></B></P>
<P align=justify>We have not paid any cash dividends on our common stock and
have no intention of paying any dividends on the shares of our common stock. Our
current policy is to retain earnings, if any, for use in our operations and in
the development of our business. Our future dividend policy will be determined
from time to time by our board of directors. </P>
<P align=center>21</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_26></A>
<P align=justify><B><I>Securities Authorized for Issuance under Equity
Compensation Plans or Individual Compensation Arrangements</I></B></P>
<P align=justify>The following table summarizes certain information regarding
our equity compensation plan or individual compensation arrangements as at
September 30, 2013: </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=bottom>
    <TD colspan="4" align=center>&nbsp;<B>Equity Compensation Plan Information</B>&nbsp;    </TD>
    </TR>
  <TR vAlign=top>
    <TD align=center nowrap><BR>
      <BR><BR><BR><BR><BR><B>Plan Category</B> <BR><BR></TD>
    <TD width="25%" align=center nowrap><BR>
      <BR><BR><B>Number of securities</B>
      <BR><B>to be issued upon</B> <BR><B>exercise of</B> <BR><B>outstanding
      options,</B> <BR><B>warrants and rights</B> <BR><B>(a)</B> </TD>
    <TD width="25%" align=center nowrap><BR>
      <BR><BR><B>Weighted-average</B>
      <BR><B>exercise price of</B> <BR><B>outstanding options,</B>
      <BR><B>warrants and rights</B> <BR><B>(b)</B> <BR></TD>
    <TD width="25%" align=center nowrap><B>Number of securities</B> <BR>
      <B>remaining
      available</B> <BR><B>for future issuances</B> <BR><B>under equity</B>
      <BR><B>compensation plans</B> <BR><B>(excluding securities</B>
      <BR><B>reflected in column</B> <BR><B>(a))</B> <BR><B>(c)</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>Equity compensation plans approved by security holders </TD>
    <TD vAlign=bottom align=right width="25%">3,075,000 </TD>
    <TD vAlign=bottom align=right width="25%">1.26 </TD>
    <TD vAlign=bottom align=right width="25%">925,000 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Equity compensation plans not approved by security holders    </TD>
    <TD vAlign=bottom align=right width="25%">Nil </TD>
    <TD vAlign=bottom align=right width="25%">NA </TD>
    <TD vAlign=bottom align=right width="25%">NA </TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Total</B> </TD>
    <TD vAlign=bottom align=right width="25%"><B>3,075,000</B> </TD>
    <TD vAlign=bottom align=right width="25%"><B>1.26</B> </TD>
  <TD vAlign=bottom align=right width="25%"><B>925,000</B></TD></TR></TABLE>
</DIV>
<P align=justify><B><I>Stock Option Plan</I></B></P>
<P align=justify>On April 17, 2007, our directors adopted the 2007 Stock Option
Plan. On May 25, 2007, our stockholders ratified and approved the 2007 Stock
Option Plan at the annual meeting of stockholders. As of September 30, 2013,
3,075,000 options have been granted to employees, directors, officers and
consultants of our company. </P>
<P align=justify>The purpose of the 2007 Stock Option Plan is to retain the
services of valued key employees and consultants of our company and such other
persons as will be select in accordance with the 2007 Stock Option Plan, and to
encourage such persons to acquire a greater proprietary interest in our company,
thereby strengthening their incentive to achieve the objectives of the
shareholders of our company, and to serve as an aid and inducement in the hiring
of new employees and to provide an equity incentive to consultants. </P>
<P align=justify>On February 2, 2011 we amended and restated our 2007 stock
option plan to increase the number of shares authorized to be issued under the
plan to 4,000,000.</P>
<P align=justify><B><I>Recent Sales of Unregistered Securities</I></B></P>
<P align=center>22</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_27></A>
<P align=justify>Since the beginning of our fiscal year ended September 30,
2013, we have not sold any equity securities that were not registered under the
Securities Act of 1933 that were not previously reported in a quarterly report
on Form 10-Q or in a current report on Form 8-K.</P>
<P align=justify><B><I>Purchases of Equity Securities by Our Company and
Affiliated Purchasers </I></B></P>
<P align=justify>None. </P>
<P align=justify><B>ITEM 6. SELECTED FINANCIAL DATA </B></P>
<P align=justify>We are a smaller reporting company as defined by Rule 12b-2 of
the Securities Exchange Act of 1934 and are not required to provide information
under this item.</P>
<P align=justify><B>ITEM 7. MANAGEMENT&#146;S DISCUSSION AND</B><B> ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATION</B></P>
<P align=justify>The following discussion should be read in conjunction with our
audited consolidated financial statements and notes thereto for the fiscal year
ended September 30, 2013, included elsewhere in this Annual Report on Form 10-K.
The following Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations contains &#147;forward-looking statements&#148;. Forward-looking
statements are generally written in the future tense and/or are preceded by
words such as &#147;may,&#148; &#147;should,&#148; &#147;forecast,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;suggest,&#148;
&#147;believe,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;plan,&#148; or other similar words. The
forward-looking statements contained in this Annual Report on Form 10-K involve
a number of risks and uncertainties, many of which are outside of our control.
Factors that could cause actual results to differ materially from projected
results include, but are not limited to, those discussed in &#147;Risk Factors&#148;
elsewhere in this Annual Report on Form 10-K. Readers are expressly advised to
review and consider those Risk Factors, which include risks associated with (1)
our ability to successfully conduct clinical and preclinical trials for our
product candidates, (2) our ability to obtain required regulatory approvals to
develop and market our product candidates, (3) our ability to raise additional
capital on favorable terms, (4) our ability to execute our development plan on
time and on budget, (5) our ability to obtain commercial partners, (6) our
ability, whether alone or with commercial partners, to successfully
commercialize any of our product candidates that may be approved for sale, and
(7) our ability to identify and obtain additional product candidates. Although
we believe that the assumptions underlying the forward-looking statements
contained in this Annual Report on Form 10-K are reasonable, any of the
assumptions could be inaccurate, and therefore there can be no assurance that
such statements will be accurate. In light of the significant uncertainties
inherent in the forward-looking statements included herein, the inclusion of
such information should not be regarded as a representation by us or any other
person that the results or conditions described in such statements or our
objectives and plans will be achieved. Furthermore, past performance in
operations and share price is not necessarily indicative of future performance.
Except as required by applicable laws including the securities laws of the
United States and Canada, we disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise. </P>
<P align=justify><B><I>Our Business </I></B></P>
<P align=center>23</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_28></A>
<P align=justify>We are a pharmaceutical company engaged in the development of
drug candidates. Our lead compounds ANAVEX 2-73 and ANAVEX PLUS, a combination
of ANAVEX 2-73 with donepezil (Aricept&#174;) are being developed to treat
Alzheimer&#146;s disease and potentially other central nervous system (CNS) diseases.
</P>
<P align=justify>In pre-clinical studies conducted in France, and in Greece,
ANAVEX 2-73 demonstrated anti-amnesic and neuroprotective properties in various
animal models including the transgenic mouse model Tg2576. Based on pre-clinical
studies, we sponsored a Phase 1 single ascending dose study of ANAVEX 2-73
initiated and completed in 2011. This study was conducted in Germany in
collaboration with ABX-CRO Advanced Pharmaceutical Services. The study indicated
that ANAVEX 2-73 was well tolerated by study subjects in doses up to 55mg. </P>
<P align=justify><B><I>Recent Corporate Developments </I></B></P>
<P align=justify>Since the commencement of our fourth quarter ended September
30, 2013, we have experienced the following significant corporate developments:
</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>On July 5, 2013, we issued 4,208,910 units in settlement of $549,000 in
  promissory notes, $26,058 of accrued interest on these notes, and $1,108,506
  in other accounts payable and accrued liabilities. Each unit consisted of one
  common share and one common share purchase warrant entitling the holder to
  purchase an additional common share at $0.75 per share until July 5, 2018.</P>
  <LI>
  <P>On July 5, 2013, we issued 2,196,133 units at $0.40 per unit for gross
  proceeds of $878,453 pursuant to private placement agreements. Each unit
  consisted of one common share and one common share purchase warrant entitling
  the holder to purchase an additional common share at $0.75 per share until
  July 5, 2018. We paid finder&#146;s fees of $89,680 and issued warrants to purchase
  43,923 shares of our common stock at $0.75 per share until July 5, 2018 in
  connection with this private placement. In addition, we incurred share
  issuance costs of $16,494. </P>
  <LI>
  <P>On July 5, 2013, we entered into the $10,000,000 Purchase Agreement with
  Lincoln Park Capital Fund, LLC (the &#147;Financing&#148;) pursuant to which we may sell
  and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to
  $10,000,000 in value of our shares of common stock from time to time over a 25
  month period. In connection with the Financing, we also entered into a
  registration rights agreement with Lincoln Park whereby we agreed to file a
  registration statement with the SEC covering the shares of our common stock
  that may be issued to Lincoln Park under the Purchase Agreement. On October
  23, 2013, the registration statement was declared effective by the SEC. </P>
  <LI>
  <P>On July 5, 2013, Christopher U. Missling, PhD. accepted the appointment by
  our board of directors to serve as our President, Chief Executive Officer,
  Chief Financial Officer, Secretary and Treasurer, and to serve as a director
  of the company. Dr. Missling has over twenty (20) years of healthcare industry
  experience in big pharmaceutical, biotech industry and investment banking.
  Most recently, from March, 2007 until his appointment, Dr. Missling served as
  the head of healthcare investment banking at Brimberg &amp; Co. in New York,
  New York. Also, Dr. Missling served as the Chief Financial Officer of Curis,
  Inc. (NASDAQ:CRIS) and ImmunoGen, Inc. (NASDAQ:IMGN). Dr. Missling earned his
MS and PhD from the University of Munich and an MBA from Northwestern University
Kellogg School of Management.</P></LI></UL><P align="center">24</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_29></A>
<P align=justify><B>RESULTS OF OPERATIONS </B></P>
<P align=justify><B><I>Revenue </I></B></P>
<P align=justify>We have not earned any revenues since our inception on January
23, 2004. We are still in the development stage and do not anticipate earning
any revenues until we can establish an alliance with other companies to develop,
co-develop, license, acquire or market our products.</P>
<P align=justify><B><I>Expenses</I></B></P>
<P align=justify>Our expenses for the fiscal year ended September 30, 2013 and
2012 were as follows: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD colspan="4" align=center>Year ended September 30, </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD colspan="4" align=center>Change  </TD>
    <TD align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=center width="12%">2013 </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="12%">2012 </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="12%">$</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="12%">% </TD>
    <TD align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Accounting and audit fees </TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;136,758</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>139,761 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(3,003</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(2.1%</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left>Amortization </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">576 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">1,858 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">(1,282</TD>
    <TD align=left width="2%">) </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">(69.0%</TD>
    <TD align=left width="2%">) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Bank charges and interest </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>4,397 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>5,963 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(1,566</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(26.3%</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left>Consulting </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">271,898 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">1,155,366 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">(883,468</TD>
    <TD align=left width="2%">) </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">(76.5%</TD>
    <TD align=left width="2%">) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Insurance </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>16,125 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>10,844 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>5,281 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>48.7% </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Investor relations </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">128,575 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">108,138 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">20,437 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">18.9% </TD>
    <TD align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Legal fees </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>176,318</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>142,923 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>33,395</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>23.4%</TD>
  <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Office and miscellaneous </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">4,019 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">9,147 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">(5,128</TD>
    <TD align=left width="2%">) </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">(56.1%</TD>
    <TD align=left width="2%">) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Registration and filing fees </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>33,634 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>26,794 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>6,840 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>25.5% </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Rent </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">12,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">12,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">NA </TD>
    <TD align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Research and development </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>263,847 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>2,653,860 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(2,390,013</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(90.1%</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left>Salaries and wages </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">1,067,294 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">1,067,294 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">NA </TD>
    <TD align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Travel </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>19,695 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>66,837 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(47,142</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(70.5%</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left>Website design and maintenance </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">2,231 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">2,231 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">NA </TD>
    <TD align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><B>Total expenses</B> </TD>
    <TD align=left width="1%" bgColor=#e6efff><B>$</B></TD>
    <TD align=right width="12%" bgColor=#e6efff><b>2,137,367</b></TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff><B>$</B></TD>
    <TD align=right width="12%" bgColor=#e6efff><B>4,321,491</B> </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff><B>2,184,124</B> </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff><b>(50.5%</b></TD>
  <TD align=left width="2%" bgColor=#e6efff><b>) </b></TD>
  </TR></TABLE>
<P align=justify><I>Year ended September 30, 2013 and 2012</I></P>
<P align=justify>Expenses for the fiscal year ended September 30, 2013 decreased by $2,184,124 over the same period in 2012. The principal contributors to the decrease were:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">1. </TD>
    <TD>
      <P align=justify>A decrease in consulting fees of $883,468 primarily as a
      result of decreased management infrastructure as well as a decrease in
      stock based compensation expense from stock options granted to consultants
      and vesting during the comparative period;</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD vAlign=top width="5%">2. </TD>
    <TD>
      <P align=justify>A decrease in research and development expenses of
      $2,390,013 due to the delay of clinical trials pending the closing of
      financing to fund these trials. This included the termination of lab fees
      of $125,000 per month accruing during the comparative
  period;</P></TD></TR></TABLE><BR><P align="center">25</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_30></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">3. </TD>
    <TD>
      <P align=justify>These decreases were offset by an increase in salaries
      and wages expense of $1,067,294 in connection with the appointment of our
      President, Chief Executive Officer, Chief Financial Officer, Secretary and
      Treasurer, which included stock based compensation expense of $1,002,500
      associated with the granting of fully vested options upon his
      appointment.</P></TD></TR></TABLE>
<P align=justify><B><I>Other income </I></B></P>
<P align=justify>Other income and (loss) for the year ended September 30, 2013, amounted to $(1,562,679) as compared to a loss of $(3,980,214) for the year ended September 30, 2012. The decrease in net other losses is primarily attributable to </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD>
      <P align=justify>a reduction of losses from the extinguishment of debt of
      $3,334,005, offset by an increase in losses on extinguishment of accounts
      payable of $976,880. During fiscal 2013, we recorded a loss of $1,472,208
      in connection with the extinguishment of five promissory notes plus
      accrued interest totaling $575,058, and trade accounts payable totaling
      $1,108,506. During fiscal 2012, we recorded a loss of $3,829,333 for the
      extinguishment of four promissory notes and accrued interest totaling
      $1,350,251. The reduced loss is a result of different settlement terms
      agreed to with the lenders;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD>
      <P align=justify>a reduction in interest expense of $87,000 as a result of
      the decreased debt levels during the current period from the settlement of
      promissory notes in the fourth quarter of 2013;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD>
      <P align=justify>a reduction of accretion expense of $98,081 as a result
      of promissory notes settled during the 2012 fiscal
year.</P></TD></TR></TABLE>
<P align=justify><B><I>Liquidity and Capital Resources</I></B></P>
<P align=justify><B><I>Working Capital </I></B></P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=3 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="25%">2013
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="25%">2012
    </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Current Assets </TD>
    <TD align=right width="25%" bgColor=#e6efff>393,449 </TD>
    <TD align=right width="25%" bgColor=#e6efff>12,577 </TD></TR>
  <TR vAlign=top>
    <TD align=left >Current Liabilities </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="25%">1,952,660 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="25%">2,888,324 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Working Capital Deficiency
</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="25%"
    bgColor=#e6efff>$           (1,559,211) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="25%"
    bgColor=#e6efff>(2,875,747) </TD></TR></TABLE></DIV>
<P align=justify>As of September 30, 2013, we had $345,074 in cash, an increase of $333,712 from September 30, 2012. As of September 30, 2013, we had a working capital deficiency of $1,559,211, a decrease in deficit of $1,316,536 from September 30, 2012. </P>
<P align=justify>The principal reason for the increase in working capital
relates to the extinguishment of five promissory notes plus accrued interest
totaling $575,058, and trade accounts payable totaling $1,108,506, in exchange
for shares of our common stock. </P>
<P align=justify>The increase in cash during the period relates to cash generated through financing activities from debt and equity issuances.  We generated cash of $861,285, after issuance costs, from the issuance of capital stock, and we generated cash of $250,000 through the issuance of promissory notes.  Some of these promissory notes issued were also settled in exchange for the issuance of capital stock during the year.</P>
<P align=center>26</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>



<A name="page_31"></A>
<P align="justify">
We do not have sufficient capital to execute our business plan over the next twelve months.  We anticipate that we will require &#36;6,000,000 for the 12-month period ending September 30, 2014 to continue our operations. If we are not able to secure
additional financing, we will not be able to implement and fund this work. </P>
<P align="justify">
<B><I>Going Concern </I></B></P>
<P align="justify">At September 30, 2013, we had an accumulated deficit of $41,204,972 since our inception and incurred a net loss of $3,700,046 for the fiscal year ended September 30, 2013. We expect to incur further losses in the development of our business, all of which casts substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to generate future profitable operations and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due. Our independent auditors included an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern in their report on our annual financial statements for the fiscal year ended September 30, 2013. </P>
<P align="justify">
<B><I>Future Financing </I></B></P>
<P align="justify">
We will require additional financing to fund our planned operations, including further strengthening our patent portfolio, securing licensing or patent rights for other compounds and related technology and any further intellectual property that we
may acquire and commencing clinical development. </P>
<P align="justify">
On July 5, 2013, the Company entered into a Purchase Agreement with Lincoln Park. Pursuant to the Purchase Agreement, Lincoln Park initially purchased 250,000 shares of the Company&rsquo;s common stock for &#36;100,000. The Company has the right, in
its sole discretion over a 25-month period, to sell to Lincoln Park up to the additional aggregate commitment of &#36;9.9 Million of shares of common stock. There are no upper limits on the per share price that Lincoln Park may pay to purchase such
common stock. Furthermore, the Company controls the timing and amount of any future sales, if any, of shares of common stock to Lincoln Park except that, pursuant to the terms of the Purchase Agreement, we would be unable to sell shares to Lincoln
Park if and when the closing sale price of our common stock is below &#36;0.50 per share, subject to adjustment as set forth in the Purchase Agreement.. Lincoln Park has no right to require any sales and is obligated to purchase common stock as
directed by the Company. </P>
<P align="justify">
Other than our rights related to the Lincoln Park financing, there can be no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If we are not able to
obtain the additional financing on a timely basis, if and when it is needed, we will be forced to delay or scale down some or all of our research and development activities or perhaps even cease the operation of our business. </P>
<P align="justify">
Since inception we have funded our operations primarily through equity and debt financings and we expect that we will continue to fund our operations through the equity and debt financing. If we raise additional financing by issuing equity
securities, our existing stockholders&rsquo; ownership will be diluted. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments. </P>
<P align="center">27</P>
<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_32"></A>

<P align="justify">
There is no assurance that we will be able to maintain operations at a level sufficient for investors to obtain a return on their investment in our common stock. Further, we may continue to be unprofitable. </P>
<P align="justify">
<B><I>Off-Balance Sheet Arrangements </I></B></P>
<P align="justify">
We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures
or capital resources that is material to our stockholders. </P>
<P align="justify">
<B>APPLICATION OF CRITICAL ACCOUNTING POLICIES </B></P>
<P align="justify">
Our financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States. Preparing financial statements requires management to make estimates and assumptions that affect the
reported amounts of assets, liabilities, revenue and expenses. These estimates and assumptions are affected by management&rsquo;s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions
involved with the following aspects of our financial statements is critical to an understanding of our financials. </P>
<P align="justify">
We base our assumptions and estimates on historical experience and other sources that we believe to be reasonable at the time. Actual results may vary from our estimates due to changes in circumstances, weather, politics, global economics,
mechanical problems, general business conditions and other factors. Our significant estimates are related to the valuation of warrants and options. </P>
<P align="justify">
There are accounting policies that we believe are significant to the presentation of our financial statements. The most significant of these accounting policies relates to the accounting for our research and development expenses and stock-based
compensation expense.</P>
<P align="justify">
<B><I>Research and Development Expenses </I></B></P>
<P align="justify">
Research and developments costs are expensed as incurred. These expenses are comprised of the costs of our proprietary research and development efforts, including salaries, facilities costs, overhead costs and other related expenses as well as costs
incurred in connection with third-party collaboration efforts. Milestone payments made by us to third parties are expensed when the specific milestone has been achieved.</P>
<P align="justify">
In addition, we incur expenses in respect of the acquisition of intellectual property relating to patents and trademarks. The probability of success and length of time in developing commercial applications of the drugs subject to the acquired
patents and trademarks is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development projects. There is no assurance the acquired patents and trademarks will ever be successfully
commercialized. Due to these risks and uncertainties, we expense the acquisition of patents and trademarks.</P>
<P align="justify">
<B><I>Stock-based Compensation </I></B></P>
<P align="justify">
We account for all stock-based payments and awards under the fair value based method. </P>
<P align="center">28</P>
<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_33"></A>

<P align="justify">
Stock-based payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based
payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if we had paid cash instead of paying with or
using equity based instruments. The cost of the stock-based payments to non-employees that is fully vested and non-forfeitable as at the grant date is measured and recognized at that date, unless there is a contractual term for services in which
case such compensation would be amortized over the contractual term.</P>
<P align="justify">
We account for the granting of share purchase options to employees using the fair value method whereby all awards to employees will be recorded at fair value on the date of the grant. The fair value of all share purchase options are expensed over
their vesting period with a corresponding increase to additional capital surplus. Upon exercise of share purchase options, the consideration paid by the option holder, together with the amount previously recognized in additional capital surplus, is
recorded as an increase to share capital. </P>
<P align="justify">
We use the Black-Scholes option valuation model to calculate the fair value of share purchase options at the date of the grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility.
Changes in assumptions can materially affect the fair value estimate and therefore the Black-Scholes model does not necessarily provide a reliable single measure of the fair value of our share purchase options.</P>
<P align="justify">
<B><I>Derivative Liabilities </I></B></P>
<P align="justify">
From time to time, we may issue convertible promissory notes which include embedded conversion options which, dependent on their specific contractual terms, may be required to be accounted for as separate derivative liabilities. These liabilities
are required to be measured at fair value. These instruments are then adjusted to reflect fair value at each period end. Any increase or decrease in the fair value is recorded in results of operations as change in fair value of derivative
liabilities. In determining the appropriate fair value, we use the binomial pricing model.</P>
<P align="justify">
Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes in assumptions can materially affect the fair value estimate and therefore the binomial model does not necessarily provide a
reliable single measure of the fair value of these instruments. </P>
<P align="justify">
<B><I>Recent Accounting Pronouncements</I></B></P>
<P align="justify">
New accounting pronouncements are issued by the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) or other standards setting bodies that we adopt according to the various timetables the FASB specifies. We do not expect the adoption of
recently issued accounting pronouncements will have a significant impact on our results of operations, financial position or cash flows. </P>
<P align="justify">
<B>ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</B></P>
<P align="justify">
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide information under this item.</P>
<P align="justify"><B>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </B></P>
<p align="center">29</p>
<hr noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">
<A name=page_F-1></A>
<P align=justify>&nbsp;</P>
<P align=justify>&nbsp;</P>
<P align=justify>&nbsp;</P>
<P align=center>&nbsp;</P>
<P align=center><B>ANAVEX LIFE SCIENCES CORP.</B></P>
<P align=center>(A Development Stage Company)</P>
<P align=center>CONSOLIDATED FINANCIAL STATEMENTS</P>
<P align=center>September 30, 2013 and 2012</P>
<P align=center>&nbsp;</P>
<P align=center>&nbsp;</P>
<P align=center>F-1</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-2></A>&nbsp;<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left  >
    <IMG
      src="bdo.gif"
      border=0 width="114" height="60"></TD>
    <TD align=left width="25%">Tel: 212-885-8000 <BR>
      Fax: 212-697-1299 <BR>
      <B>www.bdo.com </B></TD>
    <TD align=left width="25%">100 Park Avenue <BR>
      New York, NY 10017 <BR></TD>
  </TR>
</TABLE>
<P align=justify>&nbsp;</P>
<P align=justify><B>Report of Independent Registered Public Accounting Firm </B></P>
<P align=justify>To the Directors and Stockholders, <BR>
  Anavex Life Sciences
  Corp. <BR>
  (a Development Stage Company) <BR>
  New York, NY <BR>
</P>
<P align=justify>We have audited the accompanying balance sheet of Anavex Life
  Sciences Corp. (a corporation in the development stage) as of September 30, 2013
  and the related consolidated statements of operations, cash flows, and changes
  in capital deficit for the year then ended and for the period from inception
  (January 23, 2004) to September 30, 2013. These financial statements are the
  responsibility of the Company&#146;s management. Our responsibility is to express an
  opinion on these financial statements based on our audit. We did not audit the
  consolidated statements of operations, cash flows and changes in capital deficit
  for the period from inception (January 23, 2004) to September 30, 2012. Such
  statements are included in the cumulative inception to September 30, 2013 totals
  of the consolidated statements of operations and cash flows and reflect total
  revenues and net loss of $0 and $36,954,122, respectively, of the related
  cumulative totals. Those statements were audited by other auditors whose report
  has been furnished to us, and our opinion, insofar as it relates to amounts for
  the period from inception (January 23, 2004) to September 30, 2012, included in
  the cumulative totals, is based solely on the reports of the other auditors.</P>
<P align=justify>We conducted our audit in accordance with standards of the
  Public Company Accounting Oversight Board (United States). Those standards
  require that we plan and perform the audit to obtain reasonable assurance about
  whether the consolidated financial statements are free of material misstatement.
  The Company is not required to have, nor were we engaged to perform, an audit of
  its internal control over financial reporting. Our audit included consideration
  of internal control over financial reporting as a basis for designing audit
  procedures that are appropriate in the circumstances, but not for the purpose of
  expressing an opinion on the effectiveness of the Company&#146;s internal control
  over financial reporting. Accordingly, we express no such opinion. An audit also
  includes examining, on a test basis, evidence supporting the amounts and
  disclosures in the financial statements, assessing the accounting principles
  used and significant estimates made by management, as well as evaluating the
  overall financial statement presentation. We believe that our audit provides a
  reasonable basis for our opinion. </P>
<P align=justify>In our opinion, the consolidated financial statements referred
  to above present fairly, in all material respects, the financial position of
  Anavex Life Sciences Corp. at September 30, 2013, and the results of its
  operations and its cash flows for the year then ended and for the period from
  inception to September 30, 2013, in conformity with accounting principles
  generally accepted in the United States of America. </P>
<P align=justify>&nbsp;</P>
<P align=justify><FONT size=1>BDO USA, LLP, a Delaware limited liability
  partnership, is the U.S. member of BDO International Limited, a UK company
  limited by guarantee, and forms part of the international BDO network of
  independent member firms.</FONT></P>
<P align=justify><FONT size=1>BDO is the brand name for the BDO network and for
  each of the BDO Member Firms. </FONT></P>
<P align=center>F-2</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-3></A><br>
<IMG src="bdo.gif" border=0 width="114" height="60"> <BR>
<P align=justify>&nbsp;</P>
<P align=justify>The accompanying consolidated financial statements have been
  prepared assuming that the Company will continue as a going concern. As
  described in Note 1 to the consolidated financial statements, the Company had an
  accumulated deficit of $41,204,972 and negative working capital of $1,559,211 at
  September 30, 2013 and incurred a net loss of $3,700,046 for the year then ended. These conditions raise substantial doubt about the
  Company&#146;s ability to continue as a going concern. Management&#146;s plans in regard
  to these matters are also described in Note 1. The consolidated financial
  statements do not include any adjustments that might result from the outcome of
  this uncertainty. Our opinion is not modified with respect to this matter. </P>
<P align=justify>/s/ BDO USA, LLP </P>
<P align=justify>New York, NY <BR>
  December 30, 2013 </P>
<P align=center>F-3</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-4></A><br>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left  >
    <IMG
      src="bdo.gif"
      border=0 width="114" height="60"></TD>
    <TD align=left width="25%">Tel: 604&nbsp; 688 5421 <BR>
      Fax: 604&nbsp; 688  5132 <BR>
    <B>www.bdo.ca </B></TD>
    <TD align=left width="25%"><p>BDO Canada LLP<br>
      600  Cathedral Place<br>
      925 West  Georgia Street<br>
      Vancouver BC&nbsp; V6C  3L2&nbsp; Canada<BR>
    </p>
    </TD>
  </TR>
</TABLE>
<P align=justify>&nbsp;</P>
<p align="center"><b>REPORT OF  INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>
<P align=justify>To the Directors and Stockholders, <BR>
  Anavex Life Sciences
  Corp. <BR>
  (a Development Stage Company) <BR>
</P>
<p>We have audited the accompanying consolidated  balance sheet of Anavex Life Sciences Corp. (the &ldquo;Company&rdquo;) as of September 30,  2012 and the related consolidated statements of operations, cash flows and  changes in capital deficit for the year then ended and for the period from  January 23, 2004 (date of inception) to September 30, 2012. These financial  statements are the responsibility of the Company&rsquo;s management. Our  responsibility is to express an opinion on these financial statements based on  our audits.</p>
<p>We conducted our audits in accordance with the standards of the Public  Company Accounting Oversight Board (United States). Those standards require  that we plan and perform the audit to obtain reasonable assurance about whether  the financial statements are free of material misstatement. The Company is not  required to have, nor were we engaged to perform, an audit of its internal  control over financial reporting. Our audit included consideration of internal  control over financial reporting as a basis for designing audit procedures that  are appropriate in the circumstances, but not for the purpose of expressing an  opinion on the effectiveness of the Company&rsquo;s internal control over financial  reporting. Accordingly, we express no such opinion. An audit also includes  examining, on a test basis, evidence supporting the amounts and disclosures in  the financial statements. An audit also includes assessing the accounting  principles used and significant estimates made by management, as well as  evaluating the overall presentation of the financial statements. We believe  that our audits provide a reasonable basis for our opinion.</p>
<p>In our opinion, the consolidated financial statements referred to above  present fairly, in all material respects, the financial position of Anavex Life  Sciences Corp. at September 30, 2012 and the results of its operations and its  cash flows for the year then ended and for the period from January 23, 2004  (date of inception) to September 30, 2012, in conformity with accounting  principles generally accepted in the United States.</p>
<p>The  accompanying financial statements were prepared assuming that the Company will  continue as a going concern. As at September 30, 2012, the Company had an  accumulated deficit of $37,504,926 and had incurred a net loss of $8,301,705  for the year then ended. These conditions raised substantial doubt about the  Company&rsquo;s ability to continue as a going concern. Management&rsquo;s plans in regard  to these matters were described in Note 1 to the financial statements for the  period ended September 30, 2012. The financial statements did not include any  adjustments that might result from the outcome of this uncertainty.</p>
<p>/s/  BDO Canada LLP</p>
<p>Chartered  Accountants</p>
<p>Vancouver,  Canada</p>
<p>December 28,  2012</p>
<P align=justify>&nbsp;</P>
<P align=justify>&nbsp;</P>
<P align=justify><FONT size=1>BDO Canada LLP, a  Canadian limited liability partnership,&nbsp;is a member of BDO International  Limited, a UK company limited by guarantee, and forms part of the international  BDO network of independent member firms.</FONT></P>
<P align=center>F-4</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-4></A>
<P align=justify><B>ANAVEX LIFE SCIENCES CORP.</B><BR>
  (A Development Stage
  Company)<BR>
  CONSOLIDATED BALANCE SHEETS<BR>
  September 30, 2013 and 2012<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=center valign="bottom" ><B><U>ASSETS</U></B> </TD>
    <TD width="1%" align=left valign="bottom" >&nbsp;</TD>
    <TD width="17%" align=center valign="bottom">&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="17%" align=center valign="bottom">&nbsp;</TD>
    <TD width="2%" align=left valign="bottom" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="17%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">2013 </TD>
    <TD width="2%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="17%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">2012 </TD>
    <TD width="2%" align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=right valign="bottom" >&nbsp;</TD>
    <TD width="17%" align=right valign="bottom">&nbsp;</TD>
    <TD width="2%" align=right valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=right valign="bottom" >&nbsp;</TD>
    <TD width="17%" align=right valign="bottom">&nbsp;</TD>
    <TD width="2%" align=right valign="bottom" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Current </TD>
    <TD vAlign=bottom align=right width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Cash </TD>
    <TD vAlign=bottom align=left width="1%" >$</TD>
    <TD vAlign=bottom align=right width="17%">&nbsp;345,074 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >$</TD>
    <TD vAlign=bottom align=right width="17%">&nbsp;11,362 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Prepaid expenses </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>48,375 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Deferred financing charge </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%">1,215 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>393,449 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>12,577 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%">576 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="17%" bgColor=#e6efff>&nbsp;393,449 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="17%" bgColor=#e6efff>&nbsp;13,153 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=center valign="bottom" bgColor=#e6efff ><B><U>LIABILITIES</U></B> </TD>
    <TD vAlign=bottom align=center width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=center width="17%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=center width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=center width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=center width="17%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Current </TD>
    <TD vAlign=bottom align=right width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >&nbsp; &nbsp;Accounts payable and accrued
      liabilities </TD>
    <TD vAlign=bottom align=left width="1%" >$</TD>
    <TD vAlign=bottom align=right width="17%">1,741,797</TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >$</TD>
    <TD vAlign=bottom align=right width="17%">&nbsp;2,589,324 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >&nbsp; &nbsp;Promissory notes
      payable </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%" bgColor=#e6efff>210,863 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%" bgColor=#e6efff>299,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%">1,952,660 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%">2,888,324 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Derivative liability </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%" bgColor=#e6efff>904,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%">2,856,660 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%">2,888,324 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom" bgColor=#e6efff >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=center valign="bottom" bgColor=#e6efff ><B><U>CAPITAL
      DEFICIT</U></B> </TD>
    <TD vAlign=bottom align=center width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=center width="17%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=center width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=center width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=center width="17%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Capital stock </TD>
    <TD vAlign=bottom align=right width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" nowrap
      >&nbsp;&nbsp;&nbsp;Authorized:&nbsp;<BR>
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;150,000,000
      common shares, par value $0.001 per
      share&nbsp;<BR>
      &nbsp;&nbsp;&nbsp;Issued and
      outstanding:&nbsp;<BR>
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;37,237,588
      common shares (September 30, 2012 - 30,240,687) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%">37,238 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%">30,241 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Additional paid-in capital</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>38,644,523 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>34,599,514 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Share subscriptions received </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%">60,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Deficit accumulated during
      the development stage </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%" bgColor=#e6efff>(41,204,972</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%" bgColor=#e6efff>(37,504,926</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%">(2,463,211</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%">(2,875,171</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="17%" bgColor=#e6efff>&nbsp;393,449 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="17%" bgColor=#e6efff>&nbsp;13,153 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES</P>
<P align=center>F-5</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-5></A>
<P align=justify><B>ANAVEX LIFE SCIENCES CORP.</B><BR>
  (A Development Stage
  Company)<BR>
  CONSOLIDATED STATEMENTS OF OPERATIONS<BR>
  for the years ended
  September 30, 2013 and 2012<BR>
  and for the period from January 23, 2004 (Date of
  Inception) to September 30, 2013<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="15%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="15%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="15%" align=center valign="bottom" nowrap>January 23, 2004 </TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD colspan="4" align=center valign="bottom" nowrap>Year ended September 30, </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="15%" align=center valign="bottom" nowrap>(Date of Inception) to </TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="15%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">2013 </TD>
    <TD
    width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="15%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">2012 </TD>
    <TD
    width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
      width="15%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">September 30, 2013 </TD>
    <TD
    width="2%" align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Expenses </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Accounting and audit fees </TD>
    <TD vAlign=bottom align=left width="1%">$</TD>
    <TD vAlign=bottom align=right width="15%">&nbsp;136,758 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">$</TD>
    <TD vAlign=bottom align=right width="15%">&nbsp;139,761 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">$</TD>
    <TD vAlign=bottom align=right width="15%">&nbsp;798,872 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Amortization and depreciation </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>576 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>1,858 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>5,631 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Bank charges and interest </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">4,397 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">5,963 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">46,704 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Consulting fees - Note 8 and 9 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>271,898 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>1,155,366 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>12,015,989 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Insurance </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">16,125 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">10,844 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">75,121 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Investor relations </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>128,575 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>108,138 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>960,282 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Legal fees </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">176,318</TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">142,923 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">846,343</TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Management fees - Note 8 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>14,625 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Office and miscellaneous expense </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">4,019 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">9,147 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">151,703 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Registration and filing fees </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>33,634 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>26,794 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>188,032 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Rent and administration </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">12,000 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">236,670 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Research and development - Note 9 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>263,847 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>2,653,860 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>12,822,796 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Salaries and wages - Notes 8 and 9 </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">1,067,294 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">1,067,294 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Travel </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>19,695 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>66,837 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>760,850 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Website design and maintenance </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%">2,231 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%">30,648 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Loss before other income (expenses) </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">(2,137,367</TD>
    <TD vAlign=bottom align=left width="2%">) </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">(4,321,491</TD>
    <TD vAlign=bottom align=left width="2%">) </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">(30,021,560</TD>
    <TD vAlign=bottom align=left width="2%">) </TD>
  </TR>
  <TR>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Other income (expenses) </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Interest and financing fees </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>(51,341</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>(138,341</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>(677,362</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Accretion of debt discount </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">(98,081</TD>
    <TD vAlign=bottom align=left width="2%">) </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">(2,174,661</TD>
    <TD vAlign=bottom align=left width="2%">) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Change in fair value of derivative
      liability </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>15,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>67,500 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>(448,274</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Debt conversion expense </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">(504,160</TD>
    <TD vAlign=bottom align=left width="2%">) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Loss on settlement of accounts payable </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>(976,880</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>(1,754,933</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Loss on extinguishment of debt </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">(495,328</TD>
    <TD vAlign=bottom align=left width="2%">) </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">(3,829,333</TD>
    <TD vAlign=bottom align=left width="2%">) </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">(5,010,868</TD>
    <TD vAlign=bottom align=left width="2%">) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Foreign exchange gain (loss) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%" bgColor=#e6efff>(54,130</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%" bgColor=#e6efff>18,041 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%" bgColor=#e6efff>(62,350</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Net loss for the period </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="15%" bgColor=#e6efff>&nbsp;(3,700,046</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="15%" bgColor=#e6efff>&nbsp;(8,301,705</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="15%" bgColor=#e6efff>&nbsp;(40,654,168</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Basic and diluted loss per share </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="15%" bgColor=#e6efff>&nbsp;(0.12</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="15%" bgColor=#e6efff>&nbsp;(0.29</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Weighted average number of shares
      outstanding </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="15%" bgColor=#e6efff>31,908,441 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="15%" bgColor=#e6efff>28,168,784 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES</P>
<P align=center>F-6</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-6></A>
<P align=justify><B>ANAVEX LIFE SCIENCES CORP.</B><BR>
  (A Development Stage
  Company)<BR>
  CONSOLIDATED STATEMENTS OF CASH FLOWS<BR>
  for the years ended
  September 30, 2013 and 2012<BR>
  and for the period from January 23, 2004 (Date of
  Inception) to September 30, 2013<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=left valign="bottom" >&nbsp;</TD>
    <TD width="15%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="15%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="15%" align=center valign="bottom" nowrap>January 23, 2004 </TD>
    <TD width="2%" align=left valign="bottom" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=left valign="bottom" >&nbsp;</TD>
    <TD colspan="4" align=center valign="bottom" nowrap>Year ended September 30, </TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="15%" align=center valign="bottom" nowrap>(Date of Inception) to </TD>
    <TD width="2%" align=left valign="bottom" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="15%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">2013 </TD>
    <TD width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="15%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">2012 </TD>
    <TD width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="15%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">September 30, 2013 </TD>
    <TD width="2%" align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Cash Flows used in Operating Activities </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Net loss for the period </TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="15%"
    bgColor=#e6efff>&nbsp;(3,700,046</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="15%"
    bgColor=#e6efff>&nbsp;(8,301,705</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="15%"
    bgColor=#e6efff>&nbsp;(40,654,168</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Adjustments to reconcile net loss to net cash
      used in operations: </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Amortization and depreciation </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>576 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>1,858 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>5,631 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Accretion of debt discount </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">98,081 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">2,174,661 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Stock-based compensation </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>1,002,500 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>302,208 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>5,845,047 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Amortization of deferred financing charge </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">1,215 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">62,399 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">163,927 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Change in fair value of
      derivative liability </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>(15,000</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>(67,500</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>448,274 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Consulting expense recorded in exchange for
      shares to be issued </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">236,337 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Common shares issued for
      consulting expenses </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>15,895 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>406,405 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Promissory note issued for severance </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">71,500 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Common shares issued for
      severance </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>75,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>415,600 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Common shares issued for research and
      development expenses </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">800,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Management fees contributed </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>14,625 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Debt conversion expense </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">504,160 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Loss on settlement of
      accounts payable </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>976,880 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>1,754,933 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Loss on extinguishment of debt </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">495,328 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">3,829,333 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">5,010,868 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Rent contributed </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>3,750 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Unrealized foreign exchange </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">(4,937</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">(4,937</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Changes in non-cash working
      capital balances related to operations: </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >VAT recoverable </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">809 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Prepaid expenses </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>9,630 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Accounts payable and accrued liabilities </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%">465,911 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%">2,281,052 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%">6,238,459 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Net cash used in operating
      activities </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>(777,573</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>(1,692,940</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>(16,564,928</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD valign="bottom" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Cash Flows used in Investing
      Activities </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Acquisition of equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%">(5,631</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Net cash used in investing
      activities </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>(5,631</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD valign="bottom" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Cash Flows provided by
      Financing Activities </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Issuance of common shares, net of share issue
      costs </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">801,285 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">996,250 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">11,048,118 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Share subscriptions received </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>60,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>60,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Proceeds from promissory notes </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">250,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">581,500 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">5,649,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Financing fees </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>(8,150</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>(108,150</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Repayment of promissory note </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%">(100,000</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Due to related parties </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>33,665 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Shareholder advances </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%">333,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Net cash provided by
      financing activities </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>1,111,285 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>1,569,600 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>16,915,633 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="15%">&nbsp;</TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Increase (decrease) in cash
      during the period </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>333,712 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>(123,340</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="15%" bgColor=#e6efff>345,074 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Cash, beginning of period </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%">11,362 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%">134,702 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="15%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Cash, end of period </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="15%" bgColor=#e6efff>&nbsp;345,074 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="15%" bgColor=#e6efff>&nbsp;11,362 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="15%" bgColor=#e6efff>&nbsp;345,074 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P align=justify>Supplemental Cash Flow Information - Note 11</P>
<P align=center>SEE ACCOMPANYING NOTES</P>
<P align=center>F-7</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-7></A>
<P align=justify><B>Anavex Life Sciences Corp.</B><BR>
  (A Development Stage
  Company)<BR>
  Consolidated Statement of Changes in Capital Deficit<BR>
  For the
  period from January 23, 2004 (Date of Inception) to September 30, 2013<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Deficit </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD colspan="10" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"> Common Stock </TD>
    <TD
    width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Accumulated </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Shares </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Par Value </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Additional </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Common </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>During the </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Paid-in </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Shares to be </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Development </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
      width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
      width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
      width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Capital </TD>
    <TD
    width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
      width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Issued </TD>
    <TD
    width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Stage </TD>
    <TD
    width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Total </TD>
    <TD
    width="2%" align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="8%">&nbsp;</TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="8%">&nbsp;</TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="8%">&nbsp;</TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="8%">&nbsp;</TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="8%">&nbsp;</TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="8%">&nbsp;</TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued for cash on January
      23, 2004 - at $0.0033 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>12,000,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;12,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;28,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;40,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Net loss from January 23, 2004 to September 30, 2004 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">(14,395</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">(14,395</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">) </TD>
  </TR>
  <TR>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Balance, September 30, 2004 </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">12,000,000 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">12,000 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">28,000 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(14,395</TD>
    <TD vAlign=bottom align=left width="2%">) </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">25,605 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued for cash on December
      31, 2004 - at $0.0033 </TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">7,200,000 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">7,200 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">16,800 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">24,000 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Management fees contributed </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>13,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>13,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Rent contributed </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">3,000 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">3,000 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Net loss for the year </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(91,625</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(91,625</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Balance, September 30, 2005 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>19,200,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>19,200 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>60,800 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(106,020</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(26,020</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Management fees contributed </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">1,625 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">1,625 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Rent contributed </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>750 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>750 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Debt forgiven by directors </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">33,666 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">33,666 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Net loss for the year </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(25,532</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(25,532</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Balance, September 30, 2006 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>19,200,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>19,200 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>96,841 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(131,552</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(15,511</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Capital stock issued for research and development services
      on September 24, 2007 - at $3.60 </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">222,222 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">222 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">799,778 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">800,000 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued for settlement of loan
      payable on September 25, 2007 - at $3.60 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>92,500 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>93 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>332,907 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>333,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Net loss for the year </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">(1,579,993</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">(1,579,993</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">) </TD>
  </TR>
  <TR>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Balance, September 30, 2007 </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">19,514,722 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">$</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;19,515 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">$</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;1,229,526 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">$</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">$</TD>
    <TD vAlign=bottom align=right width="8%">(1,711,545</TD>
    <TD vAlign=bottom align=left width="2%">) </TD>
    <TD vAlign=bottom align=left width="1%">$</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;(462,504</TD>
    <TD vAlign=bottom align=left width="2%">) </TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES</P>
<P align=center>F-8</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-8></A>
<P align=justify><B>Anavex Life Sciences Corp.</B><BR>
  (A Development Stage
  Company)<BR>
  Consolidated Statement of Changes in Capital Deficit<BR>
  For the
  period from January 23, 2004 (Date of Inception) to September 30, 2013<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Deficit </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD colspan="10" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"> Common Stock </TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Accumulated </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Shares </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Par Value </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Additional </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Common </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>During the </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Paid-in </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Shares to be </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Development </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Capital </TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Issued </TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Stage </TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Total </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Balance, September 30, 2007 -
      brought forward </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>19,514,722 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;19,515 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;1,229,526 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%"
    bgColor=#e6efff>&nbsp;(1,711,545</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;(462,504</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Capital stock issued for cash on December 10,
      2007 - at $3.50 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">150,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">150 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">524,850 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">525,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Capital stock issued for
      consulting services on December 18, 2007 - at $3.86 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>50,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>50 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>192,950 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>193,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Capital stock issued in settlement of debt on
      December 18, 2007 - at $4.50 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">10,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">10 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">44,990 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">45,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Stock-based compensation for
      shares issued at a discount </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>65,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>65,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Capital stock issued for severance on May 15,
      2008 - at $5.24 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">65,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">65 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">340,535 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">340,600 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Common shares to be issued
      for consulting services </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>252,599 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>252,599 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Common stock issued for consulting services
      on August 19, 2008 - at $5.07 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">25,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">25 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">126,725 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(126,750</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Capital stock issued for cash
      on August 19, 2008 - at $4.25 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>142,698 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>142 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>606,325 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>606,467 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Stock-based compensation </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">1,493,937 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">1,493,937 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Net loss for the year </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(5,351,269</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(5,351,269</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Balance, September 30, 2008 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>19,957,420 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;19,957 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;4,624,838 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;125,849 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%"
    bgColor=#e6efff>&nbsp;(7,062,814</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%"
    bgColor=#e6efff>&nbsp;(2,292,170</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES</P>
<P align=center>F-9</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-9></A>
<P align=justify><B>Anavex Life Sciences Corp.</B><BR>
  (A Development Stage
  Company)<BR>
  Consolidated Statement of Changes in Capital Deficit<BR>
  For the
  period from January 23, 2004 (Date of Inception) to September 30, 2013<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Deficit </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD colspan="10" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"> Common Stock </TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Accumulated </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Shares </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Par Value </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Additional </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Common </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>During the </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Paid-in </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Shares to be </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>Development </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="8%" align=center nowrap>&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Capital </TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Issued </TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Stage </TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Total </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Balance, September 30, 2008 -
      brought forward </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>19,957,420 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;19,957 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;4,624,838 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;125,849 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%"
    bgColor=#e6efff>&nbsp;(7,062,814</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%"
    bgColor=#e6efff>&nbsp;(2,292,170</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Stock-based compensation </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">812,336 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">812,336 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Capital stock issued for
      consulting services on November 20, 2008 - $2.63 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>25,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>25 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>65,725 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(65,750</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Capital stock issued for consulting services
      on February 20, 2009 - $2.50 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">25,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">25 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">62,475 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(62,500</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Capital stock issued for cash
      on March 6, 2009 - at $2.25 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>89,148 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>89 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>200,494 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>200,583 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Capital stock issued for consulting services
      on March 20, 2009 - at $2.00 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">2,500 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">3 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">4,997 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">5,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Capital stock issued for cash
      on March 20, 2009 - at $2.25 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>10,800 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>11 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>24,289 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>24,300 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Capital stock issued for cash on June 11,
      2009 - at $2.25 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">36,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">36 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">80,964 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">81,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Capital stock issued for
      services on June 11, 2009 - at $2.25 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>29,227 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>29 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>65,731 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>65,760 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Capital stock issued for cash on June 19,
      2009 - at $2.25 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">495,556 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">496 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">1,114,504 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">1,115,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Capital stock issued for
      finders' fees on June 26, 2009 - at $2.51 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>22,222 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>22 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>55,755 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>55,777 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Shares to be issued for consulting services -
      Note 8 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">236,337 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">236,337 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Capital stock issued for cash
      on August 19, 2009 - at $2.25 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>128,888 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>129 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>289,869 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>289,998 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Less: Finders fees </TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(72,850</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(72,850</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Beneficial conversion
      features on convertible debt issuances </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>333,056 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>333,056 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Extinguishment of debt </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">487,469 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">487,469 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Cancellation of common shares </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(75,000</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(75</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>234,011 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(233,936</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Share subscriptions received </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">300,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">300,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Net loss for the year </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(5,499,419</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(5,499,419</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Balance, September 30, 2009 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>20,746,761 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;20,747 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;8,383,663 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;300,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%"
    bgColor=#e6efff>&nbsp;(12,562,233</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%"
    bgColor=#e6efff>&nbsp;(3,857,823</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES</P>
<P align=center>F-10</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-10></A>
<P align=justify><B>Anavex Life Sciences Corp.</B><BR>
  (A Development Stage
  Company)<BR>
  Consolidated Statement of Changes in Capital Deficit<BR>
  For the
  period from January 23, 2004 (Date of Inception) to September 30, 2013<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=left valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Deficit </TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD colspan="10" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"> Common Stock </TD>
    <TD width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Accumulated </TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=left valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Shares </TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Par Value </TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Additional </TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Common </TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>During the </TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=left valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Paid-in </TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Shares to be </TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Development </TD>
    <TD width="2%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Capital </TD>
    <TD width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Issued </TD>
    <TD width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Stage </TD>
    <TD width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Total </TD>
    <TD width="2%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=right valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=right valign="bottom">&nbsp;</TD>
    <TD width="2%" align=right valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=right valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=right valign="bottom">&nbsp;</TD>
    <TD width="2%" align=right valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=right valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=right valign="bottom">&nbsp;</TD>
    <TD width="2%" align=right valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=right valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=right valign="bottom">&nbsp;</TD>
    <TD width="2%" align=right valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=right valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=right valign="bottom">&nbsp;</TD>
    <TD width="2%" align=right valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=right valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=right valign="bottom">&nbsp;</TD>
    <TD width="2%" align=right valign="bottom" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Balance, September 30, 2009 -
      brought forward </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>20,746,761 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;20,747 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;8,383,663 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;300,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%"
    bgColor=#e6efff>&nbsp;(12,562,233</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%"
    bgColor=#e6efff>&nbsp;(3,857,823</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Cumulative effect of accounting changes </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(333,056</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(550,804</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(883,860</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Capital stock issued for cash
      on October 2, 2009 - at $2.25 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>266,666 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>267 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>599,733 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(300,000</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>300,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Capital stock issued in settlement of
      promissory note on February 2, 2010 - at $2.02 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">49,505 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">49 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">99,951 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">100,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Capital stock issued for cash
      on April 9, 2010 - at $2.60 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>92,499 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>93 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>240,405 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>240,498 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Capital stock issued in settlement of debt on
      April 30, 2010 - at $2.85 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">9,825 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">9 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">27,991 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">28,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Finders' fees paid in cash</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(24,050</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(24,050</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Capital stock issued for cash on June 29,
      2010 - at $2.50 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">941,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">941 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">2,351,559 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">2,352,500 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Finders' fees paid in cash</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(206,500</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(206,500</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Capital stock issued in settlement of debt on
      July 5, 2010 - at $2.50 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">400,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">400 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">999,600 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">1,000,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Capital stock issued for cash
      on September 3, 2010 - at $2.75 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>163,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>163 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>448,087 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>448,250 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Capital stock issued for finders' fees on
      September 3, 2010 - at $2.75 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">9,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">9 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(9</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Finders' fees paid in cash</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(15,125</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(15,125</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Shares issud on conversion of promissory note
      on September 30, 2010 - at $2.25 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">328,058 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">328 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">737,802 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">738,130 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Shares issud on conversion of
      promissory note on September 30, 2010 - at $2.35 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>510,638 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>511 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>1,199,489 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>1,200,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Reclassification of dervative liability on
      modification of note </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">3,144,520 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">3,144,520 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Settlementterms of accounts
      payable </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>444,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>444,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Stock-based compensation </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">770,055 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">770,055 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff >Equity component of
      convertible promissory note </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>44,220 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>44,220 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Net loss for the year </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">(8,783,037</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">(8,783,037</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >) </TD>
  </TR>
  <TR>
    <TD valign="bottom" bgColor=#e6efff >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" >Balance, September 30, 2010 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">23,516,952 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >$</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;23,517 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >$</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;18,912,335 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >$</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >$</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;(21,896,074</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >$</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;(2,960,222</TD>
    <TD vAlign=bottom align=left width="2%" >)</TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES</P>
<P align=center>F-11</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-11></A>
<P align=justify><B>Anavex Life Sciences Corp.</B><BR>
  (A Development Stage
  Company)<BR>
  Consolidated Statement of Changes in Capital Deficit<BR>
  For the
  period from January 23, 2004 (Date of Inception) to September 30, 2013<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Deficit </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD
    width="1%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD colspan="10" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"> Common Stock </TD>
    <TD
    width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Accumulated </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Shares </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Par Value </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Additional </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Common </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>During the </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Paid-in </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Shares to be </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>Development </TD>
    <TD width="2%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD
    width="1%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
      width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
      width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
      width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Capital </TD>
    <TD
    width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
      width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Issued </TD>
    <TD
    width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Stage </TD>
    <TD
    width="2%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="1%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Total </TD>
    <TD
    width="2%" align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">&nbsp;</TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">&nbsp;</TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">&nbsp;</TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">&nbsp;</TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">&nbsp;</TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">&nbsp;</TD>
    <TD width="2%" align=right valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Balance, September 30, 2010 - brought
      forward </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>23,516,952 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;23,517 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;18,912,335 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%"
    bgColor=#e6efff>&nbsp;(21,896,074</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%"
    bgColor=#e6efff>&nbsp;(2,960,222</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#ffffff>Capital stock issued for cash on November
      18, 2010 - at $2.75 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>393,846 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>393 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>1,082,682 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>1,083,075 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Less: Share issue costs </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(65,363</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(65,363</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#ffffff>Capital stock issued for finders' fees on
      November 18, 2010 - at $2.75 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>3,636 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>4 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>(4</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>) </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Shares issued on the conversion of
      promissory note on November 18, 2010 - at $2.25 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>853,075 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>853 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>1,918,565 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>1,919,418 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#ffffff>Debt conversion expense </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>504,160 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>504,160 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Shares issued on the conversion of a
      promissory note on November 18, 2010 - at $4.12 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>145,063 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>145 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>597,515 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>597,660 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#ffffff>Capital stock issued in settlement of debt
      on November 18, 2010 - at $4.12 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>181,818 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>182 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>748,908 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>749,090 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued for cash on November
      25, 2010 - at $3.35 </TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff></TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>29,851 </TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff></TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff></TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>30 </TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff></TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff></TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>99,970 </TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff></TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff></TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff></TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff></TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff></TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff></TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>100,000 </TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#ffffff>Capital stock issued for finders' fees on
      on November 25, 2010 - at $3.35 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>2,985 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>3 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>(3</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>) </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued for cash on February
      1, 2011 - at $3.75 </TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>61,014 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>61 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>228,739 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>228,800 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued for cash on May 3,
      2011 - at $3.00 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>33,334 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>34 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>99,966 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>100,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#ffffff>Capital stock issued on exercise of
      warrants for cash on June 19, 2011 - at $2.25 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>700,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>700 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>1,574,300 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>1,575,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Equity units issued in settlement of an
      account payable on September 28, 2011 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>650,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>650 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>1,059,313 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff></TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff></TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>1,059,963 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#ffffff>Stock-based compensation </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>1,273,162 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>1,273,162 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#ffffff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Net loss for the period </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(7,307,147</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(7,307,147</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD valign="bottom" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#ffffff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Balance, September 30, 2011 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>26,571,574 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;26,572 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;28,034,245 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%"
    bgColor=#e6efff>&nbsp;(29,203,221</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%"
    bgColor=#e6efff>&nbsp;(1,142,404</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>)</TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES</P>
<P align=center>F-12</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-12></A>
<P align=justify><B>Anavex Life Sciences Corp.</B><BR>
  (A Development Stage
  Company)<BR>
  Consolidated Statement of Changes in Capital Deficit<BR>
  For the
  period from January 23, 2004 (Date of Inception) to September 30, 2013<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=center width="8%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="8%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="8%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="8%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="8%">Deficit </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="8%">&nbsp;</TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD colspan="10" align=center style="BORDER-BOTTOM: #000000 1px solid"> Common Stock </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="8%">Accumulated </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="8%">&nbsp;</TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=center width="8%">Shares </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="8%">Par Value </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="8%">Additional </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="8%">Common </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="8%">During the </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="8%">&nbsp;</TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=center width="8%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="8%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="8%">Paid-in </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="8%">Shares to be </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="8%">Development </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="8%">&nbsp;</TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="8%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="8%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="8%">Capital </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="8%">Issued </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="8%">Stage </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="8%">Total </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Balance, September 30, 2011 - brought
      forward </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>26,571,574 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;26,572 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;28,034,245 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%"
    bgColor=#e6efff>&nbsp;(29,203,221</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%"
    bgColor=#e6efff>&nbsp;(1,142,404</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Capital stock issued for cash on December
      6, 2011 - at $1.25 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>615,600 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>616 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>768,884 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>769,500 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Less: Share issue costs </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(77,000</TD>
    <TD vAlign=bottom align=left width="2%">) </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(77,000</TD>
    <TD vAlign=bottom align=left width="2%">) </TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Capital stock issued for cash on February 9, 2012 - at
      $1.25 </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">270,000 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">270 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">337,230 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">337,500 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Less: Share issue costs </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(33,750</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(33,750</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Equity units issued for services on
      February 9, 2012 - at $1.99 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>8,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>8 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>15,888 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>15,896 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Equity units issued for settlement of loans payable on May
      31, 2012 </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">2,700,513 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">2,700 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">5,176,884 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">5,179,584 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Capital stock issued for services on July
      12, 2012 - at $1.00 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>75,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>75 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>74,925 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>75,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Stock-based compensation </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">302,208 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">302,208 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net loss for the period </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(8,301,705</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(8,301,705</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Balance, September 30, 2012 </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>30,240,687 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>30,241 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>34,599,514 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(37,504,926</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(2,875,171</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Equity units issued for settlement of loans payable on July
      5, 2013 - Note 5 </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">4,208,910 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">4,209 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">2,563,011 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">2,567,220 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Capital stock issued for cash on July 5, 2013 - at $0.40 -
      Note 6 </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">2,196,133 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">2,196 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">563,257 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">565,453 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Less: Share issue costs </TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(112,174</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(112,174</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Initial purchase shares issued under equity line on July 5,
      2013 - at $0.40 - Note 7 </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">591,858 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">592 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">99,750 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">100,342 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Less: Share issue costs </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(71,335</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(71,335</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Common stock to be issued for cash - at $0.50 </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">60,000 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">60,000 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Stock-based compensation </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>1,002,500 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>1,002,500 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Net loss for the period </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">(3,700,046</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">(3,700,046</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">) </TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Balance, September 30, 2013 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="8%">37,237,588 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%">$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="8%">&nbsp;37,238 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%">$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="8%">&nbsp;38,644,523 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%">$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="8%">&nbsp;60,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%">$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="8%">&nbsp;(41,204,972</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%">) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%">$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="8%">&nbsp;(2,463,211</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%">) </TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES</P>
<P align=center>F-13</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-13></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 1 </TD>
    <TD align=left width="90%" ><U>Business Description, Basis of
      Presentation and Liquidity</U> </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>Business </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>Anavex Life Sciences Corp. (the &#147;Company&#148;) is a
      pharmaceutical company engaged in the development of drug candidates. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The Company&#146;s lead compound, ANAVEX 2-73 is being
      developed to treat Alzheimer&#146;s disease through disease modification. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>In pre-clinical studies conducted in France, and in
      Greece, ANAVEX 2-73 demonstrated anti- amnesic and neuroprotective
      properties. Based on these pre-clinical studies, the Company sponsored a
      Phase 1 single ascending dose study of ANAVEX 2-73, which was initiated
      and completed in 2011. This study was conducted in Germany in
      collaboration with ABX-CRO Advanced Pharmaceutical Services. The study
      indicated that ANAVEX 2-73 was well tolerated by study subjects in doses
      up to 55mg. During the year ended September 30, 2013, clinical trials had
      been delayed due to lack of funding. On July 5, 2013, the Company
      completed the closing of a private placement offering and a $10,000,000
      purchase agreement (Note 7), the proceeds from which the Company will use
      to further its business plan and clinical trials of ANAVEX 2-73. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The Company plans to initiate a multiple ascending dose
      study of ANAVEX 2-73 in the first half of fiscal year 2014. Additionally
      we intend to identify and initiate discussions with potential partners in
      the next 12 months. Further, we may acquire or develop new intellectual
      property and assign, license, or otherwise transfer our intellectual
      property to further our goals. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>Basis of Presentation and Liquidity </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>These financial statements have been prepared in
      accordance with accounting principles generally accepted in the United
      States of America and the instructions to Form 10-K. </P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-14</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-14></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 2<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 1 </TD>
    <TD align=left width="90%" ><U>Business Description, Basis of
      Presentation and Liquidity </U>&#150; (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America on a going concern basis, which assumes that the Company will continue to realize its assets and discharge its obligations and commitments in the normal course of operations. Realization values may be substantially different from carrying values as shown, and these financial statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. At September 30, 2013, the Company had an accumulated deficit of $41,204,972 (2012 - $37,504,926), had a working capital deficit of $1,559,211 and expects to incur further losses in the development of its business, all of which casts substantial doubt about the Company&#146;s ability to continue as a going concern. The Company&#146;s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management has no formal plan in place to address this but considers obtaining additional funds by equity financing and/or from issuing promissory notes. Management expects the Company's cash requirement over the next twelve months to be approximately $6,000,000. While the Company is expending its best efforts to achieve the above plans, there is no assurance that any such activity will generate funds for operations.</P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Summary of Significant
      Accounting Policies</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify>Use of Estimates</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The preparation of financial statements in accordance
      with accounting principles generally accepted in the United States of
      America requires management to make estimates and assumptions that affect
      the reported amounts of assets and liabilities at the date of the
      financial statements and the reported amounts of revenue and expenses in
      the reporting period. The Company regularly evaluates estimates and
      assumptions related to deferred income tax asset valuations, asset
      impairment, conversion features embedded in convertible notes payable,
      derivative valuations, stock based compensation and loss contingencies.
      The Company bases its estimates and assumptions on current facts,
      historical experience and various other factors that it believes to be
      reasonable under the circumstances, the results of which form the basis
      for making judgments about the carrying values of assets and liabilities
      and the accrual of costs and expenses that are not readily apparent from
      other sources. The actual results experienced by the Company may differ
      materially and adversely from the Company&#146;s estimates. To the extent there
      are material differences between the estimates and the actual results,
      future results of operations will be affected.</P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-15</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-15></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 3<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Summary of Significant
      Accounting Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>Principles of Consolidation</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>These consolidated financial statements include the
      accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiary,
      Anavex Life Sciences (France) SA, a company incorporated under the laws of
      France. All inter-company transactions and balances have been
      eliminated.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD><P align=justify>Development Stage Company</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company is devoting substantially all of its present
      efforts to establish a new business and none of its planned principal
      operations have commenced. All losses accumulated since inception have
      been considered as part of the Company&#146;s development stage
      activities.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">d) </TD>
    <TD><P align=justify>Equipment</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>Equipment is recorded at cost and is depreciated at 33%
      per annum on the straight-line basis.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">e) </TD>
    <TD><P align=justify>Impairment of Long-Lived Assets</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company reviews the recoverability of its long-lived
      assets whenever events or changes in circumstances indicate that the
      carrying amount of such assets may not be recoverable. The estimated
      future cash flows are based upon, among other things, assumptions about
      future operating performance, and may differ from actual cash flows.
      Long-lived assets evaluated for impairment are grouped with other assets
      to the lowest level for which identifiable cash flows are largely
      independent of the cash flows of other groups of assets and liabilities.
      If the sum of the projected undiscounted cash flows (excluding interest)
      is less than the carrying value of the assets, the assets will be written
      down to the estimated fair value in the period in which the determination
      is made.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">f) </TD>
    <TD><P align=justify>Financial Instruments</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The carrying value of the Company&#146;s financial
      instruments, consisting of cash and accounts payable and accrued
      liabilities approximate their fair value due to the short-term maturity of
      such instruments. Based on borrowing rates currently available to the
      Company for similar terms and based on the short term duration of the debt
      instruments, the carrying value of the promissory notes payable
      approximate their fair value. Unless otherwise noted, it is management&#146;s
      opinion that the Company is not exposed to significant interest, currency
      or credit risks arising from these financial
      instruments.</P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-16</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-16></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 4<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Summary of Significant
      Accounting Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">g) </TD>
    <TD><P align=justify>Foreign Currency Translation</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The functional currency of the Company is the US dollar.
      Monetary items denominated in a foreign currency are translated into US
      dollars at exchange rates prevailing at the balance sheet date and
      non-monetary items are translated at exchange rates prevailing when the
      assets were acquired or obligations incurred. Foreign currency denominated
      expense items are translated at exchange rates prevailing at the
      transaction date. Unrealized gains or losses arising from the translations
      are credited or charged to income in the period in which they
      occur.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">h) </TD>
    <TD><P align=justify>Research and Development Expenses</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>Research and developments costs are expensed as incurred.
      These expenses are comprised of the costs of the Company&#146;s proprietary
      research and development efforts, including salaries, facilities costs,
      overhead costs and other related expenses as well as costs incurred in
      connection with third-party collaboration efforts. Milestone payments made
      by the Company to third parties are expensed when the specific milestone
      has been achieved.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In addition, the Company incurs expenses in respect of
      the acquisition of intellectual property relating to patents. The
      probability of success and length of time to developing commercial
      applications of the drugs subject to the acquired patents and trademarks
      is difficult to determine and numerous risks and uncertainties exist with
      respect to the timely completion of the development projects. There is no
      assurance the acquired patents will ever be successfully commercialized.
      Due to these risks and uncertainties, the acquisition costs of patents do
      not meet the definition of an asset and thus are expensed as
      incurred.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">i) </TD>
    <TD><P align=justify>Income Taxes</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company has adopted the asset and liability method of
      accounting for income taxes. Under the asset and liability method,
      deferred tax assets and liabilities are recognized for the future tax
      consequences attributable to temporary differences between the financial
      statements carrying amounts of existing assets and liabilities and their
      respective tax bases. Deferred tax assets and liabilities are measured
      using enacted tax rates expected to apply to taxable income in the years
      in which those temporary differences are expected to be recovered or
      settled.</P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-17</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-17></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 5<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Summary of Significant
      Accounting Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">i) </TD>
    <TD><P align=justify>Income Taxes &#150; (cont&#146;d)</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company has adopted the provisions of FASB ASC 740
      "Income Taxes" regarding accounting for uncertainty in income taxes. The
      Company initially recognizes tax positions in the financial statements
      when it is more likely than not the position will be sustained upon
      examination by the tax authorities. Such tax positions are initially and
      subsequently measured as the largest amount of tax benefit that is greater
      than 50% likely of being realized upon ultimate settlement with the tax
      authority, assuming full knowledge of the position and all relevant facts.
      Application requires numerous estimates based on available information.
      The Company considers many factors when evaluating and estimating its tax
      positions and tax benefits, and its recognized tax positions and tax
      benefits may not accurately anticipate actual outcomes. As additional
      information is obtained, there may be a need to periodically adjust the
      recognized tax positions and tax benefits. These periodic adjustments may
      have a material impact on the consolidated statements of
      operations.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">j) </TD>
    <TD><P align=justify>Basic and Diluted Loss per Share</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The basic loss per common share is computed by dividing
      net loss available to common stockholders by the weighted average number
      of common shares outstanding. Diluted loss per common share is computed
      similar to basic loss per common share except that the denominator is
      increased to include the number of additional common shares that would
      have been outstanding if the potential common shares had been issued and
      if the additional common shares were dilutive. For the year ended
      September 30, 2013, loss per share excludes 12,224,479 (2012 &#150; 6,025,141)
      potentially dilutive common shares (related to outstanding options and
      warrants) as their effect was anti-dilutive.</P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-18</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-18></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 6<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Summary of Significant
      Accounting Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">k) </TD>
    <TD><P align=justify>Stock-based Compensation</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company accounts for all stock-based payments and
      awards under the fair value based method.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>Stock-based payments to non-employees are measured at the
      fair value of the consideration received, or the fair value of the equity
      instruments issued, or liabilities incurred, whichever is more reliably
      measurable. The fair value of stock-based payments to non-employees is
      periodically re-measured until the counterparty performance is complete,
      and any change therein is recognized over the vesting period of the award
      and in the same manner as if the Company had paid cash instead of paying
      with or using equity based instruments. Compensation costs for stock-based
      payments with graded vesting are recognized on a straight-line basis. The
      cost of the stock-based payments to non- employees that are fully vested
      and non-forfeitable as at the grant date is measured and recognized at
      that date, unless there is a contractual term for services in which case
      such compensation would be amortized over the contractual term.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company accounts for the granting of share purchase
      options to employees using the fair value method whereby all awards to
      employees will be recorded at fair value on the date of the grant. The
      fair value of all share purchase options are expensed over their vesting
      period with a corresponding increase to additional paid-in
      capital.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company uses the Black-Scholes option valuation model
      to calculate the fair value of share purchase options at the date of the
      grant. Option pricing models require the input of highly subjective
      assumptions, including the expected price volatility. Changes in these
      assumptions can materially affect the fair value estimates.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">l) </TD>
    <TD><P align=justify>Fair Value Measurements</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The fair value hierarchy under GAAP is based on three
      levels of inputs, of which the first two are considered observable and the
      last unobservable, that may be used to measure fair value which are the
      following:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left>Level 1 - </TD>
    <TD align=left width="78%" ><P align=justify>quoted prices (unadjusted) in active markets for
      identical assets or liabilities; </P></TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="78%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" ></TD>
    <TD align=left>Level 2 - </TD>
    <TD align=left width="78%"  ><P align=justify>observable inputs other than Level I, quoted prices for
      similar assets or liabilities in active markets, quoted prices for
      identical or similar assets and liabilities in markets that are not
      active, and model-derived prices whose inputs are observable or whose
      significant value drivers are observable; and </P></TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="78%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" ></TD>
    <TD align=left>Level 3 - </TD>
    <TD align=left width="78%" ><P align=justify>assets and liabilities whose significant value drivers
      are unobservable by little or no market activity and that are significant
      to the fair value of the assets or liabilities. </P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-19</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-19></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 7<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Summary of Significant
      Accounting Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">l) </TD>
    <TD><P align=justify>Fair Value Measurements &#150; (cont&#146;d)</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The book value of cash and accounts payable and accrued
      liabilities approximate their fair values due to the short term maturity
      of those instruments. Based on borrowing rates currently available to the
      Company under similar terms, the book value of promissory notes payable
      approximates their fair values. The Company&#146;s promissory notes payable are
      based on Level 2 inputs in the ASC 820 fair value hierarchy.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>At September 30, 2013, the Company&#146;s Level 3 liabilities
      consisted of share purchase warrants that are required to be accounted for
      as liabilities pursuant to ASC 815 because the terms of the warrants
      contain provisions that are in violation of the fixed for fixed criteria
      of that guidance.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company calculated the fair value at the inception of
      these contracts and as at September 30, 2013 using the binomial option
      pricing model to determine the fair value, using the following
      assumptions:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=right width="20%">&nbsp;</TD>
    <TD align=right width="20%">At September </TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=right width="20%">At inception </TD>
    <TD align=right width="20%">30, 2013 </TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left  >&nbsp;</TD>
    <TD align=center width="20%" >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Risk-free interest rate </TD>
    <TD align=right width="20%" bgColor=#e6efff>0.28% </TD>
    <TD align=right width="20%" bgColor=#e6efff>0.10% </TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left  >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Expected life (years) </TD>
    <TD align=right width="20%" bgColor=#e6efff>1.49 </TD>
    <TD align=right width="20%" bgColor=#e6efff>1.25 </TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left  >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Expected volatility </TD>
    <TD align=right width="20%" bgColor=#e6efff>81.57% </TD>
    <TD align=right width="20%" bgColor=#e6efff>77.51% </TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left  >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Stock price </TD>
    <TD align=right width="20%" bgColor=#e6efff>$0.61 </TD>
    <TD align=right width="20%" bgColor=#e6efff>$0.65 </TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left  >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Dividend yields </TD>
    <TD align=right width="20%" bgColor=#e6efff>0.00% </TD>
    <TD align=right width="20%" bgColor=#e6efff>0.00% </TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>Certain assets and liabilities are
  measured at fair value on a nonrecurring basis; that is, the instruments are not
  measured at fair value on an ongoing basis but are subject to fair value
  adjustments only in certain circumstances (for example, when there is evidence
  of impairment). There were no assets or liabilities measured at fair value on a
  nonrecurring basis during the periods ended September 30, 2013 and 2012. </P>
<P align=center>F-20</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-20></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 8<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Summary of Significant
      Accounting Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">m) </TD>
    <TD><P align=justify>Derivative Liabilities</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company evaluates its financial instruments and other
      contracts to determine if those contracts or embedded components of those
      contracts qualify as derivatives to be separately accounted for in
      accordance with ASC 815 Derivatives and Hedging. The result of this
      accounting treatment is that the fair value of the embedded derivative is
      marked- to-market at each balance sheet date and recorded as a liability
      and the change in fair value is recorded in the consolidated statements of
      operations as other income or expense. Upon conversion or exercise of a
      derivative instrument, the instrument is marked to fair value at the
      conversion date and then that fair value is reclassified to
      equity.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The classification of derivative instruments, including
      whether such instruments should be recorded as liabilities or as equity,
      is re-assessed at the end of each reporting period. Derivative instruments
      that become subject to reclassification are reclassified at the fair value
      of the instrument on the reclassification date. Derivative instrument
      liabilities will be classified in the balance sheet as current or
      non-current based on whether or not settlement of the derivative
      instrument is expected within 12 months of the balance sheet
      date.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company uses the binomial option pricing model to
      value derivative liabilities. This model uses Level 3 inputs in the fair
      value hierarchy established by ASC 820 Fair Value Measurement.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">n) </TD>
    <TD><P align=justify>Recent Accounting Pronouncements</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>There are no new accounting pronouncements that the
      Company recently adopted or are pending the Company&#146;s adoption that are
      expected to have a material impact on the company&#146;s results of operations,
      financial position or cash flows.</P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-21</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-21></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 9<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 3 </TD>
    <TD align=left width="90%" ><U>Equipment</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">September 30, 2013 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="15%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">Accumulated </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="15%"><U>Cost</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%"><U>Depreciation</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%"><U>Net</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Computer equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>&nbsp;5,631 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>&nbsp;5,631 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">September 30, 2012 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="15%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">Accumulated </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="15%"><U>Cost</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%"><U>Depreciation</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%"><U>Net</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Computer equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>&nbsp;5,631 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>&nbsp;5,055 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>&nbsp;576 </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 4 </TD>
    <TD align=left width="90%" ><U>Derivative Liabilities</U> </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>During the year ended September 30, 2013, the Company
      issued an aggregate of 6,448,966 share purchase warrants that are required
      to be accounted for as liabilities pursuant to ASC 815 because the terms
      of the warrants contain provisions that are in violation of the fixed for
      fixed criteria of that guidance such that the warrant agreements provide
      the holder with a full ratchet down adjustment to the exercise price such
      that in the event the Company, during the term of the warrants, issues
      common stock or common stock equivalents at a price per share lower than
      the exercise price of the warrants, the exercise price of the warrants
      will be adjusted to equal the price at which the new common stock or
      common stock equivalents are issued. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>At September 30, 2013, these share purchase warrants were
      still outstanding and were being accounted for as liabilities carried at
      fair value. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>During the year ended September 30, 2012, the Company had
      derivative liabilities that consisted of embedded conversion features in
      the Company&#146;s convertible promissory notes. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>Pursuant to the guidance of ASC 815, these derivative instruments are required to be recorded as liabilities on the balance sheet measured at fair value and are marked-to-market at each balance sheet date with the change in fair value being recorded in the consolidated statements of operations as other income or expense. </P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-22</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-22></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 10<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 4 </TD>
    <TD align=left width="90%" ><U>Derivative Liabilities </U>&#150;
      (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>A summary of the Company&#146;s derivative liabilities for the
      years ended September 30, 2013 and 2012 is as follows: </P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="17%">2013 </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="17%">2012 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Balance, beginning of the
      period </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="17%" bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="17%" bgColor=#e6efff>&nbsp;67,500 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >Fair value at issuance of derivative
      liability </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="17%">919,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="17%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Change in fair value of
      derivative liability </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>(15,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>(67,500</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >Balance, end of the period </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="17%">&nbsp;904,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="17%">&nbsp;- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>The convertible promissory notes
  containing embedded conversion features that were required to be separately
  accounted for as derivative liabilities matured during the year ended September
  30, 2012 and consequently, the liability was extinguished as at September 30,
  2012.</P>
<P align=center>F-23</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-23></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 11<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 5 </TD>
    <TD align=left width="90%" ><U>Promissory Notes Payable</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD colspan="4" align=center>September 30, </TD>
    <TD align=right width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">2013 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">2012 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Promissory note dated June 6, 2012 bearing
      interest at 8% per annum, due on demand </TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>&nbsp;- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>&nbsp;49,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Promissory note dated June 26, 2012 bearing
      interest at 8% per annum, due on demand </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>250,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Promissory note dated December 31, 2012
      bearing interest at 12% per annum, due on December 31, 2013 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>100,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Promissory note dated January 9, 2013 with
      a principal balance of $84,060 (CDN$86,677), bearing interest at 12% per
      annum, secured by all the present and future assets of the Company; due on
      demand </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>84,060 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Promissory note dated January 9, 2013 with
      a principal balance of $26,803 (CDN$27,639), bearing interest at 12% per
      annum, secured by all the present and future assets of the Company; due on
      demand </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>26,803 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">210,863 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">299,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Less: current portion </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>(210,863</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>(299,000</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">&nbsp;- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">&nbsp;- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>On June 6, 2012, the Company issued a
  promissory note having a principal balance of $49,000 with terms that included
  interest at 8% per annum and matured on December 3, 2012. On July 5, 2013, this
  note, along with accrued interest of $3,200, was settled in exchange for 130,501
  units of the Company. Each unit consisted of one share of common stock of the
  Company and one share purchase warrant, with each warrant entitling the holder
  thereof to purchase one share of common stock at a price of $0.75 per share for
  a period of five years from the date of issuance. In connection with the
  issuance of this note, the Company paid a finder&#146;s fee totaling $4,900 which was
  deferred and amortized to income using the effective interest method over the
  terms of the note. As at September 30, 2013, there remained an unamortized
  balance of $Nil (September 30, 2012: $1,215) in respect of this deferred
  financing charge.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On June 26, 2012, the Company issued a
  promissory note having a principal balance of $250,000 with terms that included
  interest at 8% per annum and matured on March 31, 2013. On July 5, 2013, this
  note, along with accrued interest of $15,233, was settled in exchange for
  663,082 units of the Company. Each unit consisted of one share of common stock
  of the Company and one share purchase warrant, with each warrant entitling the
  holder thereof to purchase one share of common stock at a price of $0.75 per
  share for a period of five years from the date of issuance.</P>
<P align=center>F-24</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-24></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 12<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 5 </TD>
    <TD align=left width="90%" ><U>Promissory Notes Payable </U>&#150;
      (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On October 17, 2012, the Company issued a promissory note
      having a principal balance of $150,000 with terms that included interest
      at 8% per annum and matured on March 31, 2013. On July 5, 2013, this note,
      along with accrued interest of $5,425 was settled in exchange for 388,562
      units of the Company. Each unit consisted of one share of common stock of
      the Company and one share purchase warrant, with each warrant entitling
      the holder thereof to purchase one share of common stock at a price of
      $0.75 per share for a period of five years from the date of issuance. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On November 14, 2012, the Company issued a promissory
      note having a principal balance of $50,000 with terms that included
      interest at 8% per annum and matured on March 31, 2013. On July 5, 2013,
      this note, along with accrued interest of $1,501 was settled in exchange
      for 128,753 units of the Company. Each unit consisted of one share of
      common stock of the Company and one share purchase warrant, with each
      warrant entitling the holder thereof to purchase one share of common stock
      at a price of $0.75 per share for a period of five years from the date of
      issuance. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On December 31, 2012, the Company issued a promissory
      note having a principal balance of $100,000 with terms that included
      interest at 12% per annum and matured on June 30, 2013, in exchange for an
      accounts payable owing in respect of unpaid consulting fees.  This note
      was not repaid on June 30, 2013 and the maturity date has been extended to
      December 31, 2013. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On February 8, 2013, the Company issued a promissory note
      having a principal balance of $50,000 with terms that included interest at
      10% per annum and matured on June 8, 2013. On July 5, 2013, this note,
      along with accrued interest of $699 was settled in exchange for 126,747
      units of the Company. Each unit consisted of one share of common stock of
      the Company and one share purchase warrant, with each warrant entitling
      the holder thereof to purchase one share of common stock at a price of
      $0.75 per share for a period of five years from the date of issuance. </P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-25</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-25></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 13<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 5 </TD>
    <TD align=left width="90%" ><U>Promissory Notes Payable </U>&#150;
      (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%"  >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" >On January 9, 2013, the Company
      issued two promissory notes (the &#147;Secured Notes&#148;); </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify>The Company issued a promissory note in the amount of
      $87,865 (CDN$86,677) to the former President, Secretary, Treasurer, CFO
      and director of the Company (the &#147;President&#148;) in exchange for unpaid
      consulting fees owing to the President. The note is bearing interest at
      12% per annum and was due June 30, 2013.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>The Company issued a promissory note in the amount of
      $28,017 (CDN$27,639) to a former director of the Company (the &#147;Director&#148;)
      in exchange for unpaid consulting fees owing to the Director. The note is
      bearing interest at 12% per annum and was due June 30,
      2013.</P></TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>The Secured Notes are secured by a
  right to delay the transfer of any or all of the Company&#146;s assets until the
  obligations of the Secured Notes are satisfied, including a restriction on the
  transfer of cash by the Company and a security interest over the intellectual
  property of the Company. The security interests of the Secured Notes is ranked
  senior to any and all security interests granted prior to the issuance of the
  notes and to all subsequent security interests granted, unless the holders agree
  in writing to other terms. </P>
<P style="MARGIN-LEFT: 10%" align=justify>In addition, if the promissory notes
  are not repaid within 10 days of their maturity dates, they shall bear late fees
  in addition to interest accruing, at a rate of $100 per day per note.</P>
<P style="MARGIN-LEFT: 10%" align=justify>In an event of default by the Company
  under the terms of the promissory notes, the notes shall bear additional late
  fees of $500 per day per note.</P>
<P style="MARGIN-LEFT: 10%" align=justify>Subsequent to the issuance of these
  promissory notes, the President resigned as President, Secretary, Treasurer, CFO
  and director of the Company and the Director resigned as director of the
  Company.</P>
<P style="MARGIN-LEFT: 10%" align=justify>The Company did not repay the notes on
  June 30, 2013. The Company has disputed the issuance of the Secured Notes and
  should there be an attempt to enforce the Secured Notes or collection on them,
  the Company will consider a legal remedy. The Company had not accrued any late
  fees in connection with these promissory notes as at September 30, 2013 as the
  Company does not consider these amounts to be legally enforceable.</P>
<P align=center>F-26</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-26></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 14<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 5 </TD>
    <TD align=left width="90%" ><U>Promissory Notes Payable </U>&#150;
      (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" >Extinguishment of promissory
      notes payable and accounts payable </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On July 5, 2013, the Company issued equity units in
      settlement of certain of its promissory notes and trade accounts payable.
      Each unit consisted of one common share and common share purchase warrant
      entitling the holder to purchase an additional common share at $0.75 until
      July 5, 2018. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" >The promissory note and accounts
      payable settlements are summarized as follows: </TD>
  </TR>
</TABLE>
<BR>
<DIV align=right>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="90%" border=0>
    <TR vAlign=top>
      <TD colspan="7" align=center style="BORDER-BOTTOM: #000000 1px solid"
      >Amount Settled </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD colspan="4" align=center style="BORDER-BOTTOM: #000000 1px solid">Units issued </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp;</TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp;</TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">Accrued </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp;</TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp;</TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">Loss on </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      >&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Date of Note </TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%">Principal </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%">Interest </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%">Number </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">Fair
        Value </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%">Settlement </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff >Promissory notes payable </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right >June 6, 2012 </TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">49,000 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">3,200 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">130,501 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">98,205 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">46,005 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff >June 26, 2012 </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>250,000 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>15,233 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>663,082 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>498,972 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>233,739 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right >October 17, 2012 </TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">150,000 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">5,425 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">388,562 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">292,394 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">136,969 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff >November 14, 2012 </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>50,000 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>1,501 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>128,753 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>96,887 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>45,386 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right >February 8, 2013 </TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">50,000 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%">699 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">126,747 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">95,377 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">44,678 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>549,000 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>26,058 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>1,437,645 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>1,081,835 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="12%" bgColor=#e6efff>&nbsp;506,777 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR>
      <TD >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff >Accounts payable </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>1,108,506 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>2,771,265 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>2,085,386 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>976,880 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR>
      <TD >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>&nbsp;1,657,506 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>&nbsp;26,058 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>4,208,910 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>&nbsp;3,167,221 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>&nbsp;1,483,657 </TD>
      <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 10%" align=justify>The fair value of each unit issued was
  determined to be $0.753 determined by aggregating (i) the fair value of $0.61
  for the Company&#146;s common shares based on their quoted market price on the date
  of settlement and (ii) the fair value of $0.143 for each warrant included in the
  Company&#146;s units. The fair value of the Company&#146;s warrants was determined using
  the binomial option pricing model with the following assumptions: </P>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="40%" border=0>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Stock price </TD>
      <TD align=right width="30%" bgColor=#e6efff >$0.61 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Exercise price </TD>
      <TD align=right width="30%" >$0.75 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Expected volatility </TD>
      <TD align=right width="30%" bgColor=#e6efff >81.57% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Risk-free discount rate </TD>
      <TD align=right width="30%" >0.28% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Expected term </TD>
      <TD align=right width="30%" bgColor=#e6efff >1.49 years </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Expected dividend yield </TD>
      <TD align=right width="30%" >0.00% </TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 10%" align=justify>The loss on settlement of debt was
  reduced by an amount of $11,449 relating to the interest that accrued on the
  promissory notes that was forgiven upon settlement of the notes payable in
  exchange for shares.</P>
<P align=center>F-27</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-27></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 15<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 6 </TD>
    <TD align=left width="90%" ><P align=justify><U>Capital Stock</U> </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On May 24, 2006, the board of directors approved a six
      (6) for one (1) forward split of the authorized issued and outstanding
      common stock. The Company&#146;s authorized capital increased from 25,000,000
      shares of common stock to 150,000,000 shares of common stock. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On September 24, 2007, the Company issued 222,222 common
      shares at $3.60 per share for a total of $800,000 for research and
      development expenses. The common shares were recorded based upon the
      quoted market price of the Company&#146;s common stock on the agreement date. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On September 25, 2007, the Company settled a loan payable
      in the amount of $333,000 by issuing 92,500 common shares at $3.60 per
      share, being the quoted market price of the Company&#146;s common stock on the
      settlement date. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On December 10, 2007, the Company issued 150,000 units at
      $3.50 per unit for proceeds of $525,000. Each unit consisted of one common
      share and one common share purchase warrant entitling the holder to
      purchase an additional common share at $5.00 per share until December 10,
      2009. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On December 18, 2007, the Company issued 10,000 shares at
      $4.50 per share for a total of $45,000 pursuant to an agreement to settle
      a debt and issued 50,000 shares at $3.86 per share for a total of $193,000
      pursuant to a consulting agreement. The Company recorded compensation
      expense of $65,000 in respect of these issuances based on the excess of
      the fair value of these shares over the balances at which they were
      recorded by the Company. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On May 15, 2008, the Company issued 65,000 common shares
      at $5.24 per share for a total of $340,600 to its former CEO in accordance
      with the terms of a severance agreement upon the termination of his
      services. The common shares were recorded based upon the quoted market
      price of the Company&#146;s common stock on the agreement date. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On August 19, 2008, the Company issued 25,000 common
      shares at $5.07 per share for a total of $ 126,750 to a director of the
      Company pursuant to an agreement to provide consulting services. The
      common shares were recorded based upon the quoted market price of the
      Company&#146;s common stock on the agreement date. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On August 19, 2008, the Company issued 142,698 units at
      $4.25 per unit for proceeds of $606,467 pursuant to private placement
      agreements. Each unit consisted of one common share and one common share
      purchase warrant entitling the holder to purchase an additional common
      share at $5.00 per share until August 19, 2009. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On November 20, 2008, the Company issued 25,000 common
      shares at $2.63 per share for a total of $65,750 to a director of the
      Company pursuant to an agreement to provide consulting services. The
      common shares were recorded based upon the quoted market price of the
      Company&#146;s common stock on the issuance date. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On February 20, 2009, the Company issued 25,000 common
      shares at $2.50 per share for a total of $62,500 to a director of the
      Company pursuant to an agreement to provide consulting services. The
      common shares were recorded based upon the quoted market price of the
      Company&#146;s common stock on the issuance date. </P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-28</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-28></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 16<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 6 </TD>
    <TD align=left width="90%" ><U>Capital Stock </U>&#150; (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On March 6, 2009, the Company issued 89,148 units at
      $2.25 per unit for proceeds of $200,583 pursuant to private placement
      agreements. Each unit consisted of one common share and one common share
      purchase warrant entitling the holder to purchase an additional common
      share at $4.00 per share until March 6, 2010. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On March 20, 2009, the Company issued 10,800 units at
      $2.25 per unit for proceeds of $24,300 pursuant to private placement
      agreements. Each unit consisted of one common share and one common share
      purchase warrant entitling the holder to purchase an additional common
      share at $4.00 per share until March 20, 2010. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On March 20, 2009, the Company issued 2,500 common shares
      at $2.00 per share for a total of $5,000 to a public relations consultant
      pursuant to an agreement to provide consulting services. The common shares
      were recorded based upon the quoted market price of the Company&#146;s common
      stock on the issuance date. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On May 14, 2009, the Company entered into a revised
      consulting agreement with a director whereby the consultant returned
      75,000 common shares to the Company for cancellation. The return of shares
      was recorded in the same amount at which they were originally issued. On
      June 11, 2009 the Company issued 36,000 units at $2.25 per unit for
      proceeds of $81,000 pursuant to private placement agreements. Each unit
      consisted of one common share and one common share purchase warrant
      entitling the holder to purchase an additional common share at $4.00 per
      share until June 11, 2010. The Company paid finders&#146; fees in the amount of
      $8,100 in relation to this private placement. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On June 11, 2009 the Company issued 29,227 common shares
      at $2.25 per share for service rendered by consultants. The common shares
      were recorded based upon the fair value of the Company&#146;s common stock on
      the issuance date of the shares. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On June 19, 2009, the Company issued 495,556 units at
      $2.25 per unit for total proceeds of $1,115,000 pursuant to private
      placement agreements. Each unit consisted of one common share and one and
      one-half of a common share purchase warrant entitling the holder to
      purchase additional common shares at $2.25 per share until June 19, 2011. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On June 26, 2009, the Company issued 22,222 common shares
      at $2.51 per share for finder&#146;s fees related to the issuance of a $500,000
      note payable. The common shares were recorded based upon the quoted market
      price of the Company&#146;s common stock on the issue date. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On August 19, 2009, the Company issued 128,888 units at
      $2.25 per unit for total proceeds of $289,998. Of these placements, 40,000
      units consisted of one common share and one share purchase warrant
      entitling the holder to purchase an additional common share at $4.00 per
      share until July 9, 2010 and 88,888 Units consisted of one common share
      and one and one- eighth share purchase warrant entitling the holder to
      purchase an additional common shares at $2.25 per share until August 4,
      2011. The Company paid finders&#146; fees totalling $19,000 in respect of these
      private placements. </P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-29</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-29></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 17<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 6 </TD>
    <TD align=left width="90%" ><U>Capital Stock </U>&#150; (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On October 2, 2009 the Company issued 266,666 units at
      $2.25 per unit for proceeds of $600,000 pursuant to private placement
      agreements. Each unit consisted of one common share and one and one-eighth
      common share purchase warrant entitling the holder to purchase an
      additional common shares at $2.25 per share until October 2, 2011. The
      Company had received $300,000 of this amount in the year ended September
      30, 2010. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On February 2, 2010 the Company issued 49,505 common
      shares of the Company, at their fair value of $2.02 per share pursuant to
      an agreement with a former officer to settle an outstanding amount owed. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On April 9, 2010, the Company issued 92,499 units at
      $2.60 per unit for proceeds of $240,498 pursuant to private placement
      agreements. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase additional common
      shares at $3.50 per share until April 9, 2011. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On April 30, 2010, the Company issued 9,825 common shares
      of the Company, at $2.85 per share as consideration for terminating a
      consulting agreement and for services rendered under the agreement. The
      common shares were recorded based upon the quoted market price of the
      Company&#146;s common stock on the date of the termination of the agreement. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On June 29, 2010, the Company issued 941,000 units at
      $2.50 per unit for total proceeds of $2,352,500 pursuant to private
      placement agreements. Each unit consisted of one common share and one-half
      of a common share purchase warrant entitling the holder to purchase
      additional common shares at $3.50 per share until December 29, 2011. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On July 5, 2010, the Company issued 400,000 units in
      settlement of $1,000,000 owing to a creditor. Each unit consisted of one
      common share and one-half common share purchase warrant entitling the
      holder to purchase additional common shares at 3.50 per share until
      January 5, 2012. The fair value of the units issued was determined to be
      $1,444,000 on the date they were issued and thus the Company recorded a
      loss on settlement of accounts payable of $444,000 with a corresponding
      credit to additional paid-in capital of the same amount on date of
      issuance. The fair value of the shares included in the units was
      determined with reference to their quoted market price and the value of
      the warrants was determined using the Black-Scholes model with the
      following assumptions: exercise price - $3.50, stock price - $3.15,
      expected volatility &#150; 68.45%, expected life &#150; 1.5 years, dividend yield &#150;
      0.00%. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On September 3, 2010, the Company issued 163,000 units at
      $2.75 per unit for proceeds of $448,250 pursuant to private placement
      agreements. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase additional common
      shares at $3.75 per share until March 3, 2012. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On September 3, 2010, the Company issued 9,000 units at
      $2.75 per unit for finder&#146;s fees related to the private placement of the
      same date. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase additional common
      shares at $3.75 per share until March 3, 2012. </P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-30</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-30></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 18<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 6 </TD>
    <TD align=left width="90%" ><P align=justify><U>Capital Stock </U>&#150; (cont&#146;d) </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On September 30, 2010, the Company issued 510,638 common
      shares at $2.35 per share pursuant to the terms of a convertible note
      payable. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On September 30, 2010, the Company issued 82,310 units at
      $2.25 per unit pursuant to the terms of convertible notes payable. Each
      unit consisted of one common share and one-half common share purchase
      warrant entitling the holder to purchase additional common shares at $3.50
      per share until September 30, 2011. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On September 30, 2010, the Company issued 245,748 units
      at $2.25 per unit pursuant to the terms of convertible notes payable. Each
      unit consisted of one common share and one common share purchase warrant
      entitling the holder to purchase additional common shares at $3.00 per
      share until September 30, 2012. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On November 18, 2010, the Company issued 393,846 units at
      $2.75 per unit for proceeds of $1,083,075 pursuant to a private placement
      agreement. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase additional common
      shares at $4.50 per share until May 18, 2012. The Company paid a finder&#146;s
      fee totalling $65,363 in respect of this private placement. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On November 18, 2010, the Company issued 3,636 units at
      $2.75 per unit for finder&#146;s fees related to the private placement of the
      same date. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase additional common
      shares at $4.50 per share until May 18, 2012. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On November 18, 2010, the Company issued 853,075 units in
      the conversion of two notes payable originally convertible at $2.50. The
      Company recorded debt conversion expense of $504,160, related to the fair
      value of the additional units issued as a result of converting at the
      lower conversion price. Each unit consisted of one common share and one
      common share purchase warrant entitling the holder to purchase additional
      common shares at $3.00 per share until November 18, 2012. The fair value
      of the shares included in the units was determined with reference to their
      quoted market price and the value of the warrants was determined using the
      Black-Scholes model with the following assumptions: exercise price -
      $3.00, stock price - $4.12, expected volatility &#150; 78.33%, expected life &#150;
      2.0 years, dividend yield &#150; 0.00%, risk-free rate &#150; 0.52%. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On November 18, 2010, the Company issued 145,063 shares
      of common stock at their fair value of $4.12 per share based on their
      quoted market price pursuant to settling non- convertible interest bearing
      notes payable outstanding in the amount of $398,922, including accrued
      interest of $26,032. The Company recorded a loss on settlement of debt of
      $198,738 based on the difference between the carrying value of the debt
      settled and the fair value of the shares issued. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On November 18, 2010, the Company issued 181,818 shares
      of common stock at their fair value of $4.12 per share based on the quoted
      value of units issued in a private placement on the same date to one
      creditor in settlement of $500,000 of debt owing. The Company recorded a
      loss on settlement of accounts payable of $249,090 based on the difference
      of the carrying value of the account payable and the fair value of the
      shares issued. </P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-31</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-31></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 19<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 6 </TD>
    <TD align=left width="90%" ><U>Capital Stock </U>&#150; (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%"><P align=justify>On November 25, 2010, the Company issued 29,851 units at
      $3.35 per unit for proceeds of $100,000 pursuant to a private placement
      agreement. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase additional common
      shares at $4.50 per share until November 25, 2012. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On November 25, 2010, the Company issued 2,985 units at
      $3.35 per unit for finder&#146;s fees related to the private placement of the
      same date. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase additional common
      shares at $4.50 per share until November 25, 2012. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On February 1, 2011, the Company issued 61,014 units at
      $3.75 per unit for proceeds of $228,800 pursuant to a private placement
      agreement. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase additional common
      shares at $5.25 per share until August 1, 2012. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On May 3, 2011, the Company issued 33,334 units at $3.00
      per unit for proceeds of $100,000 pursuant to a private placement
      agreement. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase additional common
      shares at $4.00 per share until April 20, 2013. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On June 19, 2011, the Company issued 700,000 common
      shares at $2.25 per share for proceeds of $1,575,000 pursuant to the
      exercise of warrants. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On September 26, 2011, the Company issued 650,000 units
      in settlement of $975,000 of debt owing. Each unit consisted of one common
      share and one-half common share purchase warrant entitling the holder to
      purchase additional common shares at $2.00 per share until September 26,
      2012. The Company recorded a loss on settlement of accounts payable in the
      amount of $84,963 based on the fair value of shares being $975,000 at
      their issuance and the fair value of the warrants determined to be
      $84,963. The fair value of the shares included in the units was determined
      with reference to their quoted market price and the value of the warrants
      was determined using the Black-Scholes model with the following
      assumptions: exercise price - $2.00, stock price - $1.50, expected
      volatility &#150; 69%, expected life &#150; 1.0 years, dividend yield &#150; 0.00%,
      risk-free interest rate &#150; 0.10%. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On December 6, 2011, the Company issued 615,600 units at
      $1.25 per unit for proceeds of $769,500 pursuant to private placement
      agreements. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase additional common
      shares at $2.00 per share until December 6, 2012. The Company paid
      finder&#146;s fees of $77,000 in connection with this private placement. </P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-32</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-32></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 20<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 6 </TD>
    <TD align=left width="90%" ><U>Capital Stock </U>&#150; (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On February 9, 2012 the Company issued 8,000 units for
      service rendered by a director and officer of the Company. Each unit
      consisted of one common share and one-half common share purchase warrant
      entitling the holder to purchase additional common shares at $2.00 per
      share until February 9, 2013. The fair value of the units issued was
      determined to be $15,896 on the date they were issued and the Company
      recorded consulting fees of $15,896 on the statement of operations for the
      year ended September 30, 2012. The fair value of the shares included in
      the units was determined with reference to their quoted market price and
      the value of the warrants was determined using the Black-Scholes model
      with the following assumptions: exercise price - $2.00, stock price -
      $1.74, expected volatility &#150; 84.88%, expected life &#150; 1.0 years, risk free
      interest rate &#150; 0.15%, dividend yield &#150; 0.00%. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On February 9, 2012, the Company issued 270,000 units at
      $1.25 per unit for proceeds of $337,500 pursuant to private placement
      agreements. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase additional common
      shares at $2.00 per share until February 9, 2013. The Company paid a
      finder&#146;s fee of $33,750 in connection with this private placement. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On May 31, 2012, the Company issued 2,700,513 units in
      settlement of $1,297,889 in promissory notes and $52,367 of accrued
      interest on these notes, which was included in accounts payable and
      accrued liabilities Each unit consisted of one common share and one common
      share purchase warrant entitling the holder to purchase additional common
      shares at $0.75 per share until November 30, 2013. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On June 26, 2012, the Company agreed to issue 75,000
      common shares to the former president of the Company for past services and
      in final settlement of a consulting agreement dated February 1, 2007.
      These shares were issued on July 12, 2012. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On July 5, 2013, the Company issued 4,208,910 units in
      settlement of $549,000 in promissory notes, $26,058 of accrued interest on
      these notes, which was included in accounts payable and accrued
      liabilities, and $1,108,506 in other accounts payable and accrued
      liabilities. Each unit consisted of one common share and one common share
      purchase warrant entitling the holder to purchase additional common shares
      at $0.75 per share until July 5, 2018 (Note 5). </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On July 5, 2013, the Company issued 2,196,133 units at
      $0.40 per unit for gross proceeds of $878,453 pursuant to private
      placement agreements. Each unit consisted of one common share and one
      common share purchase warrant entitling the holder to purchase additional
      common shares at $0.75 per share until July 5, 2018. The Company paid
      finder&#146;s fees of $89,680 and issued warrants to purchase 43,923 shares of
      common stock at $0.75 per share until July 5, 2018 in connection with this
      private placement. In addition, the Company incurred share issuance costs
      of $16,494. </P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-33</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-33></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 21<BR>
</P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
    <TR vAlign=top>
      <TD align=left>Note 6 </TD>
      <TD align=left width="90%"><U>Capital Stock </U>&#150; (cont&#146;d) </TD>
    </TR>
    <TR>
      <TD align=left>&nbsp;</TD>
      <TD align=left width="90%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left></TD>
      <TD align=left width="90%">All of the 6,448,966 warrant agreements issued
        on July 5, 2013 contain the following provisions: </TD>
    </TR>
  </TABLE>
</DIV>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(i) </TD>
    <TD><P align=justify>a full ratchet down adjustment to the exercise price such
      that in the event the Company, during the term of the warrants, issues
      common stock or common stock equivalents at a price per share lower than
      the exercise price of the warrants, the exercise price of the warrants
      will be adjusted to equal the price at which the new common stock or
      common stock equivalents are issued;</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(ii) </TD>
    <TD><P align=justify>a put option whereby in the event of certain fundamental
      transactions, as defined in the warrant agreements, the Company may be
      required to pay the Holder an amount of cash equal to the value of the
      warrant as determined in accordance with the Black Scholes option pricing
      model, for each warrant held by the Holder; and</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(iii) </TD>
    <TD><P align=justify>a contingent call provision whereby the Company may have
      the option to call for cancellation all of any portion of the warrants for
      consideration equal to $0.001 per share, provided the quoted market price
      of the Company&#146;s common stock exceeds $1.50 for a period of twenty
      consecutive trading days, subject to certain minimum volume restrictions
      and other restrictions as provided in the warrant
      agreements.</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" >Common stock to be issued </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>During the year ended September 30, 2013, the Company
      received $60,000 in share subscriptions in respect of the issuance of
      120,000 units at $0.50 per unit. Each unit will consist of one common
      share and one common share purchase warrant entitling the holder to
      purchase additional common shares at $1.00 per share for a period of five
      years from the date of issuance. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Note 7 </TD>
    <TD align=left width="90%" ><P align=justify><U>Equity Line of Credit</U> </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On July 5, 2013, the Company entered into a $10,000,000
      purchase agreement (the &#147;Purchase Agreement&#148;) with Lincoln Park Capital
      Fund, LLC, (&#147;Lincoln Park&#148;) an Illinois limited liability company (the
      &#147;Financing&#148;) pursuant to which the Company may sell and issue to Lincoln
      Park, and Lincoln Park is obligated to purchase, up to $10,000,000 in
      value of its shares of common stock from time to time over a 36 month
      period. In connection with the Financing, the Company also entered into a
      registration rights agreement with Lincoln Park whereby the Company agreed
      to file a registration statement with the Securities and Exchange
      Commission (the &#147;SEC&#148;) covering the shares of the Company&#146;s common stock
      that may be issued to Lincoln Park under the Purchase Agreement. </P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-34</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-34></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 22<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The Company will determine, at its own discretion, the
      timing and amount of its sales of common stock, subject to certain
      conditions and limitations. The purchase price of the shares that may be
      sold to Lincoln Park under the Purchase Agreement will be based on the
      market price of the Company&#146;s shares of common stock immediately preceding
      the time of sale without any fixed discount, provided that in no event
      will such shares be sold to Lincoln Park when the closing sale price is
      less than $0.50 per share. There are no upper limits on the per share
      price that Lincoln Park may pay to purchase such common stock. The
      purchase price will be equitably adjusted for any reorganization,
      recapitalization, non-cash dividend, stock split or similar transaction
      occurring during the business days used to compute such price. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>Pursuant to the Purchase Agreement, Lincoln Park
      initially purchased 250,000 shares of the Company&#146;s common stock for
      $100,000. In consideration for entering into the Purchase Agreement, the
      Company issued to Lincoln Park 341,858 shares of common stock as a
      commitment fee and shall issue up to 133,409 shares pro rata, when and if,
      Lincoln Park purchases at the Company&#146;s discretion the remaining
      $10,000,000 aggregate commitment. The Purchase Agreement may be terminated
      by the Company at any time at its discretion without any cost to the
      Company. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>On October 23, 2013, the registration statement was
      declared effective by the SEC. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The Company incurred $71,335 in direct expenses in connection with the Purchase Agreement and registration statement.  These were recorded as share issuance costs as a charge against additional paid in capital during the year ended September 30, 2013. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Note 8 </TD>
    <TD align=left width="90%" ><P align=justify><U>Related Party Transactions</U> </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>The following amounts have been donated to the Company by
      the directors: </P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD width="15%" align=center nowrap>&nbsp;</TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="15%" align=center nowrap>&nbsp;</TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="15%" align=center nowrap>January 23, 2004 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD colspan="4" align=center nowrap>Year ended September 30, </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="15%" align=center nowrap>(Date of Inception) </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD width="15%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">2013 </TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="15%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">2012 </TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="15%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >to September 30, 2013&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD align=right width="1%" >&nbsp;</TD>
    <TD align=right width="15%">&nbsp;</TD>
    <TD align=right width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Management fees </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>14,625 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >Rent </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="15%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="15%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="15%">3,750 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Debt forgiven by directors</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>33,666 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="15%">&nbsp;- </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%">-</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="15%">52,041 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
  2013, the Company was charged consulting fees totaling $81,072 (2012: $479,434)
  by directors, officers and a significant shareholder of the Company. As at
  September 30, 2013, included in accounts payable and accrued liabilities is
  $30,447 (2012: $127,452) owing to directors and officers of the Company and a
  former director and officer of the Company.</P>
<P align=center>F-35</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-35></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 23<BR>
</P>
<P style="MARGIN-LEFT: 10%" align=justify>On July 5, 2013, pursuant to an
  employment agreement with the newly appointed President, Chief Executive
  Officer, Chief Financial Officer, Secretary and Treasurer, and Director, of the
  Company, the Company:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">i) </TD>
    <TD><P align=justify>granted 2,000,000 fully vested share purchase options
      exercisable at $0.40 per share until July 5, 2023. The Company recognized
      stock based compensation expense of $1,002,500 (2012: $Nil) during the
      year ended September 30, 2013 in connection with these options.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">ii) </TD>
    <TD><P align=justify>issued 4,000,000 shares of restricted common stock that
      vest as follows:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left>&#149; </TD>
    <TD align=left width="80%" >25% upon the Company starting a
      Phase Ib/IIb human study </TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&#149; </TD>
    <TD align=left width="80%" >25% upon the Company in-licensing
      additional assets in clinical or pre-clinical stage </TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" ></TD>
    <TD align=left><P align=justify>&#149; </P></TD>
    <TD align=left width="80%" ><P align=justify>25% upon the Company securing additional non-dilutive
      equity funding in 2013 of at least $5,000,000 with a share price higher
      than the previous funding. </P></TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&#149; </TD>
    <TD align=left width="80%" >25% upon the Company obtaining a
      listing on a major stock exchange. </TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>No stock-based compensation has been
  recorded in connection with the issuance of these shares in the financial
  statements for the year ended September 30, 2013 as none of the performance
  conditions have yet been met.</P>
<P align=center>F-36</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-36></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 24<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 9 </TD>
    <TD align=left width="90%" ><U>Commitments</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify>Share Purchase Warrants</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>A summary of the Company&#146;s share purchase warrants
      outstanding is presented below:</P></TD>
  </TR>
</TABLE>
<BR>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="60%" border=0>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD width="17%" align=center nowrap>&nbsp;</TD>
      <TD width="2%" align=center nowrap >&nbsp;</TD>
      <TD width="1%" align=center nowrap >&nbsp;</TD>
      <TD width="17%" align=center nowrap>Weighted </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD width="17%" align=center nowrap>&nbsp;</TD>
      <TD width="2%" align=center nowrap >&nbsp;</TD>
      <TD width="1%" align=center nowrap >&nbsp;</TD>
      <TD width="17%" align=center nowrap>Average </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD width="17%" align=center nowrap>&nbsp;</TD>
      <TD width="2%" align=center nowrap >&nbsp;</TD>
      <TD width="1%" align=center nowrap >&nbsp;</TD>
      <TD width="17%" align=center nowrap>Exercise </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD
      width="17%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Number of Shares </TD>
      <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
      <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
      <TD
      width="17%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Price </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    </TR>
    <TR>
      <TD >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="17%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD align=center width="17%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Balance, September 30, 2011 </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>2,655,479 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=center width="17%" bgColor=#e6efff>&nbsp;3.16 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Expired </TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="17%">(1,552,651</TD>
      <TD align=left width="2%" >) </TD>
      <TD align=left width="1%" >$</TD>
      <TD align=center width="17%">&nbsp;3.16 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Issued </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>3,147,313 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="17%"
    bgColor=#e6efff>&nbsp;0.93 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Balance, September 30, 2012 </TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="17%">4,250,141 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >$</TD>
      <TD align=center width="17%">&nbsp;1.16 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Expired </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>(1,549,628</TD>
      <TD align=left width="2%"  bgColor=#e6efff>) </TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=center width="17%" bgColor=#e6efff>&nbsp;2.56 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Issued </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="17%">6,448,966 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="17%">&nbsp;0.75 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Balance, September 30, 2013 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="17%"
    bgColor=#e6efff>9,149,479 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=center width="17%"
    bgColor=#e6efff>&nbsp;0.75 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 15%" align=justify>At September 30, 2013, the Company has
  9,149,479 currently exercisable share purchase warrants outstanding as
  follows:</P>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="50%" border=0>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="29%">Number </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="29%">Exercise Price </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="29%">Expiry Date </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="29%" bgColor=#e6efff>2,700,513 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="29%" bgColor=#e6efff>&nbsp;0.75 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="29%" bgColor=#e6efff>November 30, 2013 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="29%">6,448,966 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
      <TD align=left width="1%" >$</TD>
      <TD align=right width="29%">&nbsp;0.75 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="29%">July 5, 2018 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left
    bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="29%"
    bgColor=#e6efff>9,149,479 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="29%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="29%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 15%" align=justify>During the year ended September 30,
  2012, the exercise price and expiry of 200,000 warrants exercisable at $3.50 and
  expiring January 5, 2012 were modified and extended such that these warrants
  were exercisable at $1.50 until January 5, 2013. The fair value of this
  modification was determined to be $80,200 and was determined using the
  Black-Scholes option pricing model using the following weighted average
  assumptions: risk-free interest rate: 0.11%, expected life: 1.0 year, annualized
  volatility: 79.46%, dividend rate: 0%.</P>
<P align=center>F-37</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-37></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 25<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 9 </TD>
    <TD align=left width="90%" ><U>Commitments </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>Stock&#150;based Compensation Plan</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In April, 2007, the Company adopted a stock option plan
      which provides for the granting of stock options to selected directors,
      officers, employees or consultants in an aggregate amount of up to
      3,000,000 common shares of the Company and, in any case, the number of
      shares to be issued to any one individual pursuant to the exercise of
      options shall not exceed 10% of the issued and outstanding share capital.
      The granting of stock options, exercise prices and terms are determined by
      the Company's Board of Directors. If no vesting schedule is specified by
      the Board of Directors on the grant of options, then the options shall
      vest over a 4-year period with 25% of the options granted vesting each
      year commencing 1 year from the grant date. For stockholders who have
      greater than 10% of the outstanding common shares of the Company and who
      have granted options, the exercise price of their options shall not be
      less than 110% of the fair of the stock on grant date. Otherwise, options
      granted shall have an exercise price equal to their fair value on grant
      date.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>On February 2, 2011, the Company amended and restated the
      2007 stock option plan to increase the number of options authorized to
      4,000,000.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>A summary of the status of Company&#146;s outstanding stock
      purchase options for the year ended September 30, 2013 is presented
      below:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD width="15%" align=center nowrap>&nbsp;</TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="15%" align=center nowrap>Weighted </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="15%" align=center nowrap>Weighted </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD width="15%" align=center nowrap>Number of </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="15%" align=center nowrap>Average </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="15%" align=center nowrap>Average Grant </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD
      width="15%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Shares </TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="15%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Exercise Price </TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="15%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Date
      fair value </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Outstanding at September 30,
      2011 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="15%" bgColor=#e6efff>2,375,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>&nbsp;3.18 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >Forfeited </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="15%">(1,100,000</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="15%">&nbsp;2.82 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="15%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Granted </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>500,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>&nbsp;1.50 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>&nbsp;0.72 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >Outstanding at September 30, 2012 </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="15%">1,775,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="15%">&nbsp;2.94 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="15%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Expired </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="15%" bgColor=#e6efff>(550,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>&nbsp;3.86 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >Forfeited </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="15%">(150,000</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="15%">&nbsp;3.72 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="15%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Granted </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>2,000,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>&nbsp;0.40 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>&nbsp;0.50 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >Outstanding at September 30, 2013 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="15%">3,075,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="15%">&nbsp;1.26 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="15%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Exercisable at September 30,
      2013 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>2,305,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>&nbsp;0.79 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >Exercisable at September 30, 2012 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="15%">905,000</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="15%">2.81</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="15%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-38</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-38></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 26<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 9 </TD>
    <TD align=left width="90%" ><U>Commitments </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>Stock&#150;based Compensation Plan &#150; (cont&#146;d)</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>At September 30, 2013, the following stock options were
      outstanding:</P></TD>
  </TR>
</TABLE>
<BR>
<DIV align=right>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="85%" border=0>
    <TR vAlign=top>
      <TD colspan="3" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Number of Shares </TD>
      <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
      <TD width="1%" align=center nowrap >&nbsp;</TD>
      <TD width="11%" align=center nowrap>&nbsp;</TD>
      <TD width="2%" align=center nowrap >&nbsp;</TD>
      <TD width="1%" align=center nowrap >&nbsp;</TD>
      <TD width="22%" align=center nowrap >&nbsp;</TD>
      <TD width="2%" align=center nowrap >&nbsp;</TD>
      <TD width="1%" align=center nowrap >&nbsp;</TD>
      <TD width="11%" align=center nowrap>Aggregate </TD>
      <TD width="2%" align=center nowrap >&nbsp;</TD>
      <TD width="1%" align=center nowrap >&nbsp;</TD>
      <TD width="11%" align=center nowrap>Remaining </TD>
      <TD align=center width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap >&nbsp;</TD>
      <TD width="11%" align=center nowrap>Number </TD>
      <TD width="2%" align=center nowrap >&nbsp;</TD>
      <TD width="1%" align=center nowrap >&nbsp;</TD>
      <TD width="11%" align=center nowrap>Exercise </TD>
      <TD width="2%" align=center nowrap >&nbsp;</TD>
      <TD width="1%" align=center nowrap >&nbsp;</TD>
      <TD width="22%" align=center nowrap >&nbsp;</TD>
      <TD width="2%" align=center nowrap >&nbsp;</TD>
      <TD width="1%" align=center nowrap >&nbsp;</TD>
      <TD width="11%" align=center nowrap>Intrinsic </TD>
      <TD width="2%" align=center nowrap >&nbsp;</TD>
      <TD width="1%" align=center nowrap >&nbsp;</TD>
      <TD width="11%" align=center nowrap>Contractual </TD>
      <TD align=center width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Total </TD>
      <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
      <TD
      width="11%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Vested </TD>
      <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
      <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
      <TD
      width="11%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Price </TD>
      <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
      <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
      <TD width="22%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >Expiry Date </TD>
      <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
      <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
      <TD
      width="11%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Value </TD>
      <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
      <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
      <TD width="11%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Life
        (yrs) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>150,000 <SUP>(1)</SUP> </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="11%" bgColor=#e6efff>150,000 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=center width="11%" bgColor=#e6efff>&nbsp;3.10 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="22%" bgColor=#e6efff >June 30, 2014</TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="11%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="11%" bgColor=#e6efff>0.75 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right>500,000 <SUP>(2)</SUP> </TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="11%">- </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >$</TD>
      <TD align=center width="11%">&nbsp;2.50 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="22%" >October 19, 2013 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="11%">- </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="11%">0.05 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>5,000 <SUP>(3)</SUP> </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="11%" bgColor=#e6efff>5,000 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=center width="11%" bgColor=#e6efff>&nbsp;2.50 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="22%" bgColor=#e6efff >March 2, 2014</TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="11%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="11%" bgColor=#e6efff>0.42 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right>50,000 <SUP>(4)</SUP> </TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="11%">50,000 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >$</TD>
      <TD align=center width="11%">&nbsp;3.50 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="22%" >June 30, 2014 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="11%">- </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="11%">0.75 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>100,000 <SUP>(5)</SUP> </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="11%" bgColor=#e6efff>100,000 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=center width="11%" bgColor=#e6efff>&nbsp;3.67 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="22%" bgColor=#e6efff >March 30, 2016 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="11%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="11%" bgColor=#e6efff>2.50 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right>270,000 <SUP>(6)</SUP> </TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="11%">- </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >$</TD>
      <TD align=center width="11%">&nbsp;3.00 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="22%" >February 8, 2017 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="11%">- </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="11%">3.36 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      bgColor=#e6efff>2,000,000 <SUP>(7)</SUP> </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="11%"
    bgColor=#e6efff>2,000,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=center width="11%" bgColor=#e6efff>&nbsp;0.40 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="22%" bgColor=#e6efff >July 5, 2023 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="11%"
    bgColor=#e6efff>500,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="11%" bgColor=#e6efff>9.77 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 3px double"
      align=right>3,075,000&nbsp;&nbsp;&nbsp; &nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="11%">2,305,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=center width="11%">&nbsp;</TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="22%" >&nbsp;</TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="11%">500,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="11%">&nbsp;</TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 15%" align=justify>The aggregate intrinsic value is
  calculated as the difference between the exercise price of the underlying awards
  and the quoted market price of the Company&#146;s stock for the options that were
  in-the-money at September 30, 2013.</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="15%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(1)</SUP> </TD>
    <TD><P align=justify>As at September 30, 2013 and 2012, these options had
      fully vested. During the year ended September 30, 2012, the expiry of
      these options was extended from June 3, 2013 to June 30, 2014. The fair
      value of this modification was determined to be $18,600 and was determined
      using the Black Scholes option pricing model using the following weighted
      average assumptions: risk-free interest rate: 0.31%, expected life: 2.0
      years, annualized volatility: 84.74%, dividend rate: 0%. The Company did
      not recognize any stock-based compensation for these options during the
      year ended September 30, 2013 (2012: $18,600).</P></TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(2)</SUP> </TD>
    <TD><P align=justify>As at September 30, 2013 and 2012, none of these options
      have vested. The options vest as to 100,000 per compound entered into a
      phase II trial. The fair value of these options was calculated to be
      $740,000, which the Company has not yet recognized in the financial
      statements as the performance conditions have not yet been met.</P></TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(3)</SUP> </TD>
    <TD><P align=justify>As at September 30, 2013 and 2012, these options had
      fully vested. The Company did not recognize any stock-based compensation
      for these options during the year ended September 30, 2013 (2012:
      $nil).</P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-39</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-39></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 27<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 9 </TD>
    <TD align=left width="90%"><U>Commitments </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>Stock&#150;based Compensation Plan &#150;
      (cont&#146;d)</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(4)</SUP> </TD>
    <TD><P align=justify>As at September 30, 2013 and 2012, these options had
      fully vested. The Company did not recognize any stock-based compensation
      during the year ended September 30, 2013 (2012: $nil). During the year
      ended September 30, 2012, the expiry of these options was shortened from
      June 29, 2015 to June 30, 2014. The Company did not recognize any stock
      based compensation expense in connection with this modification because
      the fair value of the modified options was less than the fair value of the
      options under the old terms.</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(5)</SUP> </TD>
    <TD><P align=justify>As at September 30, 2013 and 2012, these options had
      fully vested. The fair value of these options at issuance was calculated
      to be $267,000. The Company did not recognize any stock-based compensation
      during the year ended September 30, 2013 (2012: $6,500).</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(6)</SUP> </TD>
    <TD><P align=justify>As at September 30, 2013 and 2012, these options had not
      vested. The options vest upon one or more compounds: entering Phase II
      trial &#150; 90,000 options; entering Phase III trial &#150; 90,000 options; and
      receiving FDA approval &#150; 90,000 options. No stock-based compensation has
      been recorded in the financial statements as none of the performance
      conditions have yet been met.</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(7)</SUP> </TD>
    <TD><P align=justify>As at September 30, 2013 these options had fully vested
      (2012: None of these options had vested). These options were granted
      during the year ended September 30, 2013 and vested immediately upon
      granting. The Company recognized stock based compensation expense of
      $1,002,500 (2012: $Nil) during the year ended September 30, 2013 in
      connection with these options.</P></TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>During the year ended September 30,
  2013, 150,000 options were forfeited for which the Company had recognized
  stock-based compensation of $Nil (2012: $163,415) during the year ended
  September 30, 2013.</P>
<P style="MARGIN-LEFT: 15%" align=justify>During the year ended September 30,
  2012, 1,100,000 options were forfeited for which the Company had recognized
  stock-based compensation of $33,493 during the year ended September 30,
  2012.</P>
<P style="MARGIN-LEFT: 15%" align=justify>The fair value of stock options
  granted has been determined using the Black-Scholes option pricing model using
  the following weighted average assumptions applied to stock options granted
  during the periods:</P>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="60%" border=0>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">2013 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">2012 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Risk-free interest rate </TD>
      <TD align=right width="25%" bgColor=#e6efff>2.73% </TD>
      <TD align=right width="25%" bgColor=#e6efff>0.83% - 2.19% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Expected life of options </TD>
      <TD align=right width="25%">10.0 years </TD>
      <TD align=right width="25%">4.25 - 5.0 years </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Annualized volatility </TD>
      <TD align=right width="25%" bgColor=#e6efff>71.39% </TD>
      <TD align=right width="25%" bgColor=#e6efff>57.87% - 95.25% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Dividend rate </TD>
      <TD align=right width="25%">0.00% </TD>
      <TD align=right width="25%">0.00% </TD>
    </TR>
  </TABLE>
</DIV>
<BR>
<P align=center>F-40</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-40></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 28<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 9 </TD>
    <TD align=left width="90%" ><U>Commitments </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>Stock&#150;based Compensation Plan &#150; (cont&#146;d)</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>At September 30, 2013, the following summarizes the
      unvested stock options:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=center width="15%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="15%">Weighted </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="15%">Weighted </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=center width="15%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="15%">Average </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="15%">Average </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=center width="15%">Number of </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="15%">Exercise </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="15%">Grant-Date </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">Shares </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">Price </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="15%">Fair
      Value </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Unvested options at September 30, 2011 </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="15%" bgColor=#e6efff>1,445,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>&nbsp;3.33 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>&nbsp;2.17 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left>Granted </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="15%">500,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">$</TD>
    <TD align=right width="15%">&nbsp;1.50 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">$</TD>
    <TD align=right width="15%">&nbsp;0.72 </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Forfeited </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="15%" bgColor=#e6efff>(900,000</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>&nbsp;2.74 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>&nbsp;1.60 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left>Vested </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="15%">(175,000</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%">) </TD>
    <TD align=left width="1%">$</TD>
    <TD align=right width="15%">&nbsp;3.71 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">$</TD>
    <TD align=right width="15%">&nbsp;2.70 </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Unvested options at September 30, 2012 </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="15%" bgColor=#e6efff>870,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>&nbsp;2.81 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>&nbsp;1.82 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left>Granted </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="15%">2,000,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">$</TD>
    <TD align=right width="15%">&nbsp;0.40 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">$</TD>
    <TD align=right width="15%">&nbsp;0.50 </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Expired </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="15%" bgColor=#e6efff>(100,000</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>&nbsp;3.86 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>&nbsp;2.49 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left>Vested </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="15%">(2,000,000</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%">) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%">$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="15%">&nbsp;0.40 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%">$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="15%">&nbsp;0.50 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Unvested options at September 30, 2013 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>770,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>&nbsp;2.68 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>&nbsp;1.74 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>As at September 30, 2013, there was no
  unrecognized compensation cost associated with unvested share-based compensation
  awards that will become vested exclusive of achieving any performance milestones
  that is expected to be recognized in the current fiscal year. There has been no
  stock-based compensation recognized in the financial statements for the year
  ended September 30, 2013 (2012: $nil) for options that will vest upon the
  achievement of performance milestones because the Company has determined that
  satisfaction of the performance milestones was not probable. Compensation
  relating to stock options exercisable upon achieving performance milestones will
  be recognized in the period the milestones are achieved.</P>
<P style="MARGIN-LEFT: 15%" align=justify>Stock-based compensation amounts,
  including those relating to shares issued for services during the years ended
  September 30, 2013 and 2012, are classified in the Company&#146;s Statement of
  Operations as follows:</P>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="70%" border=0>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="22%">2013 </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="22%">2012 </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Consulting fees </TD>
      <TD align=left width="1%" bgColor=#e6efff>$</TD>
      <TD align=right width="22%" bgColor=#e6efff>&nbsp;- </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>$</TD>
      <TD align=right width="22%" bgColor=#e6efff>&nbsp;312,903 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Research and development </TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="22%">- </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="22%">80,200 </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Salaries and wages </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="22%"
    bgColor=#e6efff>1,002,500 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="22%"
    bgColor=#e6efff>- </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%">$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="22%">&nbsp;1,002,500 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%">$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="22%">&nbsp;393,103 </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<BR>
<P align=center>F-41</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-41></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 29<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 10 </TD>
    <TD align=left width="90%"><U>Income Taxes</U> </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%"><P align=justify>The tax effects of the temporary differences that give
      rise to the Company&#146;s estimated deferred tax assets and liabilities are as
      follows: </P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=center width="17%"><U>2013</U> </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="17%"><U>2012</U> </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left><I>Tax rate</I> </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=center width="17%"><I>34%</I> </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="17%"><I>34%</I> </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Net operating loss carryforwards </TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="17%" bgColor=#e6efff>&nbsp;7,141,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="17%" bgColor=#e6efff>&nbsp;6,775,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Research and development tax credits </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">705,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">741,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Foreign exchange </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>(19,000</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>28,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Accrued bonuses </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">34,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">34,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Intangible asset costs </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>51,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>34,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Stock-based compensation </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">633,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Valuation allowance for deferred tax assets </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>(8,545,000</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>(7,612,000</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Net deferred tax assets </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="17%"
    bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="17%"
    bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>The provision for income taxes differ
  from the amount established using the statutory income tax rate as follows:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=center width="17%"><U>2013</U> </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="17%"><U>2012</U> </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Income benefit at statutory rate </TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="17%" bgColor=#e6efff>&nbsp;(1,258,000</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="17%" bgColor=#e6efff>&nbsp;(2,823,000</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Foreign income taxed at foreign statutory rate </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">(2,000</TD>
    <TD align=left width="2%">) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Debt extinguishment </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>501,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>1,302,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Research and development tax credit </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">(17,000</TD>
    <TD align=left width="2%">) </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">(175,000</TD>
    <TD align=left width="2%">) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Fair value of derivative liability </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>7,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>(23,000</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Debt accretion </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">33,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Other permanent differences </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>(5,000</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>113,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Adjustment to prior years' tax provision </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">(161,000</TD>
    <TD align=left width="2%">) </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Change in valuation allowance </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>933,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>1,575,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Income Tax Expense </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="17%"
    bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="17%"
    bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>As of September 30, 2013, the Company
  had net operating loss carry-forwards of approximately $21,022,000 (2012:
  $20,196,000) available to offset future taxable income. The carry-forwards will
  begin to expire in 2027 unless utilized in earlier years. The Company has not
  yet filed any tax returns in France as they are not yet due.</P>
<P align=center>F-42</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-42></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 30<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 10 </TD>
    <TD align=left width="90%" ><U>Income Taxes </U>&#150; (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The Company evaluates its valuation allowance
      requirements based on projected future operations. When circumstances
      change and this causes a change in management&#146;s judgment about the
      recoverability of deferred tax assets, the impact of the change on the
      valuation allowance is reflected in current income. Because management of
      the Company does not currently believe that it is more likely than not
      that the Company will receive the benefit of these assets, a valuation
      allowance equal to the deferred tax asset has been established at both
      September 30, 2013 and 2012. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>Uncertain Tax Positions </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The Company files income tax returns in the U.S. federal
      jurisdiction, various state and foreign jurisdictions. The Company&#146;s tax
      returns are subject to tax examinations by U.S. federal and state tax
      authorities, or examinations by foreign tax authorities until respective
      statute of limitation. The Company is subject to tax examinations by tax
      authorities for all taxation years commencing on or after 2005. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Note 11 </TD>
    <TD align=left width="90%" ><P align=justify><U>Supplemental Cash Flow Information</U> </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>Investing and financing activities that do not have a
      direct impact on current cash flows are excluded from the statement of
      cash flows. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>During the year ended September 30, 2013; </P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify>The Company issued three promissory notes in the
      principal amounts of $100,000, $87,865 (CDN$86,677) and $28,017
      (CDN$27,639) in exchange for accounts payable owing to three vendors in
      respect of unpaid consulting fees.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>The Company issued 4,208,910 units of the Company at
      their fair value of $1.02 per unit to settle (i) interest bearing notes
      payable outstanding in the amount of $549,000; (ii) accrued interest in
      connection with the notes payable of $26,058 included in accounts payable
      and accrued liabilities; and (iii) accounts payable of $1,108,506. Each
      unit consisted of one common share and one common share purchase warrant
      exercisable into one additional common share for $0.75 per share until
      July 5, 2018. In addition, in connection with the settlement, $11,449 of
      accrued interest with respect to the notes payable was forgiven. The
      Company recorded a loss on debt settlement of $1,472,208 as a result of
      this transaction.</P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-43</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-43></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2013
  and 2012 &#150; Page 31<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 11 </TD>
    <TD align=left width="90%" ><U>Supplemental Cash Flow
      Information </U>&#150; (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" >During the year ended September
      30, 2012: </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify>The Company issued 544,667 units of the Company at their
      fair value of $1.918 per unit to settle a convertible interest bearing
      note payable outstanding in the amount of $272,333, including accrued
      interest of $22,333 included in accounts payable and accrued liabilities
      and 2,155,846 units of the Company at their fair value of $1.918 per unit
      to settle non- convertible interest bearing notes payable outstanding in
      the amount of $1,077,923 including accrued interest of $30,034 included in
      accounts payable and accrued liabilities. Each unit consisted of one
      common share and one common share purchase warrant exercisable into one
      additional common share for $0.75 per share until November 30, 2013. The
      Company recorded a loss on debt settlement of $3,829,333 as a result of
      this transaction.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>The Company issued 75,000 common shares at their fair
      value of $1.00 per share for a total of $75,000 to the former President of
      the Company pursuant to a severance agreement.</P></TD>
  </TR>
</TABLE>
<BR>
<P align=center>F-44</P>
<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_35"></A>

<P align="justify">
<B>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS</B></P>
<P align="justify">
On November 12, 2013, the board of directors, approved the dismissal of BDO Canada LLC (&ldquo;BDO Canada&rdquo;) as the company's independent registered public accounting firm, effective November 12, 2013 </P>
<P align="justify">
No report prepared by BDO Canada included in our financial statements for the past two fiscal years, as well as the subsequent interim periods through the November 12, 2013, contained an adverse opinion, disclaimers of opinion or was qualified or
modified as to uncertainty, audit scope or accounting principles, and included explanatory paragraphs. </P>
<P align="justify">
During the two most recent fiscal years, as well as the subsequent interim period through November 12, 2013, there have been no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between us and BDO Canada
on any matter of accounting principles or practices, financial statement disclosures, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of BDO Canada, would have caused it to make reference to the subject of
such disagreements in connection with any report prepared by BDO Canada. Further, there have been no reportable events (as described in Item 304(a)(1)(v) of Regulation S-K). </P>
<P align="justify">
On November 12, 2013, the Board approved the engagement of BDO USA, LLC (&ldquo;BDO USA&rdquo;) as the company's independent registered public accounting firm to perform independent audit services. Neither the company, nor anyone on its
behalf, has consulted BDO USA regarding the application of accounting principles related to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company&rsquo;s financial statements or as
to any disagreement or reportable event as described in Item 304(a)(1)(iv) and Item 304(a)(1)(v), respectively, of Regulation S-K under the Securities Act of 1933, as amended. </P>
<P align="justify">
<B>ITEM 9A. CONTROLS AND PROCEDURES </B></P>
<P align="justify">
<B><I>Disclosure Controls and Procedures </I></B></P>
<P align="justify">
As required by Rule 13a-15 under the Securities Exchange Act of 1934, our management, with the participation of our principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rule
13a-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered by this Annual Report on Form 10-K. </P>
<P align="justify">
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized
and reported, within the time periods specified in the Securities and Exchange Commission&rsquo;s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our
reports filed under the Securities Exchange Act of 1934 is accumulated and communicated to our principal executive officer and principal financial officer to allow timely decisions regarding required disclosure.</P>
<P align="justify">
Based on its evaluation, our management, with the participation of our principal executive officer and principal financial officer, concluded that as of the end of the period covered by this Annual Report on Form 10-K, our disclosure controls and
procedures were not effective. The ineffectiveness of our disclosure controls and procedures was due to internal control
deficiencies related to internal control over financial reporting. </P>
<P align="center">30</P>
<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">

<A name=page_36></A>
<P align=justify><B><I>Management&#146;s Annual Report on Internal Control over
Financial Reporting</I></B></P>
<P align=justify>Management is responsible for establishing and maintaining
adequate internal control over our financial reporting, as such term is defined
in Rule 13a-15(f) under the Securities Exchange Act of 1934. Our chief executive
officer and chief financial officer assessed the effectiveness of our internal
control over financial reporting as of September 30, 2013.</P>
<P align=justify>Based on its evaluation under the framework in Internal
Control&#151;Integrated Framework, issued by the Committee of Sponsoring
Organizations of the Treadway Commission, our management, with the participation
of our principal executive officer and principal financial officer, concluded
that our internal control over financial reporting was not effective as of
September 30, 2013. The ineffectiveness of our internal control over financial
reporting was due to the existence of significant deficiencies constituting
material weaknesses, as described in greater detail below. A material weakness
is a control deficiency, or combination of control deficiencies, such that there
is a reasonable possibility that a material misstatement of the annual or
interim financial statements will not be prevented or detected on a timely
basis.</P>
<P align=justify><B><I>Material Weaknesses Identified </I></B></P>
<P align=justify>(1) Control environment - We did not maintain an effective
control environment. The control environment, which is the responsibility of
senior management, sets the tone of the organization, influences the control
consciousness of its people, and is the foundation for all other components of
internal control over financial reporting. Each of the following control
environment material weaknesses also contributed to the material weaknesses
discussed in items (2) and (3) below. Our control environment was ineffective
because of the following material weaknesses:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>We did not maintain a sufficient complement of personnel
      with an appropriate level of accounting knowledge, experience, and
      training in the application of Generally Accepted Accounting Principles
      (GAAP) commensurate with our financial reporting requirements and business
      environment. This material weakness resulted in a material post closing
      adjustment which has been reflected in the financial statements for the
      year ended September 30, 2013. This adjustment caused changes in current
      liabilities, stockholders' equity, and expenses, which were not originally
      recorded in accordance with ASC Topic 815 Derivatives and
  Hedging.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>There was insufficient segregation of duties in our
      finance and accounting functions due to limited personnel. During the
      fiscal year ended September 30, 2013, we had limited staff that performed
      nearly all aspects of our financial reporting process, including, but not
      limited to, access to the underlying accounting records and systems, the
      ability to post and record journal entries and responsibility for the
      preparation of the financial statements. This creates certain incompatible
      duties and a lack of review over the financial reporting process that
      would likely result in a failure to detect errors in spreadsheets,
      calculations, or assumptions used to compile the financial statements and
      related disclosures as filed with the Securities
and Exchange Commission. These control
deficiencies could result in a material misstatement to our interim or annual
financial statements that would not be prevented or detected; and </P></TD></TR></TABLE>
<BR><P align="center">31</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_37></A>
<P align=justify>(2) Monitoring of internal control over financial reporting&#151;We
did not maintain effective monitoring controls to determine the adequacy of our
internal control over financial reporting and related policies and procedures
because of the following material weaknesses:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>Our policies and procedures with respect to the review,
      supervision and monitoring of our accounting operations throughout the
      organization were either not designed and in place or not operating
      effectively.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>We did not maintain an effective internal control
      monitoring function. Specifically, there were insufficient policies and
      procedures to effectively determine the adequacy of our internal control
      over financial reporting and to monitoring the ongoing effectiveness
      thereof.</P></TD></TR></TABLE>
<P align=justify>(3) Equity Transactions&#151;We did not establish and maintain
effective controls to ensure the correct application of GAAP related to equity
transactions. Specifically, we did not adequately review private placement
agreements to identify potential derivative instruments.</P>
<P align=justify><B><I>Plan for Remediation of Material Weaknesses </I></B></P>
<P align=justify>We intend to take appropriate and reasonable steps to make
improvements to remediate these deficiencies. We intend to consider the results
of our remediation efforts and related testing as part of our year-end 2014
assessment of the effectiveness of our internal control over financial reporting
in light of our strategic plan.</P>
<P align=justify>Due to our size and nature, segregation of all conflicting
duties has not always been possible and may not be economically feasible.
However, we are in the process of implementing processes and procedures intended
to mitigate any material weaknesses identified. </P>
<P align=justify>We believe that the foregoing steps will remediate the
deficiencies identified above, and we intend to continue to monitor the
effectiveness of these steps and make any changes that our management deems
appropriate.</P>
<P align=justify><B><I>Limitations on Effectiveness of Controls </I></B></P>
<P align=justify>Our principal executive officer and principal financial officer
do not expect that our disclosure controls and procedures or our internal
control over financial reporting will prevent all errors and all fraud. A
control system, no matter how well conceived and operated, can provide only
reasonable, not absolute, assurance that the objectives of the control system
are met. Further, the design of a control system must reflect the fact that
there are resource constraints, and the benefits of controls must be considered
relative to their costs. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all
control issues and instances of fraud, if any, within our company have been
detected. These inherent limitations include the realities that judgments in
decision-making can be faulty, and that breakdowns can occur because of a simple
error or mistake. Additional controls can be
circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future
events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the
policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</P>
<P align=center>32</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>



<A name="page_38"></A>
<P align="justify">
<B><I>Changes in Internal Control over Financial Reporting </I></B></P>
<P align="justify">
On July 5, 2013 we appointed Christopher Missling as our President, Chief Executive Officer and Chief Financial Officer.  Prior to his appointment, these roles and related internal control functions were temporarily vacant as a result of the
resignation of our former principal executive officers during the second fiscal quarter.</P>
<P align="justify">
<B>ITEM 9B OTHER INFORMATION </B></P>
<P align="justify">
None. </P>
<P align="center">33</P>
<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">

<A name=page_39></A>
<P align=justify><B>PART III </B></P>
<P align=justify><B>ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE
GOVERNANCE </B></P>
<P align=justify><B><I>Directors and Executive Officers </I></B></P>
<P align=justify>Our directors are to be elected at our annual meeting and each
director elected is to hold office until his or her successor is elected and
qualified. Our board of directors may remove our officers at any time.</P>
<P align=justify>Our directors and executive officers, their age, positions
held, and duration of such, are as follows:</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left>Name </TD>
    <TD align=left width="25%">Position </TD>
    <TD align=left width="25%">Age </TD>
    <TD align=left width="25%">Date first appointed </TD></TR>
  <TR vAlign=top>
    <TD align=left>Christopher Missling, <BR>PhD <BR><BR><BR></TD>
    <TD align=left width="25%">Director, President, <BR>Chief Executive
      <BR>Officer, Chief Financial <BR>Officer, Secretary, <BR>Treasurer </TD>
    <TD align=left width="25%">47 <BR><BR><BR><BR></TD>
    <TD align=left width="25%">July 5, 2013 <BR><BR><BR><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Athanasios Skarpelos </TD>
    <TD align=left width="25%">Director </TD>
    <TD align=left width="25%">46 </TD>
    <TD align=left width="25%">January 9, 2013 </TD></TR></TABLE></DIV>
<P align=justify><B><I>Business Experience </I></B></P>
<P align=justify>The following is a brief account of the education and business
experience of directors and executive officers during at least the past five
years, indicating their principal occupation during the period, and the name and
principal business of the organization by which they were employed. </P>
<P align=justify><u>Christopher Missling, PhD</u>. Christopher Missling has over twenty (20) years of healthcare
industry experience in big pharmaceutical, biotech industry and investment
banking. Most recently, from March, 2007 until his appointment by our company,
Mr. Missling served as the head of healthcare investment banking at Brimberg
&amp; Co. in New York, New York. Also, Mr. Missling served as the Chief
Financial Officer of Curis, Inc. (NASDAQ:CRIS) and ImmunoGen, Inc.
(NASDAQ:IMGN). Mr. Missling earned his MS and PhD from the University of Munich
and an MBA from Northwestern University Kellogg School of Management. </P>
<P align=justify><u>Athanasios Skarpelos</u>. Athanasios (Tom) Skarpelos is a self-employed investor with 17
years of experience working with private and public companies. For the past 10
years, he has been focused on biotechnology companies involved in drug discovery
and drug development projects. Mr. Skarpelos was engaged as a consultant to our
company for one year effective August 2, 2010. His experience has led to
relationships with researchers at academic institutes in Europe and North
America. Mr. Skarpelos is a founder of Anavex. </P>
<P align=justify><B><I>Family Relationships </I></B></P>
<P align=justify>There are no family relationships between any director or
executive officer. </P>
<P align=center>34</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_40></A>
<P align=justify><B><I>Involvement in Certain Legal Proceedings </I></B></P>
<P align=justify>There are no material proceedings to which any director or
executive officer or any associate of any such director or officer is a party
adverse to our company or has a material interest adverse to our company.</P>
<P align=justify>No director or executive officer has been involved in any of
the following events during the past ten years:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">1. </TD>
    <TD>
      <P align=justify>any bankruptcy petition filed by or against any business
      of which such person was a general partner or executive officer either at
      the time of the bankruptcy or within two years prior to that
  time;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">2. </TD>
    <TD>
      <P align=justify>any conviction in a criminal proceeding or being subject
      to a pending criminal proceeding (excluding traffic violations and other
      minor offences);</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">3. </TD>
    <TD>
      <P align=justify>being subject to any order, judgment, or decree, not
      subsequently reversed, suspended or vacated, of any court of competent
      jurisdiction, permanently or temporarily enjoining, barring, suspending or
      otherwise limiting his involvement in any type of business, securities or
      banking activities;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">4. </TD>
    <TD>
      <P align=justify>being found by a court of competent jurisdiction (in a
      civil action), the Securities and Exchange Commission or the Commodity
      Futures Trading Commission to have violated a federal or state securities
      or commodities law, and the judgment has not been reversed, suspended, or
      vacated;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">5. </TD>
    <TD>
      <P align=justify>being the subject of, or a party to, any federal or state
      judicial or administrative order, judgment, decree, or finding, not
      subsequently reversed, suspended or vacated, relating to an alleged
      violation of: (i) any federal or state securities or commodities law or
      regulation; or (ii) any law or regulation respecting financial
      institutions or insurance companies including, but not limited to, a
      temporary or permanent injunction, order of disgorgement or restitution,
      civil money penalty or temporary or permanent cease- and- desist order, or
      removal or prohibition order; or (iii) any law or regulation prohibiting
      mail or wire fraud or fraud in connection with any business entity;
    or</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">6. </TD>
    <TD>
      <P align=justify>being the subject of, or a party to, any sanction or
      order, not subsequently reversed, suspended or vacated, of any
      self-regulatory organization (as defined in Section 3(a)(26) of the
      Securities Exchange Act of 1934), any registered entity (as defined in
      Section 1(a)(29) of the Commodity Exchange Act), or any equivalent
      exchange, association, entity or organization that has disciplinary
      authority over its members or persons associated with a
  member.</P></TD></TR></TABLE>
<P align=justify><B><I>Compliance with Section 16(a) of the Securities Exchange
Act of 1934</I></B></P>
<P align=justify>Section 16(a) of the Securities Exchange Act of 1934 requires
our executive officers and directors and persons who own more than 10% of our
common stock to file with the Securities and Exchange Commission initial
statements of beneficial ownership, reports of changes in ownership and annual
reports concerning their ownership of our common stock and other equity
securities, on Forms 3, 4 and 5 respectively. Executive officers, directors and
greater than 10% shareholders are required by the Securities and Exchange
Commission regulations to furnish us with copies of all Section 16(a) reports
that they file.</P>
<P align=justify>Based solely on our review of the copies of such forms received
by us, or written representations from certain reporting persons, we believe
that during fiscal year ended September 30, 2013, all filing requirements
applicable to our officers, directors and greater than 10% percent beneficial
owners were complied. </P>
<P align=center>35</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_41></A>
<P align=justify><B><I>Code of Ethics </I></B></P>
<P align=justify>We have adopted a code of ethics that applies to our principal
executive officer, principal financial officer, principal accounting officer or
controller, or persons performing similar functions. We have posted our policy
on our website at <U>www.anavex.com</U>. </P>
<P align=justify><B><I>Audit Committee and Audit Committee Financial
Experts</I></B></P>
<P align=justify>We do not have a standing audit committee at the present time.
We believe that our board of directors is capable of analyzing and evaluating
our financial statements and understanding internal controls and procedures for
financial reporting. The board of directors of our company does not believe that
it is necessary to have an audit committee at this time because management
believes the functions of an audit committee can be adequately performed by the
board of directors.<B> </B></P>
<P align=justify>We do not deem either of our directors as an &#147;audit committee
financial expert&#148; as defined in Item 407(d)(5)(ii) of Regulation S-K.</P>
<P align=justify><B><I>Nominating and Compensation Committees </I></B></P>
<P align=justify>We do not have standing nominating or compensation committees,
or committees performing similar functions. Our board of directors believes that
it is not necessary to have a standing compensation committee at this time
because the functions of such committee are adequately performed by our board of
directors. Our board of directors has not adopted a charter for the compensation
committee.</P>
<P align=justify>Our board of directors also is of the view that it is
appropriate for us not to have a standing nominating committee because our board
of directors has performed and is expected to perform adequately the functions
of a nominating committee. Our board of directors has not adopted a charter for
the nominating committee. There has not been any defined policy or procedure
requirements for stockholders to submit recommendations or nomination for
directors. Our board of directors does not believe that a defined policy with
regard to the consideration of candidates recommended by stockholders is
necessary at this time because we believe that, at this stage of our
development, a specific nominating policy would be premature and of little
assistance until our business operations are at a more advanced level. There are
no specific, minimum qualifications that our board of directors believes must be
met by a candidate recommended by our board of directors. There is neither a
defined, nor a typical process of identifying and evaluating nominees for
director.</P>
<P align=justify><B>ITEM 11. EXECUTIVE COMPENSATION </B></P>
<P align=justify><B><I>Summary Compensation</I></B></P>
<P align=justify>The particulars of compensation paid to the following persons
for the last two completed fiscal years: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD>
      <P align=justify>our principal executive officers;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD>
      <P align=justify>each of our two most highly compensated executive
      officers who were serving as executive officers at the end of the fiscal
      year ended September 30, 2013 who had total compensation exceeding
      $100,000; and</P></TD></TR></TABLE><BR><P align="center">36</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_42></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD>
      <P align=justify>up to two additional individuals for whom disclosure
      would have been provided under (b) but for the fact that the individual
      was not serving as our executive officer at the end of the most recently
      completed financial year, who we will collectively refer to as the named
      executive officers, for our fiscal years ended September 30, 2013 and
      2012, are set out in the following summary compensation
  table:</P></TD></TR></TABLE><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left nowrap><BR>
      <BR><BR><B>Name and Principal</B> <BR><B>Position</B>
    </TD>
    <TD width="12%" align=center nowrap><BR>
      <BR><BR><BR><B>Year</B> </TD>
    <TD width="12%" align=center nowrap><BR>
      <BR><BR><B>Salary</B> <BR><B>($)</B> </TD>
    <TD width="12%" align=center nowrap><BR>
      <BR><BR><B>Bonus</B> <BR><B>($)</B> </TD>
    <TD width="12%" align=center nowrap><BR>
      <BR><B>Stock</B> <BR><B>Awards</B>
      <BR><B>($)</B> </TD>
    <TD width="12%" align=center nowrap><BR>
      <BR><B>Option</B> <BR><B>Awards</B>
      <BR>
      <B>($)</B></TD>
    <TD width="12%" align=center nowrap><B>Other</B> <BR>
      <B>Annual</B>
      <BR><B>Compen-</B> <BR><B>sation</B> <BR>
      <B>($)</B></TD>
    <TD width="12%" align=center nowrap><BR>
      <BR><BR><B>Total</B> <BR><B>($)</B>
</TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Christopher Missling, <BR>PhD<SUP>(1)</SUP>
      <BR>President, Chief <BR>Executive Officer, Chief <BR>Financial Officer
      and <BR>Director </TD>
    <TD align=center width="12%" bgColor=#e6efff>2013 <BR>2012
    <BR><BR><BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>60,000 <BR>Nil
      <BR><BR><BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>Nil
    <BR><BR><BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>1,600,000<SUP>(5)</SUP>
      <BR>Nil <BR><BR><BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>1,002,500 <BR>Nil
      <BR><BR><BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>Nil
    <BR><BR><BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>2,662,500 <BR>Nil
      <BR><BR><BR><BR></TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Robert Chisholm<SUP>(2)</SUP>
      <BR>President, Chief <BR>Financial Officer and <BR>Director </TD>
    <TD align=center width="12%" bgColor=#e6efff>2013 <BR>2012 <BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>24,677 <BR>96,217 <BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>Nil <BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>Nil <BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>Nil <BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>Nil <BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>24,677 <BR>96,217
  <BR><BR></TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Harvey Lalach <SUP>(3)</SUP> <BR>Former
      President, <BR>Former Chief <BR>Operating, Former <BR>Director </TD>
    <TD align=center width="12%" bgColor=#e6efff>2013 <BR>2012 <BR><BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>130,000
    <BR><BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>Nil <BR><BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>75,000
<BR><BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>18,600
<BR><BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>Nil <BR><BR><BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>223,600
    <BR><BR><BR></TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>George Tidmarsh <SUP>(4)</SUP> <BR>Former
      Executive <BR>Director </TD>
    <TD align=center width="12%" bgColor=#e6efff>2013 <BR>2012 <BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>42,012 <BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>Nil <BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>15,896 <BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>33,493 <BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>Nil <BR></TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil <BR>91,401
  <BR></TD></TR></TABLE></DIV><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(1) </TD>
    <TD>
      <P align=justify>Christopher Missling was appointed as director,
      President, Chief Executive Officer, Chief Financial Officer, Secretary and
      Treasurer on July 5, 2013.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(2) </TD>
    <TD>
      <P align=justify>Robert Chisholm was appointed President and Chief
      Financial Officer on June 26, 2012. Prior to that date, Mr. Chisholm
      served as a director to the company. Mr. Chisholm resigned as President
      and Chief Financial Officer and director on January 9, 2013. These fees
      are included in consulting fees in our consolidated financial
      statements.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(3) </TD>
    <TD>
      <P align=justify>Harvey Lalach was appointed President and Secretary on
      April 25, 2006. On August 27, 2011, Mr. Lalach was appointed Chief
      Operating Officer and on May 13, 2011 he was appointed interim Chief
      Financial Officer. Mr. Lalach resigned as an officer and director of our
      company on June 26, 2012.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(4) </TD>
    <TD>
      <P align=justify>George Tidmarsh was appointed as an executive director on
      October 12, 2011 and received consulting fees and stock option awards in
      his capacity as Executive Director. Mr. Tidmarsh resigned on March 17,
      2012.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(5) </TD>
    <TD>
      <P align=justify>Mr. Missling was granted 4,000,000 shares of
      restricted common stock that vest upon the occurrence of certain financial
      and clinical milestones. The value of stock awards issued to Christopher
      Missling is presented at the quoted market price of these shares on the
      date of issuance in accordance with FASB ASC Topic 718 for the awards that
      are expected to vest.</P></TD></TR></TABLE><BR><P align="center">37</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_43></A>
<P align=justify><B><I>Consulting Agreements</I></B></P>
<P align=justify><B>Robert Chisholm </B></P>
<P align=justify>Effective June 26, 2012, Robert Chisholm was appointed
President and Chief Financial Officer of the company. Mr. Chisholm was
remunerated at a rate of CDN$7,500 per month through a company with which he is
associated. Effective January 9, 2013, Mr. Chisholm resigned from his positions
as both an officer and a director and his agreement was terminated in connection
therewith. </P>
<P align=justify><B>Harvey Lalach </B></P>
<P align=justify>We had a consulting agreement dated February 1, 2007 with
Harvey Lalach to provide management services to our company for consideration of
$7,000 per month. The contract had a two year term, and was extended for an
additional two year term expiring January 31, 2011. During the fiscal year ended
September 30, 2008, we agreed to increase the compensation of Mr. Lalach to
$12,500 per month. Effective February 1, 2011 we entered into a consulting
agreement with Mr. Lalach whereby Mr. Lalach agreed to continue to provide
management services to our company in return for compensation of $12,500 per
month for an additional two years. </P>
<P align=justify>Effective June 26, 2012 Mr. Lalach resigned his positions as
both an officer and a director. Mr. Lalach continued to consult for the company
until September 30, 2012 and was paid $15,000. In addition, we issued an
aggregate of 75,000 shares of our common stock at a deemed value of $1.00 per
share to Mr. Lalach for his past services and in final settlement of his
Consulting Agreement dated February 1, 2007 and we extended the expiry date to
June 30, 2014 of 200,000 stock options held by Mr. Lalach. </P>
<P align=justify><B>Dr. George Tidmarsh </B></P>
<P align=justify>Effective October 10, 2011 we entered into a consulting
agreement with Dr. Tidmarsh to act as our executive director for the following
consideration:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD>
      <P align=justify>a monthly consulting fee of $10,000;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD>
      <P align=justify>500,000 Share purchase options exercisable at $1.50 per
      option share until October 10, 2016 (subject to certain vesting
      provisions);</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD>
      <P align=justify>reimbursement of all reasonable
  expenditures.</P></TD></TR></TABLE>
<P align=justify>On February 9, 2012 we issued an aggregate of 8,000 units of
our securities at a price of $1.25 per unit to George Tidmarsh, a former
director of our company, for his services during the month of January, 2012.
Each unit consisted of one share of our common stock and one-half of one share
purchase warrant. Each whole warrant is exercisable at $2.00 for one share of
common stock for a period of 12 months. </P>
<P align=justify>On March 18, 2012 Dr. Tidmarsh delivered notice to us of his
resignation as both an officer and a director. On March 21, 2012, Dr. Tidmarsh
withdrew his original notice, and issued an amended notice of resignation. </P>
<P align=justify><B>Christopher Missling</B> </P>
<P align=center>38</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_44></A>
<P align=justify>In connection with Mr. Missling&#146;s appointment as Chief
Executive Officer, the Company and Mr. Missling entered into an employment
agreement commencing on July 5, 2013 and ending on July 5, 2016, whereby: (a)
the Company shall pay to Mr. Missling an initial monthly base salary of $20,000
with Mr. Missling being eligible for bonuses and salary increases; (b) Mr.
Missling received a sign-on stock option grant; (c) Mr. Missling shall receive a
restricted stock grant subject to certain vesting milestones; (d) Mr. Missling
shall be able to participate in the Company&#146;s employee benefit plans; and (e)
the Company agreed to indemnify Mr. Missling in connection with his provision of
services to the Company. </P>
<P align=justify><B><I>Outstanding Equity Awards at Fiscal Year-End</I></B></P>
<P align=justify>The following table sets forth for each named executive officer
and director certain information concerning the outstanding equity awards as of
September 30, 2013.</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center vAlign=bottom nowrap bgcolor="#EEEEEE">&nbsp; </TD>
    <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE">&nbsp; </TD>
    <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE">Option Awards </TD>
    <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE" >&nbsp;</TD>
    <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE">&nbsp; </TD>
    <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE">&nbsp; </TD>
    <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE">&nbsp; </TD>
    <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE">Stock Awards </TD>
    <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE" >&nbsp;</TD>
    <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE">&nbsp; </TD>
  </TR>
  <TR>
    <TD
      align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><BR>
      <BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR>Name </TD>
    <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><BR>
      <BR><BR><BR><BR>Number
      <BR>of <BR>Securities <BR>Underlying<BR>Exercisable <BR>Options <BR>(#)
</TD>
    <TD
      width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><BR>
      <BR><BR><BR><BR><BR><BR>Number of<BR>Securities
      <BR>Underlying <BR>Unexercisable<BR>Options <BR>(#) </TD>
    <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><BR>
      Equity <BR>Incentive
      <BR>Plan <BR>Awards: <BR>Number of <BR>Securities <BR>Underlying
      <BR>Unexercised<BR>Unearned <BR>Options <BR>(#) </TD>
    <TD
      width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><BR>
      <BR><BR><BR><BR><BR><BR><BR><BR><BR>Option <BR>Exercise
      <BR>Price <BR>($) </TD>
    <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><BR>
      <BR><BR>Option
      <BR>Expiration <BR>Date </TD>
    <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><BR>
      Number <BR>of <BR>Shares of
      <BR>Units of <BR>Stock <BR>that have <BR>not <BR>Vested <BR>(#) </TD>
    <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><BR>
      Market <BR>Value of
      <BR>Shares or <BR>Units of <BR>Stock that <BR>have not <BR>Vested <BR>($)
    </TD>
    <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE">Equity <BR>
      Incentive<BR>Plan
      <BR>Awards: <BR>Number <BR>of <BR>Unearned <BR>Shares, <BR>Units or
      <BR>Other <BR>Rights <BR>that <BR>have <BR>not <BR>Vested <BR>(#) </TD>
    <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><BR>
      Equity <BR>Incentive
      <BR>Plan <BR>Awards: <BR>Market or <BR>Payout <BR>Value of <BR>Unearned
      <BR>Shares, <BR>Units or <BR>Other <BR>Rights that <BR>have not <BR>Vested
      <BR>($) </TD></TR>
  <TR>
    <TD vAlign=bottom align=center >&nbsp;</TD>
    <TD vAlign=bottom align=center width="10%" >&nbsp;</TD>
    <TD vAlign=bottom align=center width="10%" >&nbsp;</TD>
    <TD vAlign=bottom align=center width="10%" >&nbsp;</TD>
    <TD vAlign=bottom align=center width="10%" >&nbsp;</TD>
    <TD vAlign=bottom align=center width="10%" >&nbsp;</TD>
    <TD vAlign=bottom align=center width="10%" >&nbsp;</TD>
    <TD vAlign=bottom align=center width="10%" >&nbsp;</TD>
    <TD vAlign=bottom align=center width="10%" >&nbsp;</TD>
    <TD vAlign=bottom align=center width="10%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Christopher Missling </TD>
    <TD align=center width="10%" bgColor=#e6efff>2,000,000 </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>0.40 </TD>
    <TD align=center width="10%" bgColor=#e6efff>July 5, 2023 </TD>
    <TD align=center width="10%" bgColor=#e6efff>4,000,000 </TD>
    <TD align=center width="10%" bgColor=#e6efff>1,600,000 </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Athanasios Skarpelos </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>N/A </TD>
    <TD align=center width="10%" bgColor=#e6efff>N/A </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>N/A </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>N/A </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Robert Chisholm </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>N/A </TD>
    <TD align=center width="10%" bgColor=#e6efff>N/A </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>N/A </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>N/A </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Sean Lowry </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>N/A </TD>
    <TD align=center width="10%" bgColor=#e6efff>N/A </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>N/A </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="10%" bgColor=#e6efff>N/A </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Harvey <BR>Lalach </TD>
    <TD align=center width="10%" bgColor=#e6efff>150,000 <BR>50,000 </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil <BR></TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil <BR></TD>
    <TD align=center width="10%" bgColor=#e6efff>3.10 <BR>3.50 </TD>
    <TD align=center width="10%" bgColor=#e6efff>June 30, 2014 <BR>June 30,
      2014 </TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil <BR></TD>
    <TD align=center width="10%" bgColor=#e6efff>N/A <BR></TD>
    <TD align=center width="10%" bgColor=#e6efff>Nil <BR></TD>
    <TD align=center width="10%" bgColor=#e6efff>N/A
<BR></TD></TR></TABLE></DIV>
<P align=justify>We have not adopted any other equity compensation plan other
than our 2007 Stock Option Plan. </P>
<P align=justify><B><I>Compensation of Directors</I></B></P>
<P align=center>39</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_45></A>
<P align=justify>The table below shows the compensation of our directors who
were not our named executive officers for the fiscal year ended September 30,
2013: </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left nowrap><BR><BR><BR><B>Name</B> <BR></TD>
    <TD width="12%" align=center nowrap><BR><B>Fees Earned</B> <BR><B>or Paid in</B>
      <BR><B>Cash</B> <BR><B>($)</B> </TD>
    <TD width="12%" align=center nowrap><BR><B>Stock</B> <BR><B>Awards</B>
      <BR><B>($)</B> <BR></TD>
    <TD width="12%" align=center nowrap><BR><B>Option</B> <BR><B>Awards</B>
      <BR><B>($)</B> <BR></TD>
    <TD width="12%" align=center nowrap><B>Non-Equity</B> <BR><B>Incentive Plan</B>
      <BR><B>Compensation</B><BR><B>($)</B> <BR></TD>
    <TD width="12%" align=center nowrap><B>Nonqualified</B> <BR><B>Deferred</B>
      <BR><STRONG>Compensation</STRONG> <BR><B>Earnings ($)</B> <BR></TD>
    <TD width="12%" align=center nowrap><BR><B>All Other</B>
      <BR><STRONG>Compensation</STRONG> <BR><B>($)</B> <BR></TD>
    <TD width="12%" align=center nowrap><BR><BR><B>Total</B> <BR><B>($)</B>
<BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Athanasios Skarpelos </TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="12%" bgColor=#e6efff>&nbsp; &nbsp;Nil </TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD align=center width="12%">&nbsp; </TD>
    <TD align=center width="12%">&nbsp; </TD>
    <TD align=center width="12%">&nbsp; </TD>
    <TD align=center width="12%">&nbsp; </TD>
    <TD align=center width="12%">&nbsp; </TD>
    <TD align=center width="12%">&nbsp; </TD>
    <TD align=center width="12%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Sean Lowry <SUP>(1)</SUP> </TD>
    <TD align=center width="12%" bgColor=#e6efff>30,977 </TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="12%" bgColor=#e6efff>Nil </TD>
  <TD align=center width="12%" bgColor=#e6efff>30,977</TD></TR></TABLE>
</DIV><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(1) </TD>
    <TD>
      <P align=justify>Sean Lowry was paid a fee for his service as chairman of
      the company&#146;s audit committee.</P></TD></TR></TABLE>
<P align=justify>We reimburse our directors for expenses incurred in connection
with attending board meetings. </P>
<P align=justify>During the fiscal year ended September 30, 2013, there were no
standard arrangements pursuant to which any of our directors were compensated
for services provided in their capacity as directors.</P>
<P align=justify>We currently have no formal plan for compensating our directors
for their services in their capacity as directors, although we may elect to
issue stock options to such persons in the future. Directors are entitled to
reimbursement for reasonable travel and other out-of-pocket expenses incurred in
connection with attendance at meetings of our board of directors. Our board of
directors may award special remuneration to any director undertaking any special
services on our behalf other than services ordinarily required of a director.
</P>
<P align=justify><B><I>Retirement or Similar Benefit Plans </I></B></P>
<P align=justify>There are no arrangements or plans in which we provide
retirement or similar benefits for our directors or executive officers. </P>
<P align=justify><B><I>Resignation, Retirement, Other Termination, or Change in
Control Arrangements </I></B></P>
<P align=justify>Our employment agreement with Christopher Missling, PhD
contains provisions regarding our obligations to Mr. Missling upon his
termination and upon a change of control. In the event of a change of control,
as such term is defined in the employment agreement, all of the restricted stock
granted to Mr. Missling shall vest. Depending on the nature of the termination
of Mr. Missling&#146;s services, certain of his salary, bonus and granted securities
shall vest in the amounts at such time as set forth in the agreement. A copy of
the employment agreement is set forth in its entirety as an exhibit to the
Company&#146;s Quarterly Report on Form 10-Q filed with the SEC on August 14,
2013.</P>
<P align=justify><B>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT AND RELATED STOCKHOLDER MATTERS</B></P>
<P align=center>40</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_46></A>
<P align=justify>The following table sets forth, as of December 24, 2013, certain information with respect to the beneficial ownership of our common stock by each stockholder known by us to be the beneficial owner of more than 5% of our common stock and by each of our current directors and our named executive officers and by our current directors and executive officers as a group. We have determined the number and percentage of shares beneficially owned by such person in accordance with Rule 13d-3 under the Securities Exchange Act of 1934. This information does not necessarily indicate beneficial ownership for any other purpose. </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><BR><B>Title of class</B> </TD>
    <TD align=center width="30%" ><B>Name and address of</B>
      <BR><B>beneficial owner</B> </TD>
    <TD align=center width="10%" ><B>Amount and nature of</B>
      <BR><B>beneficial ownership</B> </TD>
    <TD align=center width="10%"  ><BR></TD>
    <TD align=center width="26%"><B>Percent of</B> <BR>
    <B>class
      </B><B><SUP>(1)</SUP></B></TD>
  </TR>
  <TR>
    <TD align=center>&nbsp; </TD>
    <TD width="30%" >&nbsp; </TD>
    <TD width="10%" >&nbsp; </TD>
    <TD width="10%" >&nbsp; </TD>
    <TD width="26%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff>Common Stock </TD>
    <TD align=left width="30%" bgColor=#e6efff >Athanasios
      Skarpelos <BR>2, Place du Port <BR>Geneva, Switzerland CH 1204 </TD>
    <TD align=right width="10%" bgColor=#e6efff >5,225,832 </TD>
    <TD align=center width="10%" bgColor=#e6efff >Direct </TD>
    <TD align=center width="26%" bgColor=#e6efff>14.0% </TD></TR>
  <TR>
    <TD align=center>&nbsp; </TD>
    <TD width="30%" >&nbsp; </TD>
    <TD align=right width="10%" >&nbsp; </TD>
    <TD align=center width="10%" >&nbsp; </TD>
    <TD width="26%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff>Common Stock <BR><BR><BR></TD>
    <TD align=left width="30%" bgColor=#e6efff >Christopher
      Missling <BR>51 W 552nd Street, <BR>7th floor <BR>New York, NY 10019 </TD>
    <TD align=right width="10%" bgColor=#e6efff
      >2,000,000<SUP>(2)</SUP> <BR><BR><BR></TD>
    <TD align=center width="10%" bgColor=#e6efff ><BR><BR><BR></TD>
    <TD align=center width="26%" bgColor=#e6efff>5.1% <BR><BR><BR></TD></TR>
  <TR>
    <TD align=center >&nbsp;</TD>
    <TD align=left width="30%" >&nbsp;</TD>
    <TD align=right width="10%" >&nbsp;</TD>
    <TD align=center width="10%" >&nbsp;</TD>
    <TD align=center width="26%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff>Common Stock </TD>
    <TD align=left width="30%" bgColor=#e6efff ><B>Directors
      &amp; Executive</B><br>      <B>Officers as a group (2</B><br>      <B>persons)</B> </TD>
    <TD align=right width="10%" bgColor=#e6efff >7,225,832 </TD>
    <TD align=center width="10%" bgColor=#e6efff ></TD>
    <TD align=center width="26%" bgColor=#e6efff>18.4% </TD></TR>
  <TR>
    <TD align=center>&nbsp; </TD>
    <TD width="30%" >&nbsp; </TD>
    <TD align=right width="10%" >&nbsp; </TD>
    <TD align=center width="10%" >&nbsp; </TD>
    <TD width="26%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff>Common Stock <BR><BR><BR></TD>
    <TD align=left width="30%" bgColor=#e6efff >Euro Genet Labs
      S.A. <BR>27 Marathonos Avenue <BR>15351 Pallini <BR>Athens, Greece </TD>
    <TD align=right width="10%" bgColor=#e6efff >2,771,265
      <BR><BR><BR></TD>
    <TD align=center width="10%" bgColor=#e6efff >Direct
      <BR><BR><BR></TD>
    <TD align=center width="26%" bgColor=#e6efff>7.4% <BR><BR><BR></TD></TR>
  <TR>
    <TD align=center >&nbsp;</TD>
    <TD align=left width="30%" >&nbsp;</TD>
    <TD align=right width="10%" >&nbsp;</TD>
    <TD align=center width="10%" >&nbsp;</TD>
    <TD align=left width="26%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff>Common Stock <BR><BR><BR></TD>
    <TD align=left width="30%" bgColor=#e6efff >The Stone Hedge
      Ltd. <BR>Maritime House <BR>Frederick Street <BR>Nassau, Bahamas </TD>
    <TD align=right width="10%" bgColor=#e6efff >2,306,179
      <BR><BR><BR></TD>
    <TD align=center width="10%" bgColor=#e6efff >Direct
      <BR><BR><BR></TD>
    <TD align=center width="26%" bgColor=#e6efff>6.2%
  <BR><BR><BR></TD></TR></TABLE></DIV><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(1) </TD>
    <TD>
  <P align=justify>Percentage of ownership is based on 37,237,588 shares of our common stock issued and outstanding as of December 24, 2013. Except as otherwise indicated, we believe that the beneficial owners of the common stock listed above, based on information furnished by such owners, have sole investment and voting power with respect to such shares, subject to community property laws where applicable. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities. Shares of common stock subject to options or warrants currently exercisable or exercisable within 60 days, are deemed outstanding for purposes of computing the percentage ownership of the person holding such option or warrants, but are not deemed outstanding for purposes of computing the percentage ownership of any other person.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(2) </TD>
    <TD>
      <P align=justify>Includes 2,000,000 stock options that have vested. Does
      not include 4,000,000 shares of restricted common stock that vest pursuant
      to the achievement of certain objectives</P></TD></TR></TABLE>
<P align=justify><B><I>Changes in Control </I></B></P>
<P align=center>41</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_47></A>
<P align=justify>We are unaware of any contract or other arrangement the
operation of which may at a subsequent date result in a change of control of our
company. </P>
<P align=justify><B>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND
DIRECTOR INDEPENDENCE</B></P>
<P align=justify><B><I>Transactions with related persons </I></B></P>
<P align=justify>Prior to his appointment as an officer and director of the
Company, Christopher Missling, PhD was employed by the Company&#146;s financial
advisor and placement agent that participated in our July, 2013 private
placement. There have been no other transactions, since October 1, 2012, or
currently proposed transactions, in which we were or are to be a participant and
the amount involved exceeds the lesser of $120,000 or one percent of the average
of our total assets at year end for the last two completed fiscal years, and in
which any of the following persons had or will have a direct or indirect
material interest.</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top align=right width="4%">i. </TD>
    <TD vAlign=top align=right width="4%" >&nbsp;</TD>
    <TD >
      <P align=justify>any director or executive officer of our
  company;</P></TD></TR>
  <TR>
    <TD width="4%">&nbsp;</TD>
    <TD width="4%" >&nbsp;</TD>
    <TD >&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top align=right width="4%">ii. </TD>
    <TD vAlign=top align=right width="4%" >&nbsp;</TD>
    <TD >
      <P align=justify>any beneficial owner of shares carrying more than 5% of
      the voting rights attached to our outstanding shares of common stock;
      and</P></TD></TR>
  <TR>
    <TD width="4%">&nbsp;</TD>
    <TD width="4%" >&nbsp;</TD>
    <TD >&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top align=right width="4%">iii. </TD>
    <TD vAlign=top align=right width="4%" >&nbsp;</TD>
    <TD >
      <P align=justify>any member of the immediate family (including spouse,
      parents, children, siblings and in-laws) of any of the foregoing
      persons.</P></TD></TR></TABLE>
<P align=justify><B><I>Compensation of Named Executive Officers and Directors
</I></B></P>
<P align=justify>For information regarding compensation of named executive
officers and directors, please see &#147;Item 11. Executive Compensation.&#148;</P>
<P align=justify><B><I>Director Independence </I></B></P>
<P align=justify>We deem that Christopher Missling, PhD is not independent as
that term is defined by NASDAQ 5605(a)(2) because Mr. Missling serves as our
President, Chief Executive Officer, Secretary, Treasurer and Chief Financial
Officer. We have also determined that Athanasios Skarpelos is not independent.
</P>
<P align=justify><B>ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</B></P>
<P align=justify><B><I>Fees Paid to Our Independent Registered Public Accounting
Firm</I></B></P>
<P align=justify>The following table sets forth the aggregate fees billed or
expected to be billed to our company for professional services rendered by our
independent registered public accounting firms, for the fiscal years ended
September 30, 2013 and 2012:</P>
<P align=justify>BDO USA LLP </P>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="60%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="25%">2013
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="25%">2012
    </TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff >Audit Fees </TD>
    <TD align=right width="25%" bgColor=#e6efff>$50,000 </TD>
    <TD align=right width="25%" bgColor=#e6efff>Nil </TD></TR>
  <TR>
    <TD align=center >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff >Audit Related Fees </TD>
    <TD align=right width="25%" bgColor=#e6efff>Nil </TD>
    <TD align=right width="25%" bgColor=#e6efff>Nil
</TD></TR></TABLE></DIV><BR><P align="center">42</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_48></A><BR>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="60%" border=0>

  <TR vAlign=top>
    <TD align=center bgColor=#e6efff >Tax Fees </TD>
    <TD align=right width="25%" bgColor=#e6efff>Nil </TD>
    <TD align=right width="25%" bgColor=#e6efff>Nil </TD></TR>
  <TR>
    <TD align=center >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff >All Other Fees </TD>
    <TD align=right width="25%" bgColor=#e6efff>Nil </TD>
    <TD align=right width="25%" bgColor=#e6efff>Nil </TD></TR>
  <TR>
    <TD align=center >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff >Total Fees </TD>
    <TD align=right width="25%" bgColor=#e6efff>$50,000 </TD>
    <TD align=right width="25%" bgColor=#e6efff>Nil </TD></TR></TABLE></DIV>
<P align=justify>The fees included above to BDO USA, LLP during the year ended
September 30, 2013 relates to an estimate of the audit fees of the Company&#146;s
annual consolidated financial statements filed on Form 10-K for the year ended
September 30, 2013. </P>
<P align=justify>BDO Canada LLP </P>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="60%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="25%">2013
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="25%">2012
    </TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff >Audit Fees </TD>
    <TD align=right width="25%" bgColor=#e6efff>$30,522 </TD>
    <TD align=right width="25%" bgColor=#e6efff>$78,187</TD></TR>
  <TR>
    <TD align=center >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff >Audit Related Fees </TD>
    <TD align=right width="25%" bgColor=#e6efff>$16,214 </TD>
    <TD align=right width="25%" bgColor=#e6efff>Nil </TD></TR>
  <TR>
    <TD align=center >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff >Tax Fees </TD>
    <TD align=right width="25%" bgColor=#e6efff>$6,019 </TD>
    <TD align=right width="25%" bgColor=#e6efff>$5,161 </TD></TR>
  <TR>
    <TD align=center >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff >All Other Fees </TD>
    <TD align=right width="25%" bgColor=#e6efff>Nil </TD>
    <TD align=right width="25%" bgColor=#e6efff>Nil </TD></TR>
  <TR>
    <TD align=center >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD>
    <TD align=right width="25%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff >Total Fees </TD>
    <TD align=right width="25%" bgColor=#e6efff>$52,755 </TD>
    <TD align=right width="25%" bgColor=#e6efff>$83,348
</TD></TR></TABLE></DIV>
<P align=justify><U>Audit Fees</U>. Consist of fees billed for professional
services rendered for the audits of our financial statements, reviews of our
interim financial statements included in quarterly reports, services performed
in connection with regular filings with the Securities and Exchange Commission
and other services that are normally provided by BDO Canada LLP for the fiscal
years ended September 30, 2013 and 2012, in connection with statutory and
regulatory filings or engagements. </P>
<P align=justify><U>Audit Related Fees</U>. Consists of fees billed for
professional services rendered in connection with the Company&#146;s filing on form
S-1 Registration Statement. </P>
<P align=justify><U>Tax Fees</U>. Consist of fees billed for the preparation of
corporate tax returns </P>
<P align=justify><B><I>Policy on Pre-Approval by Audit Committee of Services
Performed by Independent Registered Public Accounting Firm</I></B></P>
<P align=justify>Our board of directors pre-approves all services provided by
our independent registered public accounting firm. All of the above services and
fees were reviewed and approved by our board of directors before the respective
services were rendered. </P>
<P align=justify>Our board of directors has considered the nature and amount of
fees billed or expected to be billed by BDO Canada LLP and BDO USA, LLP and
believes that the provision of services for activities unrelated to the audit
was compatible with maintaining BDO Canada LLP and BDO USA, LLP&#146;s independence.
</P><P align="center">43</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_49></A>
<P align=justify><B>PART IV </B></P>
<P align=justify><B>ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES </B></P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left>
      <P align=justify><B>Exhibit</B> <BR><B>Number</B> </P></TD>
    <TD align=left width="90%">
      <P align=justify><BR><B>Description</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify><B>(3)</B> </P></TD>
    <TD align=left width="90%">
      <P align=justify><B>Articles of Incorporation and Bylaws</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>3.1 </P></TD>
    <TD align=left width="90%">
      <P align=justify>Articles of Incorporation (incorporated by reference to
      an exhibit to our Registration Statement on Form SB-2 filed on January 13,
      2005) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>3.2 </P></TD>
    <TD align=left width="90%">
      <P align=justify>Bylaws (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on September 28, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>3.3 </P></TD>
    <TD align=left width="90%">
      <P align=justify>Articles of Merger filed with the Secretary of State of
      Nevada on January 10, 2007 and which is effective January 25, 2007
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on January 25, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify><B>(4)</B> </P></TD>
    <TD align=left width="90%">
      <P align=justify><B>Instruments defining rights of security holders,
      including indentures</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>4.1 </P></TD>
    <TD align=left width="90%">
      <P align=justify>Specimen Stock Certificate (incorporated by reference to
      an exhibit to our Registration Statement on Form SB-2 filed on January 13,
      2005) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>4.2 </P></TD>
    <TD align=left width="90%">
      <P align=justify>Form of Convertible Loan Agreement (incorporated by
      reference to an exhibit to our Form 8- K filed on April 3, 2009)
</P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>4.3 </P></TD>
    <TD align=left width="90%">
      <P align=justify>8% Convertible Loan Agreement dated June 3, 2009
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>4.4 </P></TD>
    <TD align=left width="90%">
      <P align=justify>8% Convertible Loan Agreement dated June 19, 2009
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on June 26, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify><B>(10)</B> </P></TD>
    <TD align=left width="90%">
      <P align=justify>&nbsp;<B>Material Contracts</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.1 </P></TD>
    <TD align=left width="90%">
      <P align=justify>Agreement between Anavex Life Sciences Corp. and Dr.
      Alexandre Vamvakides dated January 31, 2007 (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on February 7, 2007)
      </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.2 </P></TD>
    <TD align=left width="90%">
      <P align=justify>Form of Stock Option Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on February 22,
      2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.3 </P></TD>
    <TD align=left width="90%">
      <P align=justify>Shares for Services and Subscription Agreement dated
      September 11, 2007 between our company and Eurogenet Labs S.A.
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on September 27, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.4 </P></TD>
    <TD align=left width="90%">
      <P align=justify>2007 Stock Option Plan (incorporated by reference to an
      exhibit to our Current Report on Form 8-K filed on September 28, 2007)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.5 </P></TD>
    <TD align=left width="90%">
      <P align=justify>Consulting Agreement with Cameron Durrant dated May 20,
      2008 (incorporated by reference to an exhibit to our Quarterly Report on
      Form 10-QSB filed on August 18, 2008 </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.6 </P></TD>
    <TD align=left width="90%">
      <P align=justify>Form of Convertible Loan Agreement (incorporated by
      reference to an exhibit to our Current Report on Form 8-K filed on April
      3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.7 </P></TD>
    <TD align=left width="90%">
      <P align=justify>Consulting Agreement with Tariq Arshad dated March 2,
      2009 (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on April 3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.8 </P></TD>
    <TD align=left width="90%">
      <P align=justify>Consulting Agreement with Dr. Mark Smith dated January
      13, 2009 (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on April 3, 2009) </P></TD></TR></TABLE></DIV><BR><P align="center">44</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_50></A><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left>
      <P align=justify><B>Exhibit</B> <BR><B>Number</B> </P></TD>
    <TD align=left width="90%" >
      <P align=justify><BR><B>Description</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.9 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on April 3, 2009)
      </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.10 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on April 3, 2009)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.11 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Amended Consulting Agreement with Cameron Durrant dated
      May 14, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.12 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>CEO Consulting Agreement with Dr. Herve de Kergrohen
      dated June 12, 2009 (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.13 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Private Placement subscription agreement dated
      June 15, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.14 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services Agreement with Andreas Eleuthariadis
      dated June 10, 2009 (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.15 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services Agreement with Vasileios Kourafalos
      dated June 10, 2009 (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.16 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services Agreement with George Kalkanis dated
      June 10, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.17 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Stock Option Agreement with Alexandre Vamvakides dated
      June 11, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.19 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Private Placement Subscription Agreement
      Convertible Loan (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 26, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.20 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Private Placement Subscription Agreement for
      Units (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on June 26, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.21 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Consultant Services Agreement with NAD Ltd. dated July 1,
      2009 (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on November 24, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.22 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on November 24,
      2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.23 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on August 12, 2009)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.24 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Stock Option Agreement with Alexander Vamvakides dated
      October 19, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on November 24, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.25 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Promissory note issued to Stonehedge Limited on January
      1, 2010 (incorporated by reference to an exhibit to our Quarterly Report
      on Form 10-Q filed on March 31, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.26 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Second Amended Consulting Agreement with Dr. Cameron
      Durrant dated January 2, 2010 (incorporated by reference to an exhibit to
      our Current Report on Form 8-K filed on April 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.27 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Contract Lease Agreement with Euro Genet Labs SA dated
      February 1, 2010 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on April 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.28 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on April 9, 2010)
      </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.29 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on April 9, 2010)
    </P></TD></TR></TABLE></DIV><BR><P align="center">45</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_51></A><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left>
      <P align=justify><B>Exhibit</B> <BR><B>Number</B> </P></TD>
    <TD align=left width="90%" >
      <P align=justify><BR><B>Description</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.30 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Convertible Loan Agreement (incorporated by
      reference to an exhibit to our Current Report on Form 8-K filed on April
      9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.31 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement for US subscribers
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.32 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement for non-US subscribers
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.33 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate for US warrant holders
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.34 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate for non-US warrant holders
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.35 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services Agreement dated July 5, 2010 with
      Eurogenet Labs SA (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on July 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.36 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate for non-US warrant holders
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.37 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Agreement for Services with Genesis Biopharma Group LLC
      dated August 10, 2010 (incorporated by reference to an exhibit of our
      Current Report on Form 8-K filed on August 18, 2010) <I>(portions of the
      exhibit have been omitted pursuant to a request for confidential</I>
      <I>treatment)</I> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.38 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Agreement for Services with ABX-CRO Advanced
      Pharmaceutical Services dated August 10, 2010 (incorporated by reference
      to an exhibit of our Current Report on Form 8-K filed on August 18, 2010)
      <I>(portions of the exhibit have been omitted pursuant to a request
      for</I> <I>confidential treatment)</I> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.39 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.40 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (Canadian and Offshore
      Purchasers) (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.41 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (US warrant
      holders)(incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.42 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (Canadian and Offshore
      warrant holders) (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.43 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Consulting Agreement dated August 2, 2010 with Tom
      Skarpelos (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on September 27, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.44 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Independent Contractor Agreement dated September 1, 2010
      with David Tousley (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on September 27, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.45 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Sublease Contract with Genesis Research LLC dated
      September 15, 2010 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on September 27, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.46 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.47 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (non-US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on November 22, 2010) </P></TD></TR></TABLE></DIV><BR><P align="center">46</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_52></A><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left>
      <P align=justify><B>Exhibit</B> <BR><B>Number</B> </P></TD>
    <TD align=left width="90%" >
      <P align=justify><BR><B>Description</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.48 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (US Warrant Holders) (US
      Purchasers) (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.49 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (non-US Warrant Holders) (US
      Purchasers) (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.50 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Service and Subscription Agreement dated
      November 1, 2010 with Eurogenet Labs SA (incorporated by reference to an
      exhibit to our Current Report on Form 8-K filed on November 22, 2010)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.51 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Subscription Agreement with Stonehedge Limited dated
      November 17, 2010 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.52 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on November 30,
      2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.53 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate Form of Subscription
      Agreement (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on November 30, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.54 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services Agreement Form of Subscription
      Agreement (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on November 30, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.55 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (non-US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on February 7, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.56 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (non-US Warrant Holders)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on February 7, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.57 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Termination Agreement dated February 2, 2011 with Genesis
      BioPharma Group, LLC (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on February 7, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.58 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Independent Contractor Agreement with Harvey Lalach dated
      February 1, 2011 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on February 7, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.59 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Independent Contractor Agreement with Dr. Angelos
      Stergiou dated February 1, 2011 (incorporated by reference to an exhibit
      to our Current Report on Form 8-K filed on February 7, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.60 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Amended and Restated 2007 Stock Option Plan (incorporated
      by reference to an exhibit to our Current Report on Form 8-K filed on
      February 8, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.61 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Advisory Board Consulting Agreement (incorporated
      by reference to an exhibit to our Current Report on Form 8-K filed on
      February 28, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.62 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Consulting Agreement dated March 30, 2011 with Shackleton
      Consulting Corp. (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on April 13, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.63 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of subscription agreement for convertible debenture
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on April 26, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.64 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of subscription agreement for convertible debenture
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on May 9, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.65 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of warrant certificate (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on May 9, 2011)
  </P></TD></TR></TABLE></DIV><BR><P align="center">47</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_53></A><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left>
      <P align=justify><B>Exhibit</B> <BR><B>Number</B> </P></TD>
    <TD align=left width="90%" >
      <P align=justify><BR><B>Description</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.66 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Amended Stock Option Agreement dated September 16, 2011
      with Cameron Durrant (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on September 21, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.67 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Consulting Agreement dated effective October 10, 2011,
      with George Tidmarsh (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on October 14, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.68 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of subscription agreement for services (US
      purchaser) (incorporated by reference to our current report on Form 8-K
      filed on February 10, 2012) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.69 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of subscription agreement for units (Offshore
      purchasers) (incorporated by reference to our current report on Form 8-K
      filed on February 10, 2012) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.70 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Unsecured Promissory Note dated April 20, 2012 issued to
      Georgia Georgopoulou (incorporated by reference to our quarterly report on
      Form 10-Q filed on May 15, 2012) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.71 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of subscription agreements for convertible debenture
      and promissory notes (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on June 7, 2012) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.72 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Promissory Note dated October 17, 2012 issued to Akira
      International Limited (incorporated by reference to an exhibit to our
      Annual Report on Form 10-K filed on December 31, 2012) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.73 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Promissory Note dated November 12, 2012 issued to Akira
      International Limited (incorporated by reference to an exhibit to our
      Annual Report on Form 10-K filed on December 31, 2012) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.74 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of SPA (incorporated by reference to an exhibit to
      our Current Report on Form 8-K filed on July 8, 2013) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.75 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Exchange Agreement (incorporated by reference to
    an exhibit to our Current Report on Form 8- K filed on July 8, 2013)    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.76 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant (incorporated by reference to an exhibit
      to our Current Report on Form 8-K filed on July 8, 2013) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.77 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Registration Rights Agreement (incorporated by
      reference to an exhibit to our Current Report on Form 8-K filed on July 8,
      2013) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.78 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Purchase Agreement, dated as of July 5, 2013, by and
      between the Company and Lincoln Park Capital Fund, LLC (incorporated by
      reference to an exhibit to our Current Report on Form 8-K filed on July 8,
      2013) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.79 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Registration Rights Agreement, dated as of July 5, 2013,
      by and between the Company and Lincoln Park Capital Fund, LLC
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 8, 2013) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.80 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Employment Agreement, dated as of July 5, 2013, by and
      between the Company and Christopher Missling, PhD (incorporated by
      reference to an exhibit to our Quarterly Report on Form 10-Q filed on
      August 14, 2013) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify><a href="exhibit10-81.htm">10.81* </a></P></TD>
    <TD align=left width="90%" >
      <P align=justify><a href="exhibit10-81.htm">2012 Addendum to the Contract for the Transfer of a
      Patent Invention and Scientific Collaboration dated January 11, 2013
    </a></P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify><a href="exhibit10-82.htm">10.82* </a></P></TD>
    <TD align=left width="90%" >
      <P align=justify><a href="exhibit10-82.htm">Appendix A to the 2012 Addendum to the Contract for the
      Transfer of a Patent Invention and Scientific Collaboration dated January
      11, 2013 </a></P></TD></TR></TABLE>
</DIV><BR><P align="center">48</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_54></A><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left><B>Exhibit</B> <BR><B>Number</B> </TD>
    <TD align=left width="90%" ><BR><B>Description</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(14)</B> </TD>
    <TD align=left width="90%" ><B>Code of Ethics</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>14.1 </TD>
    <TD align=left width="90%" >
      <P align=justify>Code of Conduct (incorporated by reference to an exhibit
      to our Current Report on Form 8-K filed on September 28, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(21)</B> </TD>
    <TD align=left width="90%" >
      <P align=justify><B>Subsidiaries</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>21.1 </TD>
    <TD align=left width="90%" >
      <P align=justify>Anavex Life Sciences (France) SA, incorporated under the
      laws of France </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(31)</B> </TD>
    <TD align=left width="90%" >
      <P align=justify><B>Section 302 Certifications</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><a href="exhibit31-1.htm">31.1* </a></TD>
    <TD align=left width="90%" >
      <P align=justify><a href="exhibit31-1.htm">Section 302 Certification of Christopher Missling, PhD.
    </a></P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(32)</B> </TD>
    <TD align=left width="90%" >
      <P align=justify><B>Section 906 Certifications</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><a href="exhibit32-1.htm">32.1* </a></TD>
    <TD align=left width="90%" >
      <P align=justify><a href="exhibit32-1.htm">Section 906 Certification of Christopher Missling, PhD.      </a></P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(99)</B> </TD>
    <TD align=left width="90%" >
      <P align=justify><B>Additional Exhibits</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>99.1 </TD>
    <TD align=left width="90%" >
      <P align=justify>Insider Trading Policy Adopted August 27, 2010
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on September 27, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(101)</B> </TD>
    <TD align=left width="90%" >
      <P align=justify><B>XBRL</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>101.INS* </TD>
    <TD align=left width="90%" >
      <P align=justify>XBRL INSTANCE DOCUMENT </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>101.SCH* </TD>
    <TD align=left width="90%" >
      <P align=justify>XBRL TAXONOMY EXTENSION SCHEMA </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>101.CAL* </TD>
    <TD align=left width="90%" >
      <P align=justify>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>101.DEF* </TD>
    <TD align=left width="90%" >
      <P align=justify>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>101.LAB* </TD>
    <TD align=left width="90%" >
      <P align=justify>XBRL TAXONOMY EXTENSION LABEL LINKBASE </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>101.PRE* </TD>
    <TD align=left width="90%" >
  <P align=justify>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE  </P></TD></TR></TABLE>
</DIV>
<P align=justify>* Filed herewith.</P>
<P align=center>49</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_55></A>
<P align=center><B>SIGNATURES </B></P>
<P
align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>Date: December 30, 2013</B> </TD>
    <TD align=left width="50%"><B>ANAVEX LIFE SCIENCES CORP.</B>
</TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="5%" >By: </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="45%"
    ><I>/s/ Christopher Missling, PhD</I> </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="5%" >Name: </TD>
    <TD align=left width="45%"  >Christopher
      Missling, PhD </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="5%" >Title: </TD>
    <TD align=left width="45%" >Chief Executive Officer and Chief Financial<br>
    Officer  (Principal Executive Officer, Principal<br>
    Financial Officer, Principal Accounting<br>
    Officer)</TD>
</TR></TABLE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons
on behalf of the registrant and in the capacities and on the dates indicated.
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><B>Signatures</B>    </TD>
    <TD align=left width="1%"  >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="32%"><B>Title(s)</B> </TD>
    <TD align=left width="1%"  >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="32%"><B>Date</B> </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="1%"  >&nbsp;</TD>
    <TD width="32%">&nbsp; </TD>
    <TD width="1%"  >&nbsp;</TD>
    <TD width="32%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/ Christopher
      Missling</I> </TD>
    <TD align=left width="1%"  >&nbsp;</TD>
    <TD align=left width="32%">Chief Executive Officer, Chief Financial</TD>
    <TD align=left width="1%"  >&nbsp;</TD>
    <TD align=left width="32%">December 30, 2013 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Christopher Missling </TD>
    <TD align=left width="1%"  >&nbsp;</TD>
    <TD align=left width="32%"> Officer (Principal  Executive Officer, Principal</TD>
    <TD align=left width="1%"  >&nbsp;</TD>
    <TD align=left width="32%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%"  >&nbsp;</TD>
    <TD align=left width="32%"> Financial Officer, Principal Accounting </TD>
    <TD align=left width="1%"  >&nbsp;</TD>
    <TD align=left width="32%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%"  >&nbsp;</TD>
    <TD align=left width="32%">Officer)</TD>
    <TD align=left width="1%"  >&nbsp;</TD>
    <TD align=left width="32%">&nbsp; </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="1%"  >&nbsp;</TD>
    <TD width="32%">&nbsp; </TD>
    <TD width="1%"  >&nbsp;</TD>
    <TD width="32%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/ Athanasios
      Skarpelos</I> </TD>
    <TD align=left width="1%"  >&nbsp;</TD>
    <TD align=left width="32%">Director </TD>
    <TD align=left width="1%"  >&nbsp;</TD>
    <TD align=left width="32%">December 30, 2013 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Athanasios Skarpelos </TD>
    <TD align=left width="1%"  >&nbsp;</TD>
    <TD align=left width="32%">&nbsp; </TD>
    <TD align=left width="1%"  >&nbsp;</TD>
    <TD align=left width="32%">&nbsp;</TD></TR></TABLE>
<BR><P align="center">50</P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
